(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 1 April 2004 (01.04.2004)

PCT

(10) International Publication Number WO 2004/026888 A2

(51) International Patent Classification7:

C07H

(21) International Application Number:

PCT/US2003/029577

(22) International Filing Date:

19 September 2003 (19.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/412,479


19 September 2002 (19.09.2002) U

(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE). UNIVERSITY OF SASKATCHEWAN [CA/CA]; Kirk Hall, 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 (CA). QIAGEN GMBH [DE/DE]; Max-Volmer-Strasse 4, 40724 Hilden (DE).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LIPFORD, Grayson, B. [US/US]; 38 Bates Road, Watertown, MA 02472 (US). MOOKHERJEE, Neeloffer [IN/CA]; Apt 408, 2233 Allison Road,, Vancouver, BC V6T IT7 (CA). BABIUK, Lorne [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA). BROWNLIE, Robert [CA/CA]; 123 O'Brien Crescent, Saskatoon, Saskatchewan S7K 5K3 (CA). GRIEBEL, Philip [CA/CA]; Box 36, RR5, Saskatoon, Saskatchewan S7K 3J8 (CA). MUTWIRI, George [CA/CA]; 569 Nordstrum Road, Saskatoon, Saskatchewan S7K 7X6 (CA). HECKER, Rolf [DE/DE]; Benrodestr. 60, 40597 Düsseldorf (DE).
- (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (national): AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU; CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

[Continued on next page]

(54) Title: TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES



(57) Abstract: Novel amino acid and nucleotide sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) Toll-like receptor 9 (TLR9) are provided. Also provided are amino acid and nucleotide sequences for dog (canine), cat (feline), mouse (murine), and human TLR9. Comparison of these sequences, especially in combination with functional assessment for species-specific CpG motif preferences, permits identification of specific regions and amino acid residues of interest in TLR9 ligand interaction. Novel chimeric TLR9 receptor molecules, cells expressing these molecules, and methods for their use in screening assays for TLR9 ligands are also provided.





MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES

Background of the Invention

Synthetic oligodeoxynucleotides (ODN) and DNA containing immunostimulatory CpG motifs (CpG DNA) function as potent adjuvants and activators of the innate immune system. Heeg K et al. (2000) *Int Arch Allergy Immunol* 121:87-97; Krieg AM (2001) *Vaccine* 19:618-22. A wide variety of CpG-containing sequences have been screened for biological activity and it is reported that optimal CpG DNA sequences can vary among species. Rankin R et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:333-40.

5

10

15

20

25

30

Toll-like receptor 9 (TLR9) has recently been identified as a receptor for CpG ODN. Hemmi H et al. (2000) *Nature* 408:740-5. The molecular mechanism by which TLR9 recognizes CpG DNA is not understood.

Summary of the Invention

Toll-like receptor 9 (TLR9) is known to be involved in innate immunity and to signal in response to CpG DNA. To date, the amino acid sequences only of human and murine TLR9 have been reported, and, interestingly, these two species are known to prefer different CpG motifs. The structural basis for this species-specific CpG motif preference has not yet been fully elucidated. The instant invention provides, in part, novel amino acid and nucleotide sequences of rat, pig, cow, and horse TLR9. These novel TLR9 sequences are useful for elucidating certain key structural features of TLR9. Specifically, comparison of sequences of murine, human, and these novel TLR9 sequences permits identification of areas of highly conserved sequence, areas of group conservation, and areas of hypervariability. In addition, such comparisons permit an assessment of evolutionary relatedness among TLR9 molecules of the various species, as well as an assessment of inter-species homologies. Importantly, such comparisons permit a rational basis for identifying amino acids in TLR9 that may be involved in the CpG binding site, as well as amino acids involved in conferring species specificity for particular CpG motifs. Such information may be used to design and construct novel TLR9 molecules which incorporate specific point or regional mutations and which possess desired ligand binding characteristics. Such information may also be useful in designing and identifying novel ligands for TLR9 of a given species.

- 2 -

In one aspect, the invention provides isolated polypeptides having amino acid sequences for rat, pig (porcine), cow (bovine), horse (equine), and sheep (ovine) TLR9 polypeptides. These amino acid sequences correspond to SEQ ID NOs 1, 5, 9, 13, and 17, respectively. Each of these sequences is believed to include at least a majority of an extracellular domain, as well as a transmembrane region and at least part of a TLR/IL-1 receptor (TIR) domain. To the extent any such sequence may lack an amino-terminal and/or carboxy-terminal sequence, such sequence is ascertainable, without undue experimentation, using conventional molecular biology techniques and the sequence information provided herein.

5

10

15

20

25

30

In another aspect the invention provides isolated polypeptides having amino acid sequences for essentially the whole extracellular domain, optionally including a signal peptide, of each of rat, porcine, bovine, equine, and ovine TLR9. These amino acid sequences correspond to SEQ ID NOs 2, 6, 10, 14, and 18, respectively. Such extracellular domains are believed to include sequence specifically involved in binding to TLR9 ligand, such as CpG DNA. In addition, such extracellular domains are believed to include sequence that confers species specificity for particular CpG motifs.

Isolated nucleic acid molecules encoding the polypeptides just described above are also provided according to further aspects of the invention. Such nucleic acid molecules include, but are not limited to, nucleic acid molecules having sequences provided by SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively. Isolated nucleic acid molecules encoding the TLR9 polypeptides of SEQ ID NOs 1, 5, 9, 13, 17; and 2, 6, 10, 14, and 18 also include nucleic acid molecules that differ in sequence from SEQ ID NOs 3, 7, 11, 15, 19; and 4, 8, 12, 16, and 20, respectively, due to degeneracy of the genetic code. Such nucleic acid molecules will hybridize, under stringent conditions, with suitably selected nucleic acid molecules having sequences selected from SEQ ID NOs 3, 4, 7, 8, 11, 12, 15, 16, 19, and 20.

In another aspect the invention provides a vector which includes an isolated nucleic acid molecule of the invention. In one embodiment the vector is an expression vector and the isolated nucleic acid molecule of the invention is operably linked to a regulatory sequence in the vector. When present within a cell, an expression vector according to this aspect of the invention causes the cell to express a polypeptide of the invention.

The invention according to another aspect provides a cell in which a vector of the invention is present. In one embodiment the cell containing the vector expresses a

- 3 -

polypeptide of the invention. In certain embodiments the cell also contains a reporter construct that transduces a TLR9-mediated signal in response to contact of the polypeptide of the invention or a TLR9 with a suitable TLR9 ligand. The cell containing the vector, and optionally containing the reporter construct, can be used in screening methods also provided by the invention.

5

10

15

20

25

30

In yet another aspect the invention provides an antibody or antibody fragment that binds specifically to an isolated polypeptide of the invention. In certain embodiments the antibody or antibody fragment binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide. More specifically, the antibody or antibody fragment binds uniquely to one of the isolated polypeptides of the invention. In one embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide also binds to either mouse or human TLR9. In another embodiment the antibody or antibody fragment that binds uniquely to one of rat, porcine, bovine, equine, or ovine TLR9 polypeptide does not also bind to either mouse or human TLR9. In some embodiments the antibody or antibody fragment binds selectively to a chimeric TLR9 polypeptide of the invention. In certain embodiments the antibody or antibody fragment of the invention is a monoclonal antibody or fragment of a monoclonal antibody.

In one aspect the invention provides a method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species. The method involves aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species; generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

-4-

In another aspect the invention provides a method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9. The method according to this aspect of the invention involves aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9; generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution; generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids. In one embodiment the method according to this aspect of the invention is performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

5

10

15

20

25

30

In another aspect the invention also provides an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (extracellular domain (ECD) of murine TLR9) except for substitution of at least one key amino acid identified according to the method above. The polypeptide according to this aspect of the invention is a chimeric TLR9 polypeptide. Preferably the polypeptide according to this aspect of the invention binds to CpG DNA optimized for human TLR9 better than does the isolated polypeptide having an amino acid sequence identical to SEQ ID NO:30 (ECD of murine TLR9). In one embodiment the polypeptide includes only one substituted amino acid. The isolated polypeptide according to this aspect of the invention may further include sequence involved in TLR/IL-1R signal transduction, e.g., intracellular domain of TLR9 as provided in SEQ ID NOs 29 and 33. For example, in one embodiment a polypeptide according to this aspect of the invention is an isolated polypeptide having an amino acid sequence identical to SEQ ID NO:29 (full length murine TLR9) except for substitution of at least one key amino acid identified according to the method above.

WO 2004/026888

5

10

15

20

- 5 -

PCT/US2003/029577

In another aspect the invention provides an isolated nucleic acid molecule including a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described. In one embodiment the isolated nucleic acid molecule has a nucleic acid sequence encoding a chimeric TLR9 polypeptide just described.

In yet another aspect, the invention provides a screening method to identify a TLR9 ligand. The method involves contacting a polypeptide (including a chimeric TLR9 polypeptide) of the invention with a candidate TLR9 ligand; measuring a signal in response to the contacting; and identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment the candidate TLR9 ligand is an immunostimulatory nucleic acid. In one embodiment the candidate TLR9 ligand is a CpG DNA.

The invention also provides, in yet a further aspect, a screening method to identify species-specific CpG-motif preference of an isolated polypeptide of the invention. The method according to this aspect of the invention involves contacting an isolated polypeptide of the invention with a CpG DNA including a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACTTT, GACGCT, GACGAT, GACGGT, GACGTC, GACGTA, and GACGTG; measuring a signal in response to the contacting; and identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling. In one embodiment the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

TCCATGACGTTTTTGATGTT (SEQ ID NO:39), (SEQ ID NO:40), TCCATAACGTTTTTGATGTT (SEQ ID NO:41), TCCATCACGTTTTTGATGTT TCCATTACGTTTTTGATGTT (SEQ ID NO:42), 25 (SEQ ID NO:43), TCCATGGCGTTTTTGATGTT (SEQ ID NO:44), TCCATGCCGTTTTTGATGTT (SEQ ID NO:45), TCCATGTCGTTTTTTGATGTT (SEQ ID NO:46), TCCATGATGTTTTTGATGTT TCCATGAAGTTTTTGATGTT (SEQ ID NO:47), 30 TCCATGAGGTTTTTGATGTT (SEQ ID NO:48), (SEQ ID NO:49), TCCATGACATTTTTGATGTT TCCATGACCTTTTTGATGTT (SEQ ID NO:50), TCCATGACTTTTTTGATGTT (SEQ ID NO:51), (SEQ ID NO:52), 35 TCCATGACGCTTTTGATGTT TCCATGACGATTTTGATGTT (SEQ ID NO:53), TCCATGACGGTTTTGATGTT (SEQ ID NO:54),

- 6 -

TCCATGACGTCTTTGATGTT (SEQ ID NO:55), TCCATGACGTATTTGATGTT (SEQ ID NO:56), and TCCATGACGTGTTTGATGTT (SEQ ID NO:57).

In certain embodiments of the screening methods of the invention, the signal includes expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway. In one embodiment the reporter gene is operatively linked to a promoter sensitive to NF- κ B. In one embodiment the signal in response to contacting is binding of the candidate TLR9 ligand or CpG DNA to the polypeptide of the invention.

In one embodiment the screening method is performed on a plurality of test compounds. In one embodiment the response mediated by the TLR9 signal transduction pathway is measured quantitatively and the response mediated by the TLR9 signal transduction pathway associated with each of the plurality of test compounds is compared with a response arising as a result of an interaction between the functional TLR9 and a reference immunostimulatory compound.

15

20

25

10

5

Brief Description of the Figures

Figure 1 depicts a Clustal W multiple sequence alignment of deduced amino acid sequences for cat (feline), dog (canine), cow (bovine), mouse (murine), sheep (ovine), pig (porcine), horse (equine), human, and rat TLR9 polypeptides. The deduced amino acid sequences for feline, canine, bovine, murine, ovine, porcine, equine, human, and rat TLR9 polypeptides shown in the figure correspond to SEQ ID NOs 25, 21, 9, 29, 17, 5, 13, 33, and 1, respectively. Lines labeled "multiple" refer to the multiple sequence alignment of all six sequences shown. Lines labeled "mo/hu" refer to a paired sequence alignment of mouse and human TLR9 sequences alone.

Figure 2 is a cladogram depicting an evolutionary relatedness tree for rat, murine, porcine, bovine, equine, and human TLR9 polypeptides in Figure 1.

Figure 3 is a graph depicting species specificity of TLR9 signaling with selected oligonucleotides having strong specificity for human (2006), mouse (5890), or neither (1982).

30

Detailed Description of the Invention

The present invention provides novel amino acid and nucleotide sequences for TLR9 derived from rat, pig, cow, horse, and sheep. These sequences can be used to identify key features of the primary sequences of these and related TLR molecules, including previously

known primary sequences of human and mouse (murine) TLR9. Such key features include binding site information and species specificity toward particular CpG motifs. Native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to identify and to design novel TLR9 ligands. Additionally, the native and novel chimeric TLR9 polypeptides designed with the aid of this information can be expressed in vitro or in vivo and used in screening assays to compare various TLR9 ligands, including CpG DNA.

In one aspect the invention provides isolated TLR9 polypeptides, and isolated nucleic acid molecules encoding them, from rat, pig, cow, horse, and sheep. The term "isolated" as used herein with reference to a nucleic acid molecule or polypeptide means substantially free of or separated from components with which it is normally associated in nature, e.g., other nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids or polypeptides are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid or polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the nucleic acid or polypeptide may represent only a small percentage by weight of such a preparation. The nucleic acid or polypeptide is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

10

15

20

25

30

An amino acid sequence of rat TLR9 is provided as SEQ ID NO:1. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:1 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of rat TLR9 (See Figure 1). Amino acids numbered 1-821 of SEQ ID NO:1 are presumptively extracellular domain and correspond to SEQ ID NO:2. SEQ ID NO:3 is a nucleotide sequence of rat TLR9 cDNA having an open reading frame corresponding to nucleotides 1-3096. SEQ ID NO:4 is a nucleotide sequence of rat cDNA encoding amino acids 1-821 of SEQ ID NO:1.

An amino acid sequence of porcine TLR9 is provided as SEQ ID NO:5. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:5 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of porcine TLR9

(See Figure 1). Amino acids numbered 1-819 of SEQ ID NO:5 are presumptively extracellular domain and correspond to SEQ ID NO:6. SEQ ID NO:7 is a nucleotide sequence of porcine TLR9 cDNA having an open reading frame corresponding to nucleotides 77-3166. SEQ ID NO:8 is a nucleotide sequence of porcine cDNA encoding amino acids 1-819 of SEQ ID NO:5.

5

10

15

20

25

30

An amino acid sequence of bovine TLR9 is provided as SEQ ID NO:9. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:9 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of bovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:9 are presumptively extracellular domain and correspond to SEQ ID NO:10. SEQ ID NO:11 is a nucleotide sequence of bovine TLR9 cDNA having an open reading frame corresponding to nucleotides 84-3170. SEQ ID NO:12 is a nucleotide sequence of bovine cDNA encoding amino acids 1-818 of SEQ ID NO:9.

An amino acid sequence of equine TLR9 is provided as SEQ ID NO:13. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:13 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of equine TLR9 (See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:13 are presumptively extracellular domain and correspond to SEQ ID NO:14. SEQ ID NO:15 is a nucleotide sequence of equine TLR9 cDNA having an open reading frame corresponding to nucleotides 115-3207. SEQ ID NO:16 is a nucleotide sequence of equine cDNA encoding amino acids 1-820 of SEQ ID NO:13.

An amino acid sequence of ovine TLR9 is provided as SEQ ID NO:17. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:17 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of ovine TLR9 (See Figure 1). Amino acids numbered 1-818 of SEQ ID NO:17 are presumptively extracellular domain and correspond to SEQ ID NO:18. SEQ ID NO:19 is a nucleotide sequence of ovine TLR9 cDNA having an open reading frame corresponding to nucleotides 92-3178. SEQ ID NO:20 is a nucleotide sequence of ovine cDNA encoding amino acids 1-818 of SEQ ID NO:17.

-9-

SEO ID NO:1 (Rat TLR9)

MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAEPRSNITSLSLIANRI HHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL SHTNILVLDASSLAGLHSLRVLFMDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL LLSYNLIVKLGAEDLANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHHLSHLEGLVLKDSSLHSLN SKWFOGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSFKSLVSLQELNMNGIF ${\tt FRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW}$ PASLTPALPSTPVSKNFMVRCKNLRFTMDLSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK VLDLSYNKLDLYHSKSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS 10 VEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKLSFRDNHLSFFNWSSLA FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV $\verb|MNLTVLDVSSNPLHCACGAPFVDLLLEVQTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLL|$ AVAVGTVLPLLQHLCGWDVWYCFHLCLAWLPLLTRGRRSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEERRG RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQRLLEDRKDVVVLVILRPDA15 HRSRYVRLRQRLCRQSVLFWPHQPNGQGSFWAQLSTALTRDNHHFYNRNFCRGPTAE

SEQ ID NO:2 (Rat TLR9)

MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAEPRSNITSLSLIANRI
HHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFLAMRMLEELNLSYNGITTVPRLPSSLTNLSL
SHTNILVLDASSLAGLHSLRVLFMDGNCYYKNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPRQLPPSLEYL
LLSYNLIVKLGAEDLANLTSLRMLDVGGNCRRCDHAPDLCTECRQKSLDLHPQTFHHLSHLEGLVLKDSSLHSLN
SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSFKSLVSLQELNMNGIF
FRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFVDLSNNRISGPPTLSRVAPEKADEAEKGVPW
PASLTPALPSTPVSKNFMVRCKNLRFTMDLSRNNQVTIKPEMFVNLSHLQCLSLSHNCIAQAVNGSQFLPLTNLK
VLDLSYNKLDLYHSKSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYSTS
VEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKLSFRDNHLSFFNWSSLA
FLPNLRDLDLAGNLLKALTNGTLPNGTLLQKLDVSSNSIVFVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
MNLTVLDVSSNPLHCACGAPFVDLLLEVOTKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFG

SEQ ID NO:3 (Rat TLR9)

30

35

40

45

50

 $\verb|ctgggtaccctgccttcctaccctgtgaactgaagcctcatggcctggtagactgcaactggctcttcctg|$ aagtetgtgeeteaettetetgeegeagaacceegtteeaacateaccageettteettgategeeaaccgeate $\verb|caccacctgcacacctcgactttgtccacctgccaacgtgcgacagctgaacctcaagtggaactgtccgccc| \\$ cctggcctcagccccttgcacttctcctgccgcatgaccattgagcccaaaaccttcctggctatgcgcatgctg gaagagctgaacctgagctataacggtatcaccactgtgccccgcctgcccagctccctgacgaatctgagccta agccaccaccaccatcetggtactcgatgccagcagcctcgctggcctgcacagcctgcgagttctcttcatggac qqqaactqctactacaaqaacccctqcaacqqqqcqqtgaacgtgaccccqgacgccttcctgggcttgagcaac ctcacccacttgtcccttaagtataacaacctcacagaggtgccccgccaactgccccccagcctggagtacctc $\verb|ctgctgtcctataacctcatcgtcaagctgggggccgaagacctagccaacctgacctcccttcgaatgcttgat|$ gtgggtgggaattgccgtcgctgtgatcacgccccgacctctgtacagaatgccggcagaagtcccttgatctg caccctcaqactttccatcacctgagccaccttgaaggcctggtgctgaaggacagttctctccactcgctgaac tccaagtggttccagggtctggcgaacctctcggtgctggacctaagcgagaactttctctacgagagcatcaac aaaaccagcgcctttcagaacctgacccgtctgcgcaagctcgacctgtccttcaattactgcaagaaggtatcg ttcgcccgcctccacctggcaagttccttcaagagcctggtgtcgctgcaggagctgaacatgaacggcatcttc aatttcatcaaccaqqcqcaqctcaqcgtctttagtaccttccgagcccttcgcttttgtggacctgtccaataat cgcatcagegggcetccaacgctgtccagagtcgcccccgaaaaggcagacgaggcggagaagggggttccatgg cctgcaagtctcaccccagctctcccgagcactcccgtctcaaagaacttcatggtcaggtgtaagaacctcaga ttcaccatggacctgtctcggaacaaccaggtgactatcaagccagagatgttcgtcaacctctcccatctccag tgtctgagcctgagccacaactgcatcgcgcaggctgtcaatggctctcagttcctgccgctgaccaacctgaag qtqctqqacctqtcctataacaagctggacctgtaccattcgaaatcgttcagtgagctcccacagttgcaggcc

- 10 -

ctggacctgagctacaacagccattcagcatgcaggggataggccacaacttcagttttctggccaatctg tccaggttacagaaccttagcctggcacacaatgacattcacagccgcgtgtcctcacgcctctacagcacctca gtggagtatctggacttcagcggcaacggtgtgggccgcatgtgggacgaggaggacctttacctctatttcttc caagacctgagaagcctgattcatctggacctgtctcagaataagctgcacatcctccggccccagaacctcaac ttcctgcccaatctgcgagacctggacctggcaggcaatctactaaaggccctgaccaacggcaccctgcctaat $\verb"ggcacgctcctccagaaactggatgtcagtagcaacagtatcgtctttgtggtcccagccttctttgctctggcg"$ gtagagctaaaagaggtcaacctcagccataacatcctcaagactgtggatcgctcctggttttgggcccattgtg $\verb|atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgcaccctttgtagacttactg|$ ctggaagtgcagaccaaggtgcctggcctggctaacggtgtgaagtgtggcagtccccgccagctgcagggccgc agcatcttttgcgcaagacctgcggctgtgcctggatgacgtcctttctcgggactgcttttggcctttcactcctg $\verb|gctgtggccgtgggcacggtgttgcctttactgcagcatctctgcggctgggacgtctggtactgtttccatctg|$ tgcctggcatggctacctttgctgacccgtggccggcgcagcgcccaagctctcccttatgatgccttcgtggtg ttcgataaggcgcagagcgcggttgctgactgggtgtataacgagcttcgagtgcggctagaggagcggcggt 15 egccgagccctacgcttgtgtctggaggaccgagattggctgcctggccagacactcttcgagaacctctgggcc tecatetatggcageegeaagaetetgtttgtgetggeeeacaeggaeaaggteagtggeeteetgegeaeeage ttcctgctggctcagcagcgcctgctggaggaccgcaaggacgtggtggtgttggtgatcctgcgccctgatgcc caccgctcccgctacgtgcgactgcgccagcgcctctgccgccagagtgtgctcttctggcccaatcagcccaac gggcagggcagcttctgggcccagctgagtacagccctgactagggacaaccaccttctataaccggaacttc 20 tgccggggacctacagcagaatag

SEQ ID NO:4 (Rat TLR9)

atggttetetgtegeaggaceetgeaceeettgteteteetggtacaggeegeagtgetggetgaggetetggee ctgggtaccctgcctgcctaccctgtgaactgaagcctcatggcctggtagactgcaactggctcttcctg 25 aagtetgtgeeteaettetetgeegeagaaeeeegtteeaaeateaeeageettteettgategeeaaeegeate caccacctgcacacctcgactttgtccacctgcccaacgtgcgacagctgaacctcaagtggaactgtccgccc cctggcctcagccccttgcacttctcctgccgcatgaccattgagcccaaaaccttcctggctatgcgcatgctg gaagagetgaacetgagetataacggtateaceactgtgeeeegeetgeeeageteeetgaegaatetgageeta agccacaccaacatcctggtactcgatgccagcagcctcgctggcctgcacagcctgcgagttctcttcatggac 30 gggaactgctactacaagaacccctgcaacggggcggtgaacgtgaccccggacgccttcctgggcttgagcaac ctcacccacttgtcccttaagtataacaacctcacagaggtgccccgccaactgccccccagcctggagtacctc ctgctgtcctataacctcatcgtcaagctgggggccgaagacctagccaacctgacctcccttcgaatgcttgat gtgggtgggaattgccgtcgctgtgatcacgcccccgacctctgtacagaatgccggcagaagtcccttgatctg $\verb|caccetcagactttccatcacctgagecaccttgaaggcctggtgctgaaggacagttctctccactcgctgaac| \\$ 35 $\verb|tccaagtggttccagggtctggcgaacctctcggtgctggacctaagcgagaactttctctacgagagcatcaac| \\$ aaaaccagcgcctttcagaacctgacccgtctgcgcaagctcgacctgtccttcaattactgcaagaaggtatcg ttcgcccgcctccacctggcaagttccttcaagagcctggtgtcgctgcaggagctgaacatgaacggcatcttc aatttcatcaaccaggcgcagctcagcgtctttagtaccttccgagcccttcgctttgtggacctgtccaataat 40 cgcatcagcgggcctccaacgctgtccagagtcgcccccgaaaaggcagacgagggggagaagggggttccatqq cctgcaagtctcaccccagctctcccgagcactcccgtctcaaagaacttcatggtcaggtgtaagaacctcaga ttcaccatggacctgtctcggaacaaccaggtgactatcaagccagagatgttcgtcaacctctcccatctccag tgtotgagcctgagccacaactgcatcgcgcaggctgtcaatggctctcagttcctgccgctgaccaacctgaag gtgctggacctgtcctataacaagctggacctgtaccattcgaaatcgttcagtgagctcccacagttgcaggcc ctggacctgagctacaacagccagccattcagcatgcaggggataggccacaacttcagttttctggccaatctg tccaggttacagaaccttagcctggcacacaatgacattcacagccgcgtgtcctcacgcctctacagcacctca gtggagtatetggaetteageggeaaeggtgtgggeegeatgtgggaegaggaggaeetttaeetetatttette caagacctgagaagcctgattcatctggacctgtctcagaataagctgcacatcctccggccccagaacctcaac 50 ttcctgcccaatctgcgagacctggacctggcaggcaatctactaaaggccctgaccaacggcaccctgcctaat ggcacgctcctccagaaactggatgtcagtagcaacagtatcgtctttgtggtcccagccttctttgctctggcg gtagagctaaaagaggtcaacctcagccataacatcctcaagactgtggatcgctcctggtttgggcccattgtg atgaacctgacggttctagacgtgagcagcaaccctctgcattgtgcctgcggtgcaccctttgtagacttactg ctggaagtgcagaccaaggtgcctggcctggctaacggtgtgaagtgtggcagtccccgccagctgcagggccgc 55 agcatetttgegcaagacetgeggetgtgeetggatgaegteetttetegggaetqetttgge

- 11 -

SEQ ID NO:5 (Porcine TLR9)

 ${\tt MGPRCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRANVTSLSLLSNRIH}$ HLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCOGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL LSYNHIVTLTPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLDT RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF RSLSETTLOPLVQLPMLQTLRLOMNFINQAQLSIFGAFPGLLYVDLSDNRISGAARPVAITREVDGRERVWLPSR NLAPRPLDTLRSEDFMPNCKAFSFTLDLSRNNLVTIOSEMFARLSRLECLRLSHNSISOAVNGSOFVPLTSLRVL DLSHNKLDLYHGRSFTELPRLEALDLSYNSOPFTMOGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQOLCSASLC 10 ALDFSGNDLSRMWAEGDLYLRFFOGLRSLVWLDLSONHLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL PKLETLDLAGNOLKALSNGSLPSGTOLRRLDLSGNSIGFVNPGFFALAKOLEELNLSANALKTVEPSWFGSMVGN ALGLVVPMLHHLCGWDLWYCFHLCLAWLPHRGQRRGADALFYDAFVVFDKAQSAVADWVYNELRVQLEERRGRRA LRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPDAYRS 15 RYVRLRQRLCRQSVLLWPHQPRGQGSFWAQLGTALTRDNHHFYNRNFCRGPTTAE

SEQ ID NO:6 (Porcine TLR9)

MGPRCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRANVTSLSLLSNRIH
HLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNSITTVPALPDSLVSLSLS
RTNILVLDPTHLTGLHALRYLYMDGNCYYKNPCQGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLL
LSYNHIVTLTPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLDT
RWFRGLDRLQVLDLSENFLYDCITKTTAFQGLARLRSLNLSFNYHKKVSFAHLHLAPSFGHLRSLKELDMHGIFF
RSLSETTLQPLVQLPMLQTLRLQMNFINQAQLSIFGAFPGLLYVDLSDNRISGAARPVAITREVDGRERVWLPSR
NLAPRPLDTLRSEDFMPNCKAFSFTLDLSRNNLVTIQSEMFARLSRLECLRLSHNSISQAVNGSQFVPLTSLRVL
DLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASLC
ALDFSGNDLSRMWAEGDLYLRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSLKHLHLRDNNLAFFNWSSLTLL
PKLETLDLAGNQLKALSNGSLPSGTQLRRLDLSGNSIGFVNPGFFALAKQLEELNLSANALKTVEPSWFGSMVGN
LKVLDVSANPLHCACGATFVGFLLEVQAAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFG

30 SEQ ID NO:7 (Porcine TLR9)

50

gggcaggctgcctgccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctcttcctgaa gtccgtgccccacttctcggcggcagcgccccgggccaacgtcaccagcctctccttactctccaaccgcatcca $\verb|ccacctgcacgactccgacttcgtccacctgtccagcctacgaactctcaacctcaagtggaactgcccgccggc|$ tggcctcagccccatqcacttcccctqccacatqaccatcqaqcccaacaccttcctqqccgtgcccaccctgga. ccgcaccaacatcctqqtqctaqaccccacccacctcactgqcctacatgccctgcgctacctgtacatggatgq caactgctactacaagaacccctgccaggggggcgctggaggtggtgccggggtgccctcctcggcctgggcaacct cacacatctctcactcaaqtacaacaatctcacqqaqqtqccccqcaqcctqccccccaqcctqqaqaccctqct qttqtcctacaaccacattqtcaccctgacqcctgaggacctgqccaatctgactgccctgcgcgtgcttgatgt gggggggaactgccgccgctgtgaccatgcccgcaacccctgcagggagtgcccaaaggaccaccccaagctgca ctctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaagacagttctctctacaacctggacac gaccacggccttccagggcctggcccgactgcgcagcctcaacctgtccttcaattaccacaagaaggtgtcctt ccgctcgctcagtgagaccacgctccaacctctggtccaactgcctatgctccagaccctgcgcctgcagatgaa cttcattaaccaggcccagctcagcatctttggggccttccctggcctgctgtacgtggacctatcggacaaccg catcagcggagctgcaaggccagtggccattactagggaggtggatggtagggagagggtctggctgccttccag cttggacctgtctcggaacaacctggtgacaatccagtcggagatgtttgctcgcctctcacgcctcgagtgcct $\tt gcgcctgagccacaacagcatctcccaggcggtcaatggctctcagtttgtgccgctgaccagcctgcgggtgct$ ggacctgtcccacaacaagctggacctgtatcacgggcgctcgttcacggagctgccgcgcctggaagcactgga cctcagctacaatagccagccctttaccatqcaggqtgtgggccacaacctcagcttcgtggcccagctgcccgc

cctgcgctacctcagcctggcgcacaatgacatccatagccgagtgtcccagcagctctgtagcgcctcactgtg egecetggaetttageggeaaegatetgageeggatgtggggetgagggagaeetetateteegettetteeaagg $\verb|cctaagaagcctagtctggacctgtcccagaaccacctgcacaccctcctgccacgtgccctggacaacct|\\$ $\verb|ccccaaaagcctgaagcatctgcatctccgtgacaataacctggccttcttcaactggagcagcctgaccctcct|$ ${\tt gcccaagctggaaaccctggacttggctggaaaccagctgaaggccctaagcaattggcagcctgccatctggcac}$ ccagctgcggaggctggacctcagtggcaacagcatcggctttgtgaaccctggcttctttgccctggccaagca gttagaagageteaaceteagegeeaatgeeeteaagaeagtggageeeteetggtttggetegatggtgggeaa cctgaaagtcctagacgtgagcgccaaccctctgcactgtgcctgtggggcgaccttcgtgggcttcctgctgga ggtacaggctgccgtggcctgggccatgccgcgtcaagtgtggcagtccgggggcagctccagggccatagcat $\verb|ctttgcgcaagacctgcgctctggatgagaccctctcgtggaactgttttggcatctcgctggccat|\\$ $\verb|ggccctgggcctggttgtgcccatgctgcaccacctctgcggctgggacctctggtactgcttccacctgtgcct|$ ggcctggctgccccaccgagggcagcgggggggcgcagacgccctgttctatgatgccttcgtggtctttgacaa actgcgcctgtgcctggaggagcgagactggttacctggcaagacgctcttcgagaacctgtgggcctcagtcta cagcagccgcaagaccctgtttgtgctggcccacacggaccgtgtcagcggcctcttgcgtgccagtttcctgct $\verb"ggcccagcagcgcctgctggaggaccgcaaggacgttgtagtgctggtgatcctgcgcccgatgcctaccgctc"$ ccgctacgtgcggctgcgccagcgcctctgccgccagagtgtcctcctctggccccaccagccccgtgggcaggg cagcttctgggcccagctgggcacagccctgaccagggacaaccaccttctataaccggaacttctgccgggg $\verb|ccccacgacagccgaatagcactgagtgacagcccagttgccccagccccctggatttgcctcttgcctgggg|$ ${\tt tgccccaacctgctttgctcagccacaccacctgctctgctccctgttccccacccccacccccagcctggcatgt}$

SEQ ID NO:8 (Porcine TLR9)

10

20

25 ggcaggctgcctgccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctcttcctgaag $\verb|tccgtgcccacttctcggcggcagcgccccgggccaacgtcaccagcctctccttactctccaaccgcatccac|$ cacctgcacgactccgacttcgtccacctgtccagcctacgaactctcaacctcaagtggaactgcccgccggct ggcctcagccccatgcacttcccctgccacatgaccatcgagcccaacaccttcctggccgtgcccaccctggag cgcaccaacatcctggtgctagaccccaccccacctggcctacatgccctgcgctacctgtacatggatqqc aactgctactacaagaacccctgccagggggcgctggaggtggtgccggggtgccctcctcggcctgggcaacctc acacateteteacteaagtacaacaateteaeggaggtgeeeegcageetgeeeeecageetggagaeeetgetg ttgtcctacaaccacattgtcaccctgacgcctgaggacctggccaatctgactgccctgcgcgtgcttgatgtg ggggggaactgccgccgctgtgaccatgcccgcaacccctgcagggagtgcccaaaggaccaccccaagctgcac 35 tetgacacettcagecacetgagecgcetegaaggeetggtgttgaaagacagttetetetacaacetggacace accacggccttccagggcctggcccgactgcgcagcctcaacctgtccttcaattaccacaagaaggtgtccttt $\verb|cgctcgctcagtgagaccacgctccaacctctggtccaactgcctatgctccagaccctgcgcctgcagatgaac| \\$ $\verb|ttcattaaccaggcccagctcagcatctttggggccttccctggcctgctgtacgtggacctatcggacaaccgc|$ ${\tt atcagcggagctgcaaggccagtggccattactagggaggtggatggtagggagagggtctggcttccagg}$ $\verb| aacctcgctccacgtccactggacactctccgctcagaggacttcatgccaaactgcaaggccttcagcttcacc| \\$ $\verb|ttggacctgtctcggaaccaacctggtgacaatccagtcggagatgtttgctcgcctctcacgcctcgagtgcctg|$ $\verb|cgcctgagccacaacagcatctcccaggcggtcaatggctctcagtttgtgccgctgaccagcctgcgggtgctg|$ 45 $\tt gacetgtcccacaacaagctggacetgtatcacgggcgctcgttcacggagctgccgcctggaagcactggac$ $\verb|ctcagctacaatagccagccctttaccatgcagggtgtgggccacaacctcagcttcgtggcccagctgcccgcc|$ $\verb|ctgcgctacctcagcctggcgcacaatgacatccatagccgagtgtcccagcagctctgtagcgcctcactgtgc|\\$ gccctggactttagcggcaacgatctgagccggatgtgggctgagggagacctctatctccgcttcttccaaggc $\verb|ctaagaagcctagtctggacctgtcccagaaccacctgcacacctcctgccacgtgccctggacaacctc|\\$ 50 $\verb|cccaaaaagcctgaagcatctccgtgacaataacctggccttcttcaactggagcagcctgaccctcctg|$ $\verb|cccaagetggaaaccetggaattggctggaaaccagetgaaggccctaagcaattggcagcctgccatctggcacc| \\$ cagctgcggaggctggacctcagtggcaacagcatcggctttgtgaaccctggcttctttgccctggccaagcag $\verb|ttagaagagctcaacctcagcgccaatgccctcaagacagtggagccctcctggtttggctcgatggtgggcaac| \\$ $\verb|ctgaaagtcctagacgtgagcgccaaccctctgcactgtgcctgtggggcgaccttcgtggggcttcctgctggag|$ 55 gtacaggctgccgtgcctgggctgcccagccgcgtcaagtgtggcagtccggggcagctccagggccatagcatc tttgcgcaagacctgcgcctctgcctggatgagaccctctcgtggaactgttttggc

- 13 -

SEQ ID NO:9 (Bovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIVTLAPEDLANLTALRVLDVGGNCRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSFGSLVSLEKLDMHGIFF
RSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLPR
GLAPGPLDAVSSKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD
LSHNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
RLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL
KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVA
LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWYYNELRVQLEERRGRRAL
RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPAAYRSR
YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNRHFYNRNFCRGPTTAE

SEQ ID NO:10 (Bovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGAPRANVTSLSLISNRIH

HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
HTSILVLGPTHFTGLHALRFLYMDGNCYYMNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSFGSLVSLEKLDMHGIFF
RSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFVDLSDNRISGAATPAAALGEVDSRVEVWRLPR

GLAPGPLDAVSSKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLD
LSHNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
RLEALDLAGNQLKALSNGSLPPGIRLQKLDVSSNSIGFVIPGFFVRATRLIELNLSANALKTVDPSWFGSLAGTL
KILDVSANPLHCACGAAFVDFLLERQEAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFG

SEQ ID NO:11 (Bovine TLR9)

30

35

40

45

50

gggaagtgggegecaagcatectteeetgeagetgecteccaacetgeeegecagaceetetggagaageegeat teestgteatgggecestastgtgcccegeacccetttetetetgstgcaggeggeggeactggcageggece tggccgagggcaccctgccttcctgccctgtgagctccagccccatggtcaggtggactgcaactggctgt tectgaagtetgtgeegeaetttteggetggageeeeeegggeeaatgteaeeageeteteettaateteeaaee $\tt gcatccaccttgcatgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtggaactgcc$ cgccggccggcctcagccccatgcacttcccctgccgtatqaccatcqaqcccaacaccttcctqqctqtqccca $\verb|tggacggcaactgctactacatgaacccctgcccggggccctggaggtggccccaggcgccctcctcggcctgg|$ gcaacctcacgcacctgtcgctcaagtacaacatctcacggaggtgccccgccgcctgccccccagcctggaca ccctgctgctgtcctacaaccacattgtcaccctggcacccgaggacctggccaacctgactgccctgcgcgtgc ttqacqtqqqtqqqaactgccgccgctgcgaccatgcccgcaacccctgcagggagtgcccaaagaacttcccca agctgcaccctgacaccttcagtcacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaac tagagaaagattqqttccqcqqcctqqqcagqctccaaqtqctcqacctqaqtqaqaacttcctctatqactaca tcaccaagaccaccatcttcaacqacctgacccagctqcqcaqactcaacctqtccttcaattaccacaaqaaqq tgtccttcgcccacctgcacctagcqtcctcctttgggagtctggtgtccctggagaagctggacatgcacggca tettetteegeteeeteaccaacateacgeteeagtegetqaeccggetqeecaaqetecaqaqtetqeatetqe agctgaacttcatcaaccaggcccagctcagcatcttttggggccttcccgagcctgctcttcgtggacctgtcgg acaaccgcatcagcggagccgcgacgccagcggccgccctggqqgaggtggacagcagggtgqaagtctqqcqat tgcccaggggcctcgctccaggcccgctggacgccgtcagctcaaaggacttcatgccaagctgcaacctcaact teacettggacetgteacggaacaacetggtgacaatceagcaagagatgtttaccegcetetecegcetecagt gcctgcgcctgagccacaacagcatctcgcaggcggttaatggctcccagttcgtgccgctgaccagcctgcgaq

tgetegaeetgteeeacaacaagetggaeetgtaeeatgggegeteatteaeggagetgeegeagetggaggeae tggaceteagetaeaacageeageeetteageatgeagggegtgggeeacaaeeteagettegtggeeeagetge cctccctgcgctacctcagccttgcgcacaatggcatccacagccgcgtgtcacagaagctcagcagcgcctcgt tgcgcgccctggacttcagcggcaactccctgagccagatgtgggccgaggggagacctctatctctgctttttca aaggettgaggaacetggtccagetggacetgtccgagaaceatetgcacaceeteetgcctcgtcacetggaca acctgcccaagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgaccg tcctgccccggctggaagccctggatctggcaggaaaccagctgaaggccctgagcaacggcagcctgccgcctg gcatccggctccagaagctggacgtgagcagcaacagcatcggcttcgtgatccccggcttcttcgtccgcgcga ctcggctgatagagcttaacctcagcgccaatgccctgaagacagtggatccctcctggttcggttccttagcag tggagagacaggaggccgtgcccgggctgtccaggcgcgtcacatgtggcagtccgggccagctccagggccgca gcatcttcacacaggacctgcgcctctgcctggatgagaccctctccttggactgcttttggcctctcactgctaa $\verb|tggtggcgctggcctggcagtgcccatgctgcaccacctctgtggctgggacctctggtactgcttccacctgt|$ gtctggcccatttgccccgacggcggcggcgggggggggaggacaccctgctctatgatgccgtcgtggtcttcg acaaggtgcagagtgcagtggctgattgggtgtacaacgagctccgcgtgcagctggaggagcgccgggggcgcc gggcgctccgcctctgcctggaggagcgagactggctccctggtaagacgctcttcgagaacctgtgggcctcgg ${\tt tctacagcagccgcaagaccatgttcgtgctggaccacacggaccgggtcagcggcctcctgcgcccagcttcc}$ tgctggcccagcagcgcctgttggaggaccgcaaggacgtcgtagtgctggtgatcctgcgccccgccgcctatc ggtcccgctacgtgcggctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagcccagtggcc agggtagtttctgggccaacctgggcatagccctgaccagggacaaccgtcacttctataaccggaacttctgcc ggggccccacgacagccgaatagcacagagtgactgcccag

SEQ ID NO:12 (Bovine TLR9)

20

atgggcccctactgtgccccgcaccccctttctctctctggtgcaggcggcgcactggcageggccctggccgag 25 ggcaccctgcctgccttcctgccctgtgagctccagccccatggtcaggtggactgcaactggctgttcctgaag ${\tt tetgtgccgcacttttcggctggagccccccgggccaatgtcaccagcctctccttaatctccaaccgcatccac}$ cacttgcatgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtggaactgcccgccggcc ggcctcagccccatgcacttcccctgccgtatgaccatcgagcccaacaccttcctggctgtgcccaccctggag 30 $\tt cacaccag catect ggt gct agg ccc cacct teac cgg cct gcac gcc tt gcg ctt tct gt a cat gg acgg ccc acccact to the composition of the composition$ aactgctactacatgaacccctgcccgcgggccctggaggtggccccaggcgccctcctcggcctgggcaacctc acgcacctgtcgctcaagtacaacaacctcacggaggtgccccgcctgcccccccagcctggacaccctgctg ctgtcctacaaccacattgtcaccctggcacccgaggacctggccaacctgactgccctgcgcgtgcttgacgtg ggtgggaactgeegecgetgegaceatgeeegeaaceeetgeagggagtgeeeaaagaaetteeeeaagetgeae 35 cctgacaccttcagtcacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaactagagaaa accaccatettcaacgacetgacccagetgegeagacteaacetgteettcaattaccacaagaaggtgteette gcccacctgcacctagcgtcctcctttgggagtctggtgtccctggagaagctggacatgcacggcatcttcttc cgctccctcaccaacatcacgctccagtcgctgacccggctgcccaagctccagagtctgcatctgcagctgaac ttcatcaaccaggcccagctcagcatctttggggccttcccgagcctgctcttcgtggacctgtcggacaaccgc atcageggageeggegecageggeegeettgggggggggtggacageagggtggaagtetggegattgeecagg ggcctcgctccaggcccgctggacgccgtcagctcaaaggacttcatgccaagctgcaacctcaacttcaccttg gacctgtcacggaacaacctggtgacaatccagcaagagatgtttacccgcctctcccgcctccagtgcctgcgc ctgagccacaacagcatctcgcaggcggttaatggctcccagttcgtgccgctgaccagcctgcgagtgctcgac ctgtcccacaacaagctggacctgtaccatgggcgctcattcacggagctgccgcagctggaggcactggacctc cgctacctcagccttgcgcacaatggcatccacagccgcgtgtcacagaagctcagcagcgcctcgttgcgcgcc ctggacttcagcggcaactccctgagccagatgtgggccgaggggagacctctatctctgctttttcaaaggcttg aggaacctggtccagctggacctgtccgagaaccatctgcacaccctcctgcctcgtcacctggacaacctgccc 50 aagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgaccgtcctgccc cggctggaagccctggatctggcaggaaaccagctgaaggccctgagcaacggcagcctgccgcctggcatccgg ctccagaagctggacgtgagcagcaacagcatcggcttcgtgatccccggcttcttcgtccgcgcgactcggctg atagagettaaceteagegeeaatgeeetgaagaeagtggateeeteetggtteggtteettageagggaeeetg aaaatcctagacgtgagcgccaacccgctccactgcgcctgcggggcggcctttgtggacttcctgctggagaga caggaggccgtgcccgggctgtccaggcgcgtcacatgtggcagtccgggccagctccagggccgcagcatcttc acacaggacctgcgcctctgcctggatgagaccctctccttggactgctttggc

- 15 -

SEQ ID NO:13 (Equine TLR9)

MGPCHGALOPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI HHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLIL SRTNILOLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYL 5 LLSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSFGSLLSLQELDMHGIF FRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS RDLTPGPLDTPSSEDFMPSCKNLSFTLDLSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV $\verb|LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCSTSL|$ 10 WALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNNYLAFFNWSSLTL LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRNSIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG SLEVLDVSANPLHCACGAAFVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGLSLLV VALGLAMPMLHHLCGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDKAQSAVADWVYNELRVRLEERRGRR ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDARR 15 SRYVRLRQRLCRQSVLFWPHQPSGQRSFWAQLGMALTRDNRHFYNQNFCRGPTMAE

SEO ID NO:14 (Equine TLR9)

MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAAPRDNVTSLSLLSNRI
HHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLIL
SRTNILQLDPTSLTGLHALRFLYMDGNCYYKNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYL
LLSYNHIVTLAPEDLANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN
PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSFGSLLSLQELDMHGIF
FRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYIDLSDNRISGAVEPVATTGEVDGGKKVWLTS
RDLTPGPLDTPSSEDFMPSCKNLSFTLDLSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQV
LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCSTSL
WALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLLRLRNNYLAFFNWSSLTL
LPNLETLDLAGNQLKALSNGSLPSGTQLQRLDVSRNSIIFVVPGFFALATRLRELNLSANALRTEEPSWFGFLAG
SLEVLDVSANPLHCACGAAFVDFLLQVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFG

SEQ ID NO:15 (Equine TLR9)

30

40

45

50

ctctqttctctgagctqttqccgcgtgaagggactgcgagcacaaagcatcctctctgcagctgcccagtg tgccagctggaccctctggatcatctcccactccctgtcatgggcccttgccatggtgccctgcagcccctgtct ctcctggtgcaggcggccatgctggccgtggctctggcccaaggcaccctgcctcccttcctgccctgtgagctc cagcccacggcctggtgaactgcaactggctgttcctgaagtccgtgcccacttctcagcagcagcaccccgg gacaatgtcaccagcctttccttgctctccaaccgcatccaccacctccacgactccgactttgcccaactgtcc aacctqcaqaaactcaacctcaaatggaactgcccgccagccggcctcagccccatgcacttcccctgccacatg accategageceaacaettteetggetgtaeceaecetggaggagetgaaectgagetaeaaeggeateaegaetgtgcctgccctgcccagctccctcgtgtccctgatcctgagccgcaccaacatcctgcagctagaccccaccagc acggtgccccgcagcctgccccctagcctggagtacctgctgttgtcctacaaccacattgtcaccctggcacct qaqqacctqqccaatctqactqccctqcqtqtqctcgatgtgggggaaactgccgccgctgtgaccatgcacgc aacccctgcgtggagtgcccacataaattcccccagctgcactccgacaccttcagccacctaaqccqcctaqaa ggcctcgtgttgaaggatagttctctctaccagctgaaccccagatggttccgtggcctgggcaacctcacagtg ctcgacctgagtgagaacttcctctacgactgcatcaccaaaaccaaggcattccagggcctggcccagctgcqa agactcaacttgtccttcaattaccataagaaggtgtccttcgcccacctgacgctggcaccctccttcgggagc gcccgcctgcccatgctccagcgtctgtatctgcagatgaacttcatcaaccaggcccagctcggcatcttcaag gacttccctggtctgcgctacatagacctgtcagacaaccgcatcagtggagctgtggagccggtggccaccaca ggggaggtggatggtgggaagaaggtctggctgacatccagggacctcactccaggcccactggacacccccagc tctgaggacttcatgccaagctgcaagaacctcagcttcaccttggacctgtcacggaacaacctggtaacagtc cagccagagatgtttgcccagctctcgcgcctccagtgcctgcgcctgagccacaacagcatctcgcaggcggtc

aatggctcacagttcgtgccactgaccagcctgcaggtgctggacctgtcccataacaaactggacctgtaccat ggtgtgggccacaacctcagctttgtggcccagctgcccaccctgcgctacctcagcctggcacacaatggcatc cacagccgtgtgtcccagcagctctgcagcacctcgctgtgggccctggacttcagcggcaattccctgagccag atgtgggctgagggagacctctatctccgcttcttccaaggcctgagaagcctaatccggctagacctgtcccag aatcgtctgcataccctcctgccatgcaccctgggcaacctccccaagagcttgcagctgctgcgtctccgtaac cagetgaaggetetgageaatggeageetgeettetggeaceeageteeagaggetggaegteageaggaacage atcatcttcgtggtccctggcttctttgctctggccacgaggctgcgagagctcaacctcagtgccaacgccctc aggacagaggagccctcctggtttggtttcctagcaggctcccttgaagtcctagatgtgagcgccaaccctctg cactgcgcctgtggggcagcctttgtggacttcctgctgcaggttcaggctgccgtgcctggtctgcccagccgc gtcaagtgtggcagtccgggccagctccagggccgcagcatcttcgcacaagacctgcgcctctgcctggacaag tecetetectgggaetgttttggteteteattgetggttgtggeeetgggeetggeeatgeetatgttgeaceae $\verb"ctctgcggctgggacctctggtactgcttccacctgggcctggcctggctgcccggcgggggtggcagcggggc$ geggatgeeetgagetatgatgeetttgtggtettegaeaaggeacagagegeagtggeegaetgggtgtaeaat gaactgegggtgeggetagaggagegeegtgggegeegggegeteegeetgtgtetggaggagegtgaetggeta cctggcaagacgctgttcgaaaacctgtgggcctcagtctacagcagccgcaagatgctgtttgtgctggcccac acqqaccaqqtcaqtqqcctcttqcqtqccaqcttcctqctqqcccaqcagcgtctgctgqaggaccgcaaggac gttgtggtgctggtaatcctgagccctgacgccgccgttcccgttacgtgcggctgcgccagcgcctctgccgc cagagtgtcctcttctggccccaccagcctagtggccagcgcagcttctgggcccagctaggcatggccctgacc agggacaaccgccacttctataaccagaacttctgccggggcccgacgatggctgagtagcacagagtgacagcc tggcatgtacaacccccagccctgaccttgcctctctgcctatgatgcccagtctgcctcactctgtgacgcccc tgctctgcctccgccaccctcacccctggcatacagcaggcactcaataaatgccactggcaggccaaacagcca aaaaaaaaaaaaa

25

20

10

SEQ ID NO:16 (Equine TLR9)

atgggcccttgccatggtgccctgcagcccctgtctctcctggtgcaggcggccatgctggccgtggctctggcc caaggcaccetgcctcccttcctgccctgtgagctccagccccacggcctggtgaactgcaactggctgttcctg aagtccgtgccccacttctcagcagcaccccgggacaatgtcaccagcctttccttgctctccaaccgcatc 30 caccacctccacgactccgactttgcccaactgtccaacctgcagaaactcaacctcaaatggaactgcccgcca geoggeoteagececatgeactteccetgecacatgaceategageceaacactttectggetgtacceaccetg agccgcaccaacatcctgcagctagaccccaccagcctcacgggcctgcatgccctgcgcttcctatacatggat ggcaactgctactacaagaacccctgcgggcgggccctggaggtggccccaggcgccctccttggcctgggcaac 35 ctcacccacctgtcactcaagtacaacatcacaacggtgccccgcagcctgccccctagcctggagtacctg ctgttgtcctacaaccacattgtcaccctggcacctgaggacctggccaatctgactgccctgcgtgtgctcgat gtgggtggaaactgccgccgctgtgaccatgcacgcaacccctgcgtggagtgcccacataaattcccccagctg cactcogacacettcagecacetaagecgectagaaggeetegtgttgaaggatagttetetetetaceagetgaae aaaaccaaggcattccagggcctggcccagctgcgaagactcaacttgtccttcaattaccataagaaggtgtcc ttccgctcactcagccagaagacgctccagccactggcccgcctgcccatgctccagcgtctgtatctgcagatg aacttcatcaaccaggcccagctcggcatcttcaaggacttccctggtctgcgctacatagacctgtcagacaac cgcatcagtggagctgtggagccggtggccaccacaggggaggtggatggtgggaagaaggtctggctgacatcc agggacctcactccaggcccactggacacccccagctctgaggacttcatgccaagctgcaagaacctcagcttc ctgcgcctgagccacaacagcatctcgcaggcggtcaatggctcacagttcgtgccactgaccagcctgcaggtg ctggacctgtcccataacaactggacctgtaccatgggcgctcgtttacggagctgccgcgactggaggccctg gacctcagctacaacagccagcccttcagcatgcggggtgtgggccacaacctcagctttgtggcccagctgccc 50 accetgegetaceteageetggeacacaatggeatecacageegtgtgteecageagetetgeageacetegetg tgggccctggacttcagcggcaattccctgagccagatgtgggctgagggagacctctatctccgcttcttccaa ggcctgagaagcctaatccggctagacctgtcccagaatcgtctgcataccctcctgccatgcaccctgggcaac etecceaagagettgeagetgetgegteteegtaacaattaeetggeettetteaattggageageetgaeeete 55 acccagetecagaggetggacgteageaggaacageateatettegtggtecetggettetttgetetggeeaeg aggctgcgagagctcaacctcagtgccaacgccctcaggacagaggagccctcctggttttggtttcctagcaggc tcccttgaagtcctagatgtgagcgccaaccctctgcactgcgcctgtggggcagcctttgtggacttcctgctg ${\tt caggttcaggctgccgtgcctggtctagcccagccgcgtcaagtgtggcagtccgggccagctccagggccgcagcatcttcgcacaagacctgcgcctctgcctggacaagtccctctcctgggactgttttggt\\$

SEQ ID NO:17 (Ovine TLR9)

5 MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
RTSILVLGPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK
DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF

10 RSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFVDLSDNRISGAARPVAALGEVDSGVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP
QLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTPGFFVLANRLKELNLSANALKTVDPFWFGRLTETL

15 NILDVSANPLHCACGAAFVDFLLEMQAAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFGFSLLMVA
LGLAVPMLHHLCGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSAVADWVYNELRVQLEERRGRRAL
RLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPAAYRSR
YVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNRHFYNRNFCRGPTTAE

20 SEQ ID NO:18 (Ovine TLR9)

MGPYCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGAPRANVTSLSLISNRIH
HLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFLAVPTLEELNLSYNGITTVPALPSSLVSLSLS
RTSILVLGPTHFTGLHALRFLYMDGNCYYKNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLL
LSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLEK

DWFRGLGRLQVLDLSENFLYDYITKTTIFRNLTQLRRLNLSFNYHKKVSFAHLQLAPSFGGLVSLEKLDMHGIFF
RSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFVDLSDNRISGAARPVAALGEVDSGVEVWRWPR
GLAPGPLAAVSAKDFMPSCNLNFTLDLSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTRLRVLD
LSYNKLDLYHGRSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSASLRA
LDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQLRLRDNNLAFFNWSSLTVLP

QLEALDLAGNQLKALSNGSLPPGTRLQKLDVSSNSIGFVTPGFFVLANRLKELNLSANALKTVDPFWFGRLTETL
NILDVSANPLHCACGAAFVDFLLEMQAAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFG

SEQ ID NO:19 (Ovine TLR9)

gtcggcacgggaagtgagcgccaagcatccttccctgcagctgccgcccaacttgcccgccagaccctctggaga agccgcattccctgccatgggcccctactgtgccccgcacccctttctctctggtgcaggcggcqqcqctggc aqcaqccctqqccaqqqcaccctqcctqccttcctgccctgtgagctccagccccggggtaaggtgaactgcaa ctqqctqttcctqaaqtctqtqccqcqcttttcgqccggagcccccggggccaatgtcaccagcctctccttaat ctccaaccgcatccaccacttgcacgactctgacttcgtccacctgtccaacctggggtcctcaacctcaagtg gaactgcccgccggccggcctcagccccatgcacttcccctgccgcatgaccatcgagcccaacaccttcctggc 40 atccctqtcqctqaqccqcaccagcatcctggtgctaggccccacccacttcaccggcctgcacgccctgcgctt tctgtacatggacggcaactgctactataagaacccctgccagcaggccgtggaggtggccccaggcgccctcct tggcctgggcaacctcacgcacctgtcgctcaagtacaacaacctcacggaggtgccccgccgcctgcccccag cctggacaccctgctgctgtcctacaaccacatcatcaccctggcacccgaggacctggccaatctgactgccct gcgtgtgcttgatgtgggcgggaactgccgccgctgcgaccacgcccgcaacccctgcagggagtgcccaaagaa cttccccaagctgcaccctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaggacagttctct tgactacatcaccaagaccaccatcttcaggaacctgacccagctgcgcagactcaacctgtccttcaattacca caagaaggtgtccttcgcccacctgcaactggcaccctcctttgggggcctggtgtccctggagaagctggacat gcacggcatcttcttccgctccctcaccaacaccacgctccggccgctgacccagctgcccaagctccagagtct gagtctgcagctgaacttcatcaaccaggccgagctcagcatctttggggccttcccgagcctgctcttcgtgga cctqtcqqacaaccqcatcagcggagctgcgaggccggtggccgccctcggggaggtggacagcggggtggaagt ctggcqqtqqcccaqqggcctcgctccaggcccgctggccgccgtcagcgcaaaggacttcatgccaagctgcaa

- 18 -

cctcaacttcaccttggacctgtcacggaacaacctggtgacgatccagcaggagatgtttacccgcctctcccg ectecagtgeetgegeetgageeacaacageatetegeaggeggttaatggetegeagttegtgeegetgaeeeg $\verb|cctgcgagtgctcgacctgtcctacaacaagctggacctgtaccatgggcgctcgttcacggagctgccgcagct|\\$ $\tt ggaggcactggacctcagctacaacagccagcccttcagcatgcagggcgtgggccacaacctcagcttcgtggc$ $\verb|ccagctgccgtccctgcgctacctcagccttgcgcacaacggcatccacagccgcgtgtcacagaagctcagcag|$ $\verb|cgcctcgctgcgccctggacttcagcggcaactccctgagccagatgtgggccgagggagacctctatctctg|$ cttcttcaaaggcttgaggaacctggtccagctggacctgtccaagaaccacctgcacaccctcctgcctcgtca cctggataacctgcccaagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcag cctgactgttctgccccagctggaagccctggatctggcgggaaaccagctgaaggccctgagcaacggcagcct ${\tt gccacctggcacccggctccagaagctggacgtgagcagcaacagcatcggctttgtgacccctggcttctttgt}$ ccttgccaaccggctgaaagagcttaacctcagcgccaacgccctgaagacagtggatcccttctggttcggtcg cttaacagagaccctgaatatcctagacgtgagcgccaacccgctccactgtgcctgcggggggcctttgtgga cttcctgctggagatgcaggcggtgcctgggctgtccaggcgcgtcacgtgtggcagtccgggccagctcca gggccgcagcatcttcgcacaggacctgcgcctctgcctggatgagaccctctccttggactgcttttggcttctc $\verb|gctgctaatggtggcctgggcctggcggtgcccatgctgcaccacctctgtggctgggacctgtggtactgctt|$ ccacctgtgtctggcccatttgccccgacggcggcggcagcggggggaggacaccctgctctacgatgccttcgt ggtcttcgacaaggcgcagagtgcagtggccgactgggtgtacaacgagctccgcgtgcagctggaggagcgccg $\verb|cgggcgccgggcgctccgcctctgcctggaagagagagactggctccctggcaagacgctcttcgagaacctgtg|$ ggcctcggtctacagcagccgtaagaccatgttcgtgctggaccacacggaccgggtcagtggcctcctgcgcgc cagetteetgetggeecageagegeetgttggaggacegeaaggatgtegtggtgetggtgateetgegeecege cgcctaccggtcccgctacgtgcggctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagcc cagtggccagggtagcttctgggccaacctgggcatggccctgaccagggacaaccgccacttctataaccggaa cttctgccggggccccacgacagccgaatagcacagagtgactgcccag

25 SEQ ID NO:20 (Ovine TLR9)

10

20

atgggcccctactgtgccccgcacccctttctctctctggtgcaggcggcggcggctggcagccctggcccag ggcaccctgcctgccttcctgccctgtgagctccagccccggggtaaggtgaactgcaactggctgttcctgaag $\verb|tctgtgccgcgcttttcggccggagcccccgggccaatgtcaccagcctctccttaatctccaaccgcatccac|$ cacttgcacgactctgacttcgtccacctgtccaacctgcgggtcctcaacctcaagtggaactgcccgccggcc ggceteagececatgeaettececetgeegeatgaecategageceaacacettectggetgtgeecacectggag cgcaccagcatcctggtgctaggccccacccacttcaccggcctgcacgccctgcgctttctgtacatggacggc aactgctactataagaacccctgccagcaggccgtggaggtggccccaggcgccctccttggcctgggcaacctc acgcacctgtcgctcaagtacaaccacctcacggaggtgccccgccgcctgcccccagcctggacaccctgctg $\verb|ctgtcctacaaccacatcatcaccctggcacccgaggacctggccaatctgactgccttgcgtgtgcttgatgtg|\\$ 35 ggcgggaactgccgccgctgcgaccacgcccgcaacccctgcagggagtgcccaaagaacttccccaagctgcac cctgacaccttcagccacctgagccgcctcgaaggcctggtgttgaaggacagttctctctacaaactagagaaa accaccatcttcaggaacctgacccagctgcgcagactcaacctgtccttcaattaccacaagaaggtgtccttc ${\tt gcccacctgcaactggcaccctcctttgggggcctggtgtccctggagaagctggacatgcacggcatcttcttc}$ cgctccctcaccaacaccacgctccggccgctgacccagctgcccaagctccagagtctgagtctgcagctgaac ttcatcaaccaggccgagctcagcatctttggggccttcccgagcctgctcttcgtggacctgtcggacaaccgc atcageggagetgegaggeeggtggeegeeteggggaggtggacageggggtggaagtetggeggtggeeeagg $\verb|ggcctcgctccaggccgccgtcagcgcaaaggacttcatgccaagctgcaacctcaacttcaccttg|$ $\tt gacctgtcacggaacaacctggtgacgatccagcaggagatgtttacccgcctctccggcctccagtgcctgcgc\\$ $\verb|ctgagccacaacagcatctcgcaggctgatctcgcagttcgtgccgctgacccgcctgcgagtgctcgac| \\$ $\verb|ctgtcctacaacaagctggacctgtaccatgggcgctcgttcacggagctgccgcagctggaggcactggacctc|\\$ ${\tt agctacaaccagccagcccttcagcatgcagggcgtgggccacaacctcagcttcgtggcccagctgccgtccctg}$ $\verb|cgctacctcagcettgcgcacaacggcatccacagccgcgtgtcacagaagctcagcagcgcctcgctgcgcgcc|\\$ 50 $\verb|ctggacttcageggcaactcctgagccagatgtgggccgagggagacctctatctctgcttcttcaaaggcttg|\\$ ${\tt aggaacctggtccagctggacctgtccaagaaccacctgcacacctcctgcctcgtcacctggataacctgccc}$ ${\tt aagagcctgcggcagctgcgtctccgggacaataacctggccttcttcaactggagcagcctgactgttctgccc}$ $\verb|cagctggaagccctgagcagcctgagcagcctgagcagcctgagcagcctggcacctggcacccgg| \\$ $\verb|ctccagaagctggacgtgagcagcaacagcatcggctttgtgacccctggcttctttgtccttgccaaccggctg|$ 55 aaagagettaaeeteagegeeaaegeeetgaagaeagtggateeettetggtteggtegettaaeagagaeeetg aatateetagaegtgagegeeaaceegeteeactgtgeetgeggggeggeetttgtggaetteetgetggagatg

- 19 -

caggcggccgtgcctgggctgtccaggcgcgtcacgtgtggcagtccgggccagctccagggccgcagcatcttcgcacaggacctgcgcctctgcctggatgagaccctctccttggactgctttggc

Complete nucleotide and amino acid sequences for canine and feline TLR9 are publicly available. For example, an amino acid sequence for canine TLR9 is available as GenBank accession number BAC65192 and its corresponding nucleotide sequence is available as GenBank accession number AB104899. An amino acid sequence for feline TLR9 is available as GenBank accession number AAN15751 and its corresponding nucleotide sequence is available as GenBank accession number AY137581.

Complete nucleotide and amino acid sequences for canine and feline TLR9 were also determined independently from those available from public databases.

An amino acid sequence of canine TLR9 is provided as SEQ ID NO:21. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:21 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of canine TLR9 (See Figure 1). Amino acids numbered 1-822 of SEQ ID NO:21 are presumptively extracellular domain and correspond to SEQ ID NO:22. SEQ ID NO:23 is a nucleotide sequence of canine TLR9 cDNA having an open reading frame corresponding to nucleotides 91-3186. SEQ ID NO:24 is a nucleotide sequence of canine cDNA encoding amino acids 1-822 of SEQ ID NO:21.

An amino acid sequence of feline TLR9 is provided as SEQ ID NO:25. Based on comparison with known amino acid sequences of human and murine TLR9, it appears that SEQ ID NO:25 includes sequence for at least a majority of the extracellular domain, all of the transmembrane domain, and at least a portion of the intracellular domain of feline TLR9 (See Figure 1). Amino acids numbered 1-820 of SEQ ID NO:25 are presumptively extracellular domain and correspond to SEQ ID NO:26. SEQ ID NO:27 is a nucleotide sequence of feline TLR9 cDNA having an open reading frame corresponding to nucleotides 87-3179. SEQ ID NO:28 is a nucleotide sequence of feline cDNA encoding amino acids 1-820 of SEQ ID NO:25.

30

10

15

20

25

SEQ ID NO:21 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRI HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL SRTNILVLDPATLAGLYALRFLFLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL

- 20 -

LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRLNLSFNYHKKVSFAHLHLASSFGSLLSLQELDIHGIF FRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYVDLSDNRISGAAEPAAATGEVEADCGERVWP QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA SLRALDFSGNTLSQMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSSL ALLPKLEALDLAGNQLKALSNGSLPNGTQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFSLSL LAVALSLAVPMLHQLCGWDLWYCFHLCLAWLPRRGRRRGVDALAYDAFVVFDKAQSSVADWVYNELRVQLEERRG RRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILCPDA HRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNRHFYNQNFCRGPTTA

SEQ ID NO:22 (Canine TLR9)

MGPCRGALHPLSLLVQAAALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAAPRGNVTSLSLYSNRI
HHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFLAVPTLEDLNLSYNSITTVPALPSSLVSLSL
SRTNILVLDPATLAGLYALRFLFLDGNCYYKNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYL
LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD
PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRLNLSFNYHKKVSFAHLHLASSFGSLLSLQELDIHGIF
FRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYVDLSDNRISGAAEPAAATGEVEADCGERVWP
QSRDLALGPLGTPGSEAFMPSCRTLNFTLDLSRNNLVTVQPEMFVRLARLQCLGLSHNSISQAVNGSQFVPLSNL
RVLDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA
SLRALDFSGNTLSQMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLLRLRDNYLAFFNWSSL
ALLPKLEALDLAGNQLKALSNGSLPNGTQLQRLDLSGNSIGFVVPSFFALAVRLRELNLSANALKTVEPSWFGSL
AGALKVLDVTANPLHCACGATFVDFLLEVQAAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFS

25

30

35

45

50

55

10

SEQ ID NO:23 (Canine TLR9)

gccctggccctggcccagggcaccctgcctgccttcctgccctgtgagctccagcccatggcctggtgaactgc ${\tt aactggctgttcctcaagtccgtgccccgcttctcggcagctgcaccccgcggtaacgtcaccagcctttccttg}$ tactccaaccgcatccaccacctccatgactatgactttgtccacttcgtccacctgcggcgtctcaatctcaaq tggaactgcccgcccgccagcctcagccccatqcactttccctqtcacatqaccattqaqcccaacaccttcctq gtgtccctqtccctqaqccqcaccaacatcctqqtqctqqaccctqccaccctqqcaqqcctttatqccctqcqc tteetgtteetggatggeaactgetaetaeaagaacccetgeeageaggeectgeaggtggeeceaqqtqeecte ctgggcctgggcaacctcacacacctgtcactcaagtacaacaacctcaccgtggtgccgcggggcctgccccc agcctggagtacctgctcttgtcctacaaccacatcatcaccctggcacctgaggacctggccaatctgactgcc ctgcgtgtcctcgatgtgggtgggaactgtcgccgctgtgaccatgcccgtaacccctgcagggagtgccccaag ggcttcccccagctgcaccccaacaccttcggccacctgagccacctcgaaggcctggtgttgagggacagctct ctctacagcctggaccccaggtggttccatggcctgggcaacctcatggtgctggacctgagtgaqaacttcctq tatgactgcatcaccaaaaccaaagccttctacggcctggcccggctgcgcagactcaacctgtccttcaattat cataagaaggtgtcctttgcccacctgcatctggcatcctccttcgggagcctactgtccctgcaggagctggac atacatggcatcttcttccgctcgctcagcaagaccacgctccagtcqctqqcccacctqcccatqctccaqcqt ctgcatctgcagttgaactttatcagccaggcccagctcagcatcttcgqcgccttccctqqactqcqgtacqtq gacttgtcagacaaccgcatcagtggagctgcagagcccgcggctgccacaggggaggtagaggcagactgtggg gagagagtetggccacagtcccgggacettgctctgggcccactgggcacccccggctcagaggccttcatgccg agctgcaggaccctcaacttcaccttggacctgtctcggaacaacctagtgactgttcagccggagatgtttgtc cggctggcgcgcctccagtgcctgggcctgagccacaacagcatctcgcaggcggtcaatqqctcqcagttcqtq cctctgagcaacctgcgggtgctggacctgtcccataacaagctggacctgtaccacgggcqctcgttcacggaq ctgccgcggctggaggccttggacctcaqctacaacaqccaqcccttcaqcatqcqqqqcqtqqqccacaatctc agetttgtggcacagetgecageeetgeqetaceteaqeetqqeqcacaatqqcatecacagegqqqtqteccag cageteegeagegeetegeteegggeeetggaetteagtggcaataceetgagecagatgtgggeegagggagae ctctatctccgcttcttccaaggcctgagaagcctggttcaqctqqacctqtcccaqaatcqcctqcataccctc ctgccacgcaacctggacaacctccccaagagcctgcggctcctgcqqctccgtgacaattacctqqctttcttc $\verb|aactggagcagccttggccctcctacccaagcttggaagcccttggaccttggcgggaaaccagctgaaggccctgagc|$

- 21 -

aatggcagettgcccaacggcacccagetccagaggctggacctcagcggcaacagcatcggcttcgtggtcccc agcttttttgccctggccgtgaggcttcgagagctcaacctcagcgccaacgccctcaagacggtggagccctcc tggtttggttccctggcgggtgccctgaaagtcctagacgtgaccgccaaccccttgcattgcgcttgcggcgca ggccagctccagggccgcagcatcttcgcacaggacctgcgcctctgcctggacgaagcgctctcctgggtctgt ttcagcctctcgctgctgtggccctgagcctqqctqtqcccatgctqcaccaqctctqtqqctqqqacctc tggtactgettccacctgtgcctggcctggctgcccqqcqqqggcgqcqqqqqtqtqqatqccctqqcctat gacgccttcgtggtcttcgacaaggcgcagagctcggtggcggactgggtgtacaatgagctgcgggtacagcta gaggagegeegtgggegeegggegetaegeetgtgtetggaggaacgtgaetgggtaeceggcaaaaecetette gagaacctctgggcctcagtttacagcagccgcaagacgctgtttgtgctggcccgcacggacagagtcagcggc ctcctgcgtgccagcttcctgctggcccaacagcgcctgctggaggaccgcaaggacgtcgtggtgctggtgatc $\verb|ctgtgccccgacgcccaccgctcccgctatgtgcggctgcgccagcgcctctgccgccagagtgtcctcctctgg|$ $\verb|ccccaccagcccagtggccagcttctgggcccagctgggcacggccctgaccagggacaaccgccacttc| \\$ tacaaccagaacttctgccggggccccacgacagcctgataggcagacagcccagcaccttcgcqcccctacacc ctgcctgtctgtctgggatgcccgacctgctggctctacaccgccgctctgtctcccctacacccaqccctgqca taaagcgaccgctcaataaatgctgctggtagac

SEQ ID NO:24 (Canine TLR9)

5

10

15

55

 $\verb|atgggcccctgccgtggcgccctgcacccctgtctctcctggtgcaggctgccgcgctagccctggccctggcc|$ 20 $\verb|cagggcaccctgcctgcctgcctgtgagctccagccccatggcctggtgaactgcaactggctgttcctc|$ aagtccgtgccccgcttctcggcagctgcaccccgcggtaacgtcaccagcctttccttgtactccaaccgcatc gccagcctcagccccatgcactttccctgtcacatgaccattgagcccaacaccttcctggctgtqcccacccta gaggacctgaatctgagctataacagcatcacqactqtqcccqcctqcccaqttcqcttqtqtccctqtccctq 25 agccgcaccaacatcctggtgctggaccctgccaccctggcaggcctttatgccctgcgcttcctgttcctggat ggcaactgctactacaagaacccctgccagcaggccctgcaggtggccccaggtgccctcctgggcctgggcaac ctcacacacctgtcactcaagtacaacaacctcaccgtggtgccgggggcctgcccccagcctggagtacctg ctcttgtcctacaaccacatcatcaccctggcacctgaggacctggccaatctgactgccctgcgtgtcctcgat gtgggtgggaactgtcgccgctgtgaccatgcccgtaacccctgcagggagtgccccaagggcttcccccagctg 30 aaaaccaaagccttctacggcctggcccggctgcgcagactcaacctgtccttcaattatcataagaaggtqtcc ttccgctcgctcagcaagaccacgctccagtcgctggcccacctgcccatgctccagcgtctgcatctgcagttg 35 aactttatcagccaggcccagctcagcatcttcggcgccttccctggactgcggtacgtggacttqtcagacaac cgcatcagtggagctgcagagcccgcggctgccacaggggaggtagaggcagactgtggggagagagtctggcca cagtcccgggaccttgctctgggcccactgggcaccccggctcagaggccttcatgccgagctgcaggaccctc aacttcaccttggacctgtctcggaacacctagtgactgttcagccggagatgtttgtccggctggcgcctc $\verb|cagtgcctgagcctcacaacagcatctcgcaggcggtcaatggctcgcagttcgtgcctctgagcaacctg|$ 40 cgggtgctggacctgtcccataacaagctggacctgtaccacgggcgctcqttcacqqaqctqccqcqqctqqaq gccttggacctcagctacaacagccagcccttcagcatgcggggggtgggccacaatctcagctttgtggcacag $\verb|ctgccagccetgcgctacctcagcctggcgcacaatggcatccacagccgcgtgtcccagcagctccgcagcgcc|\\$ tcgctccgggccctggacttcagtggcaataccctgagccagatgtgggccgaggggagacctctatctccgcttc ttccaaggcctgagaagcctggttcagctggacctgtcccagaatcgcctgcataccctcctgccacgcaacctg 45 gacaaceteeccaagageetgeggeteetgeggeteegtgacaattaeetggetttetteaaetggageageetg gccctcctacccaagctggaagccctggacctggcgggaaaccagctgaaggccctgagcaatggcagcttgccc aacggcacccagetccagaggctggacctcagcggcaacagcatcggcttcgtggtccccagctttttttgccctg gcgggtgccctgaaagtcctagacgtgaccgccaaccccttgcattgcgcttgcggcgcaaccttcgtggacttc 50 ttgctggaggtgcaggctgcggtgcccggcctgcctagccgtgtcaagtgcggcagcccgggccagctccaggqc cgcagcatcttcgcacaggacctgcgcctctgcctggacgaagcgctctcctgggtctgtttcagc

SEQ ID NO:25 (Feline TLR9)

MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRI HHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTVPALPSSLVSLSL SRTNILVLDPANLAGLHSLRFLFLDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYL LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF FRSLSETTLRSLVHLPMLQSLHLQMNFINQAQLSIFGAFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS GDLALGPPGTPSSEGFMPGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCLLLSRNSISQAVNGSQFMPLTSLQV LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASL RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL LPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG TLKVLDVTGNPLHCACGAAFVDFLLEVQAAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFGLSLLT VALGLAVPMLHHLCGWDLWYCFHLCLAWLPRRGRRRGADALPYDAFVVFDKAQSAVADWVYNELRVRLEERRGRR ALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILRPDAHR SRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNQHFYNQNFCRGPTTAE

SEQ ID NO:26 (Feline TLR9)

10

30

35

50

55

MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAAPRGNVTSLSLYSNRI HHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFLAVPTLEELNLSYNSITTVPALPSSLVSLSL SRTNILVLDPANLAGLHSLRFLFLDGNCYYKNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYL LLSYNHIITLAPEDLANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSFGSLLSLQQLDMHGIF FRSLSETTLRSLVHLPMLQSLHLQMNFINQAQLSIFGAFPGLRYVDLSDNRISGAMELAAATGEVDGGERVRLPS GDLALGPPGTPSSEGFMPGCKTLNFTLDLSRNNLVTIQPEMFARLSRLQCLLLSRNSISQAVNGSQFMPLTSLQV LDLSHNKLDLYHGRSFTELPRLEALDLSYNSQPFSMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSASL RALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLLRLRDNYLAFFNWSSLVL LPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVASSFFALATRLRELNLSANALKTVEPSWFGSLAG TLKVLDVTGNPLHCACGAAFVDFLLEVQAAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFG

SEQ ID NO:27 (Feline TLR9)

agggtctgcgagctccaqqcattcttctctgccatcgctgcccaqtctqccatccaqaccctctqqaqaaqccc tggccctggcccagggcaccctgcctgcctttctgccctgtgagctccagcgccacggcctggtgaattgcgact ggctgttcctcaagtccgtgcccacttctcggcggcagcgcccgtggtaacgtcaccagcctttccctgtact ccaaccgcatccacctccacqactccqactttgtccacctqtccaqcctqcqqcqtctcaacctcaaatqqa actgcccacccgccagcctcagccccatgcacttcccctgtcacatgaccattgagccccacaccttcctggccg tgcccaccctggaggagctgaacctgagctacaacagcatcacgacagtacccgccctgcccagttccctcgtqt ccctgtccttgagccgtaccaacatcctggtgctggaccctgccaacctcgcagggctgcactccctgcgctttc tqttcctqqatqqcaactqctactacaaqaacccctqccqcaqqccctqcaqqtqqcccqqqqccctccttq gcctgggcaaccttacgcacctgtcactcaagtacaaccacctcactgcggtgccccgcqgcctgcccccaqcc tggagtacctgctattgtcctacaaccacatcatcaccctgqcacctgaggacctggccaacctgaccgccctqc gtgtgctcgatgtgggggggggggggccgctgtgtgaccacgcccgcaacccctgtatggagtgccccaagggct tecegeacetgeaceetgacacetteageeacetgaaceacetegaaggeetggtgtaaggacagetetetet actgcatcaccaaaaccacagccttccagggcctggcccaqctgcqcaqactcaacttgtctttcaattaccaca aqaaqqtqtcctttqcccacctqcatctqqcqccctccttcqqqaqcctqctctccctqcaqcaqctqqacatqc atggcatettetteeqetegeteagegagaccaegeteeggtegetggteeacetgeeeatgeteeagagtetge acctgcaqatqaacttcatcaatcaqqcccaqctcaqcatcttcqqqqqccttccctqqcctqcqatacqtqqacc tqtcaqacaaccqcataaqtqqaqccatqqaqctqqcqqctqccacqqqqqaqqtqqatqqtqqqqqqaqaqatcc qqctqccatctqqqqacctaqctctqqqcccaccqqqcacccctaqctccqaqqqcttcatqccaqqctqcaaqa gcctgcaggtgctggacctgtcccataacaagctggacctgtaccatgggcgctctttcacggagctgccgcggc tggaggccctggacctcagctacaacagccagcccttcagcatgcagggcgtgggtcacaacctcagctttgtgg $\verb|cacagctgccggccctgcgctatctcagcctggcgcacaacgacatccacagccgtgtgtcccagcagctctgca|\\$ gcqcctcgctgcgggccttggacttcagcgqcaatgccttqaqccqqatqtqqqccqagggaqacctqtatctcc acttetteegaggeetgaggageetggteeggttggatetqteecaqaategeetgcataceetettgeeacqea ccctggacaacctccccaagagcctgcggctgctgcgtctccgtgacaattatctggctttcttcaactggaqca

 $\tt gcctggtcctcctccccaggctggaagcctggacctggcgggaaaccagctgaaggccctgagcaacggcagct$ tgcctaatggaacccagctccagaggctggacctcagcagcaacagtatcagcttcgtggcctccagcttttttg $\verb|ctctggccaccaggctgcgagagctcaacctcagtgccaacgccctcaagacggtggagccctcctggttcggtt|\\$ ctctagcgggcaccctgaaagtcctagatgtgactggcaaccccttgcactgcgcctgtgggggggccttcqtqq $\verb|acttcttgctggaggtgcaggctgcagtgccggcctgccaggccacgtcaagtgtggcagtccaggtcagctcc| \\$ agggccgcagcatctttgcgcaggatctgcgcctctgcctggatgaggccctctcctgggactgttttggcctct $\verb|cgctgctgaccgtggccttggccgtgcccatgctgcaccacctctgtggctgggacctctggtactgct|\\$ tggtcttcgacaaggcacagagcgcggtggccgactgggtgtacaacgagctgcgggtacggctagaggagcgcc gtggacgccgagcgctccgcctgtgcctggaggaacgtgactggctacccggtaaaacgctctttgagaacctqt ccagctttctgctggcccagcagcgcctgctggaggaccgcaaggacgttgtggtgctggtgatcctgcgccccg acgcccaccgctcccgctatgtgcggctgcgccagcgcctctgccgccagagcgtcctcctctggccccaccagc ccagtggccagcgcagcttctgggcccagctgggcacggccctgaccagggacaaccagcacttctataaccaga acttctgccggggccccacgacggcagagtgaccgcccagcaccccaagcctcctacaccttgcctgtctgcctg ggatgccggg

SEQ ID NO:28 (Feline TLR9)

5

10

15

atgggcccctgccatggcgccctgcaccccctgtctctcctggtgcaggctgccgcgctggccgtggccctggcc 20 $\verb|cagggcaccctgcctgcctgtgagctccagcgccacggcctggtgaattgcgactggctgttcctc|\\$ ${\tt aagtccgtgccccacttctcggcggcagcgcccgtggtaacgtcaccagcctttccctgtactccaaccgcatc}$ caccacctccacgactttgtccacctgtccagcctgcggcgtctcaacctcaaatggaactgcccaccc gccagcctcagcccatgcacttcccctgtcacatgaccattgagcccacaccttcctggccgtgcccaccctg gaggagetgaacetgagetacaacagcatcacgacagtacccgccctgcccagttccctcgtgtccctgtccttg 25 agecgtaccaacatcctggtgctggaccctgccaacctcgcagggctgcactccctgcgctttctgttcctggat ggcaactgctactacaagaacccctgcccgcaggccctgcaggtggccccgggcgccctccttggcctgggcaac cttacgcacctgtcactcaagtacaaccacctcactgcggtgccccgcggcctgcccccagcctggagtacctq $\verb|ctattgtcctacaaccaccatcatcaccctggcacctgaggacctggccaacctgaccgccctgcgtgtgctcgat|\\$ gtgggtgggaactgccgtcgctgtgaccacgcccgcaacccctgtatggagtgccccaagggcttcccgcacctg 30 $\verb|cccagatggttccatgccetgggcaacctcatggtgctggacctgagtgagaacttcctatatgactgcatcacc|$ aaaaccacagccttccagggcctggcccagctgcgcagactcaacttgtctttcaattaccacaagaaggtgtcc $\verb|ttccgctcagcgagaccacgctccggtcgctggtccacctgcccatgctccagagtctgcacctgcagatg|$ ${\tt aacttcatcaatcaggcccagctcagcatcttcggggccttccctggcctgcgatacgtggacctgtcagacaac}$ ggggacctagctctgggcccaccgggcacccctagctccgagggcttcatgccaggctgcaagaccctcaacttc ctgctcctgagccgcaacagcatctcgcaggcagtcaacggctcacaatttatgccgctgaccagcctgcaggtg 40 ctggacctgtcccataacaagctggacctgtaccatgggcgctctttcacggagctgccgcggctggaggccctg gaceteagetacaacagecagecetteageatgeagggegtgggtcacaaceteagetttgtggcacagetgeeg gccctgcgctatctcagcctggcgcacaacgacatccacagccgtgtgtcccagcagctctgcagcgcctcqctq cgggccttggacttcagcggcaatgccttgagccggatgtgggccgagggagacctgtatctccacttcttccga ggcctgaggagcctggtccggttggatctgtcccagaatcgcctgcataccctcttgccacgcaccctggacaac 45 ctccccaagagcctgcggctgctgcgtctccgtgacaattatctggctttcttcaactggagcagcctggtcctc ctccccaggctggaagccctggacctggcgggaaaccagctgaaggccctgagcaacggcagcttgcctaatqqa acccagetecagaggetggaceteageageaacagtateagettegtggeetecagetttttttgetetggeeace accetgaaagteetagatgtgaetggeaaceceetgeaetgegeetgtggggggggeettegtggaettettgetg 50 gaggtgcaggctgcagtgcccggcctgccaggccacgtcaagtgtggcagtccaggtcagctccagggccgcagc ${\tt atctttgcgcaggatctgcgcctctgcctggatgaggccctctcctgggactgttttggc}$

Complete nucleotide and amino acid sequences for murine and human TLR9 are publicly available. For example, an amino acid sequence of murine TLR9 is available as

GenBank accession no. AAK29625, provided as SEQ ID NO:29. Amino acids numbered 1-821 of SEQ ID NO:29 presumptively include the entire extracellular domain and correspond to SEQ ID NO:30. SEQ ID NO:31 corresponds to GenBank accession number AF348140, which is a nucleotide sequence of murine TLR9 cDNA. SEQ ID NO:32 is a nucleotide sequence of murine cDNA encoding amino acids 1-821 of SEQ ID NO:29.

An amino acid sequence of human TLR9 is available as GenBank accession no. AAF78037, provided as SEQ ID NO:33. Amino acids numbered 1-820 of SEQ ID NO:33 presumptively include the entire extracellular domain and correspond to SEQ ID NO:34. SEQ ID NO:35 corresponds to GenBank accession number AF245704, which is a nucleotide sequence of human TLR9 cDNA. SEQ ID NO:36 is a nucleotide sequence of human cDNA encoding amino acids 1-820 of SEQ ID NO:33.

SEQ ID NO:29 (Murine TLR9)

10

MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAASCSNITRLSLISNRI 15 HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPLHFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL SHTNILVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTPGALLGLSNLTHLSLKYNNLTKVPRQLPPSLEYL LVSYNLIVKLGPEDLANLTSLRVLDVGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGLVLKDSSLHTLN SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRKLNLSFNYRKKVSFARLHLASSFKNLVSLQELNMNGIF FRSLNKYTLRWLADLPKLHTLHLOMNFINOAOLSIFGTFRALRFVDLSDNRISGPSTLSEATPEEADDAEOEELL 20 SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLOCLSLSHNSIAOAVNGSOFLPLTNLO VLDLSHNKLDLYHWKSFSELPQLQALDLSYNSQPFSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSLS FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV $\verb|MNLTVLDVRSNPLHCACGAAFVDLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLL|$ AVAVGMVVPILHHLCGWDVWYCFHLCLAWLPLLARSRRSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEERRG 25 RRALRLCLEDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDRVSGLLRTSFLLAQQRLLEDRKDVVVLVILRPDA HRSRYVRLRQRLCRQSVLFWPQQPNGQGGFWAQLSTALTRDNRHFYNQNFCRGPTAE

SEQ ID NO:30 (Murine TLR9)

30 MVLRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWLFLKSVPRFSAAASCSNITRLSLISNRI
HHLHNSDFVHLSNLRQLNLKWNCPPTGLSPLHFSCHMTIEPRTFLAMRTLEELNLSYNGITTVPRLPSSLVNLSL
SHTNILVLDANSLAGLYSLRVLFMDGNCYYKNPCTGAVKVTPGALLGLSNLTHLSLKYNNLTKVPRQLPPSLEYL
LVSYNLIVKLGPEDLANLTSLRVLDVGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGLVLKDSSLHTLN
SSWFQGLVNLSVLDLSENFLYESINHTNAFQNLTRLRKLNLSFNYRKKVSFARLHLASSFKNLVSLQELNMNGIF

FRSLNKYTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFVDLSDNRISGPSTLSEATPEEADDAEQEELL
SADPHPAPLSTPASKNFMDRCKNFKFTMDLSRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQ
VLDLSHNKLDLYHWKSFSELPQLQALDLSYNSQPFSMKGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLNSNS
VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLSLRDNYLSFFNWTSLS
FLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPAFFALAVELKEVNLSHNILKTVDRSWFGPIV
40 MNLTVLDVRSNPLHCACGAAFVDLLLEVQTKVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFG

SEO ID NO:31 (Murine TLR9)

aagceteatggeetggtggaetgeaattggetgtteetgaagtetgtaeceegtttetetgeggeageateetge tecaacateaceegeeteteettgateteeaacegtateeaceacetgeacaaeteegaettegteeacetgtee aacetgeggeagetgaaceteaagtggaactgteeacecactggeettageeectgeacttetettgeeacatg accattgagcccagaaccttcctggctatgcgtacactggaggagctgaacctgagctataatggtatcaccact 5 gtgccccgactgcccagctccctggtgaatctgagcctgagccacaccaacatcctggttctagatgctaacagc ctcgccggcctatacagcctgcgcgttctcttcatggacgggaactgctactacaagaacccctgcacaqqaqcq gtgaaggtgaccccaggcgccctcctgggcctgagcaatctcacccatctgtctctgaagtataacaacctcaca aaggtgccccgccaactgcccccagcctggagtacctcctggtgtcctataacctcattgtcaagctggggcct 10 $\verb| aatccctgtatagaatgtggccaaaagtccctccacctgcaccctgagaccttccatcacctgagccatctggaa| \\$ $\verb|ggcctggtgctgaaggacagctctctccatacactgaactcttcctggttccaaggtctggtcaacctctcggtg|$ ctggacctaagcgagaactttctctatgaaagcatcaaccaccactgcctttcagaacctaacccgcctgcgc ${\tt aagctcaacctgtccttcaattaccgcaagaaggtatcctttgcccgcctccacctggcaagttccttcaagaac}$ 15 gccgatctgcccaaactccacactctgcatcttcaaatgaacttcatcaaccaggcacagctcagcatctttggt $\verb|accttccgagcccttcgctttgtggacttgtcagacaatcgcatcagtgggccttcaacgctgtcagaagccacc| \\$ $\verb|cctgaagaggcagatgatgcagaggaggtgttgtctgcggatcctcacccagctccactgagcacccct| \\$ gcttctaagaacttcatggacaggtgtaagaacttcaagttcaccatggacctgtctcggaacaacctggtgact atcaagccagagatgtttgtcaatctctcacgcctccagtgtcttagcctgagccacaactccattgcacaggct 20 gtcaatggctctcagttcctgccgctgactaatctgcaggtgctggacctgtcccataacaaactqqacttqtac aagggtataggccacaatttcagttttgtggcccatctgtccatgctacacagccttagcctggcacacaatgac attcatacccgtgtgtcctcacatctcaacagcaactcagtgaggtttcttgacttcagcggcaacggtatgggc $\verb|cgcatgtgggatgaggggggcctttatctccatttcttccaaggcctgagtggcctgctgaagctggacctgtct|\\$ 25 caaaataacctgcatatcctccggccccagaaccttgacaacctccccaagagcctgaagctgctgagcctccga aaccagctaaaggccctgaccaatggcaccctgcctaatggcaccctcctccagaaactggatgtcagcagcaac agtategtetetgtggteceageettettegetetggeggtegagetgaaaqaqqteaaceteaqeeacaacatt ctcaagacggtggatcgctcctggtttgggcccattgtgatgaacctgacagttctagacgtgagaagcaaccct 30 $\verb|ctgcactgtgcctgtggggcagccttcgtagacttactgttggaggtgcagaccaaggtgcctggcctagtaat| \\$ ggtgtgaagtgtggcagccccggccagctgcagggccgtagcatcttcgcacaggacctgcggctgtgcctggat gaggtcctctcttgggactgctttggcctttcactcttggctgtggccgtgggcatggtggtgcctatactgcac catctctgcggctgggacgtctggtactgttttcatctgtgcctggcatggctacctttgctggcccgcagccga $\verb|cgcagcgcccaag| \verb|ctcccctatgatgccttcgtggtgttcgataaggcacagagcgcagttgcggactgggtg| \\$ 35 tataacgagctgcgggtgcggctggaggagcgggcgcggtcgccgagccctacgcttgtgtctggaggaccgagat tggctgcctggccagacgctcttcgagaacctctgggcttccatctatgggagccgcaagactctatttqtqctq gcccacacggaccgcgtcagtggcctcctgcgcaccagcttcctgctqqctcaqcaqcqcctqttqqaaqaccqc aaggacgtggtggtggtggtgatcctgcgtccggatgcccaccgctcccgctatgtgcgactgcgccagcgtctc tgccgccagagtgtgctcttctggccccagcagcccaacgggcagggggcttctgggcccagctgagtacagcc 40 ctgactagggacaaccgccacttctataaccagaacttctgccggggacctacagcagaatagctcagagcaaca

SEQ ID NO:31 (Murine TLR9)

atggttctccgtcgaaggactctgcaccccttgtccctcctggtacaggctgcagtgctgqctqaqactctqqcc $\verb|ctgggtaccctgccttcctaccctgtgagctgaagcctcatggcctggtggactgcaattggctgttcctg|$ ${\tt aagtctgtaccccgtttctctgcggcagcatcctgctccaacatcacccgcctctccttgatctccaaccgtatc}$ $\verb|caccacctgcacaactccgacttcgtccaacctgtccaacctgcggcagctgaacctcaagtggaactgtccaccc|$ actggccttagccccctgcacttctcttgccacatgaccattgagcccagaaccttcctggctatgcgtacactg gaggagetgaacctgagetataatggtatcaccactgtgccccgactgcccagetccctggtgaatctgagcctq 50 ${\tt agccaccaccaaccatcctggttctagatgctaacagcctcgccggcctatacagcctgcgcgttctcttcatggac}$ $\tt gggaactgctactacaagaacccctgcacaggagcggtgaaggtgaaccccaggcgcctcctgggcctgagcaat$ $\verb|ctcacccatctgtctctgaagtataacaacctcacaaaggtgccccgccaactgcccccagcctggagtacctc|$ ctggtgtcctataacctcattgtcaagctggggcctgaagacctggccaatctgacctcccttcgagtacttgat gtgggtgggaattgccgtcgctgcgaccatgccccaatccctgtatagaatgtggccaaaagtccctccacctq 55 caccetgagacettecateacetgageeatetggaaggeetggtgetgaaggaeageteteteeatacaetqaae tcttcctggttccaaggtctggtcaacctctcggtgctggacctaagcgagaactttctctatgaaagcatcaac $\verb|cacacca| atgccttca| acccgcctgcgca| agctca| acctgtccttca| attaccgca| agaaggta| tcc| acccca| atgccttca| acccgca| agaaggta| accc| acccca| atgccttca| acccgca| agaaggta| accc| acccca| atgccttca| acccgca| acccc| accc| acccc| accc| acccc| accc| acccc| acccc| acccc| acccc| acccc| acccc| acccc| acccc| acccc$

tttgcccgcctccacctggcaagttccttcaagaacctggtgtcactgcaggagctgaacatgaacqqcatcttc ttccgctcgctcaacaagtacacgctcagatggctggccgatctgcccaaactccacactctgcatcttcaaatg aacttcatcaaccaggcacagctcagcatctttggtaccttccgagcccttcgctttgtggacttgtcagacaat cgcatcagtgggccttcaacgctgtcagaagccacccctgaagaggcagatgatgcagagcaggaggagctgttg tetgeggateeteacceageteeactgageacceetgettetaagaaetteatggaeaggtgtaagaaetteaag ttcaccatggacctgtctcggaacaacctggtgactatcaagccagagatgtttgtcaatctctcacgcctccag tgtcttagcctgagccacaactccattgcacaggctgtcaatggctctcagttcctgccgctgactaatctgcag gtgctggacctgtcccataacaaactggacttgtaccactggaaatcgttcagtgagctaccacagttgcaggcc $\verb"ctggacctgagctacaacagccagccctttagcatgaagggtataggccacaatttcagttttgtggcccatctg"$ 10 tecatgetacacageettageetggcacacaatgacatteataceegtgtgteetcacatetcaacageaactea $\verb|gtgaggtttcttgacttcagcggcaacggtatgggccgcatgtgggatgagggggcctttatctccatttcttc|$ caaggcctgagtggcctgctgaagctggacctgtctcaaaataacctgcatatcctccggccccaqaaccttqac ttcctgcccaacctggaagtcctagacctggcaggcaaccagctaaagqccctgaccaatqqcaccctgcctaat 15 ggcaccetectecagaaactggatgtcagcagcaacagtatcgtctctgtqqtcccaqccttcttcqctctqqcq gtcgagctgaaagaggtcaacctcagccacaacattctcaagacggtggatcgctcctggtttgggcccattgtg atgaacctgacagttctagacgtgagaagcaaccctctgcactgtgcctgtggggcagccttcgtagacttactg ttggaggtgcagaccaaggtgcctggcctagtgtgtgaagtgtggcagccccggccagctgcaggccgt agcatettegeacaggacetgeggetgtgeetggatgaggteetetettgggaetgetttgge

20

SEQ ID NO:33 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRI HHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSL SHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYL 25 LLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPOLHPDTFSHLSRLEGLVLKDSSLSWLN ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIF FRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLOP GDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLOCLRLSHNCISOAVNGSOFLPLTGLOV LDLSRNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSOVSOOLCSTSL 30 ${\tt RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF}$ LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS $\verb|ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLA||$ VALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRG ${\tt RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDG}$ 35 RRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE

SEQ ID NO:34 (Human TLR9)

MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRI
HHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSL
SHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYL
LLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN
ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIF
FRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQP
GDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQV
45 LDLSRNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL
RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHF
LPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLAS
ALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDBALSWDCFA

50 SEQ ID NO:35 (Human TLR9)

aggetggtataaaaatettaetteetetattetetgageegetgetgeeeetgtgggaagggaeetegagtgtga ageateetteeetgtagetgetgteeagtetgeeegeeagaeeetetggagaageeeetgeeeeeageatgggt ttetgeegeagegeeetgeaeeegetgteteteeetggtgeaggeeateatgetggeeatgaeeetggeeetggg

accttgcctgccttcctaccctgtgagctccagccccacggcctggtgaactgcaactggctgttcctgaagtct gtgccccacttctccatggcagcaccccgtggcaatgtcaccagcctttccttgtcctccaaccgcatccaccac $\verb|ctccatgattctgacttttgcccacctgcccagcctgcggcatctcaacctcaagtggaactgcccgccggttggc|\\$ $\verb|ctcag| cccatgcccttgccaccttgaccatcgagcccagcaccttcttggctgtgcccacccttggaagag| \\$ $\verb|ctaaacctgagctacaacaacatcatgactgtgcctgcgctgcccaaatccctcatatccctgtccctcagccat|\\$ accaacatectgatgetagactetgeeageetegeeggeetgeatgeeetgegetteetatteatggaeggeaac tgttattacaagaacccctgcaggcaggcactggaggtggccccgggtgccctccttggcctgggcaacctcacc cacctgtcactcaagtacaaccacctcactgtggtgccccgcaacctgccttccagcctggagtatctgctgttg tcctacaaccgcatcgtcaaactggcgcctgaggacctggccaatctgaccgccctgcgtgtgctcgatgtgggc 10 ggaaattgccgccgctgcgaccacgctcccaacccctgcatggagtgccctcgtcacttcccccagctacatccc ${\tt aaggccttccagggcctaacaagctgcgcaagcttaacctgtccttcaattaccaaaagagggtgtcctttgcc}$ cacctgtctctggccccttccttcgggagcctggtcgccctgaaggagctggacatgcacggcatcttcttccgc 15 tcactcgatgagaccacgctccggccactggcccgcctgcccatgctccagactctgcgtctgcagatgaacttc ateaaccaggcccageteggcatetteagggcctteeetggcctgegctaegtggacctgteggacaacegcate agcggagcttcggagctgacagccaccatgggggaggcagatggaggggagaaggtctggctgcagcctggggac cttgctccggccccagtggacactcccagctctgaagacttcaggcccaactgcagcaccctcaacttcaccttg gatctgtcacggaacaacctggtgaccgtgcagccggagatgtttgcccagctctcgcacctgcagtgcctgcgc ctgagccacaactgcatctcgcaggcagtcaatggctcccagttcctgccgctgaccggtctgcaggtgctagac ctgtcccgcaataagctggacctctaccacgagcactcattcacggagctaccgcgactggaggccctggacctc aqctacaacaqccaqccctttqqcatqcaqqqcqtqqqccacaacttcagcttcgtggctcaccttgcgcaccctg cgccacctcaqcctggcccacaacaacatccacagccaagtgtcccagcagctctgcagtacgtcgctgcgggcc ctggacttcagcggcaatgcactgggccatatgtgggccgaggggagacctctatctgcacttcttccaaggcctg 25 ageggtttgatetggetggaettgteccagaacegeetgeacaceeteetgececaaaceetgegeaaceteece ${\tt aagagcctacaggtgctgcgtctccgtgacaattacctggccttctttaagtggtggagcctccacttcctgccc}$ ctccggaggctggatgtcagctgcaacagcatcagcttcgtggcccccggcttcttttccaaggccaaggagctg cgagageteaacettagegeeaacgeeeteaagacagtggaceaeteetggtttgggeeeetggegagtgeeetg caaatactagatgtaagcgccaaccctctgcactgcgcctgtggggcggcctttatggacttcctgctggaggtg caqqctqccqttqcccqqtctqcccagccgggtgaagtgtggcagtccgggccagctccagggcctcagcatcttt $\verb|ctgggcctgggtgtgcccatgctgcatcacctctgtggctgggacctctggtactgcttccacctgtgcctggcc| \\$ ${\tt tggcttccctggcgggggggggaaagtggggagatgaggatgccctgccctacgatgccttcgtggtcttcgac}$ 35 ${\tt aaaacgcagagcgcagtggcagactgggtgtacaacgagcttcgggggcagctggaggagtgccgtgggcgctgg}$ gcactccgcctgtgcctggaggaacgcgactggctgcctggcaaaaccctctttgagaacctgtgggcctcggtc tatggcagccgcaagacgctgtttgtgctggcccacacggaccgggtcagtggtctcttgcgcgccagcttcctg $\verb|ctggcccagcagcgcctgctggaggaccgcaaggacgtcgtggtgctggtgatcctgagccctgacggccqccqc|\\$ tcccgctacgtgcggctgcgccagcgcctctgccgccagagtgtcctcctctggccccaccagcccaqtqgtcag 40 cqcaqcttctqqqcccaqctqqgcatqqccctgaccagggacaaccaccacttctataaccggaacttctgccag tggtctgaccctccctgctcgcctccctcaccccacacctgacacagagca

SEQ ID NO:36 (Human TLR9)

- 28 -

aaaaccaaggccttccagggcctaacacagctgcgcaagcttaacctqtccttcaattaccaaaaqaqqqtqtcc tttgcccacctgtctctggccccttccttcgggagcctggtcgccctgaaqqaqctqqacatqcacqqcatcttc ttccgctcactcgatgagaccacgctccggccactggcccgcctgcccatgctccaqactctqcqtctgcaqatq aacttcatcaaccaggcccagctcggcatcttcagggccttccctggcctgcgctacgtggacctgtcggacaac cgcatcagcggagcttcggagctgacagccaccatgggggaggcagatggaggggagaaggtctggctgcagcct ggggaccttgctccggccccagtggacactcccagctctgaagacttcaggcccaactgcagcaccctcaacttc ${\tt accttggatctgtcacggaaccacctggtgaccgtgcagccggaactgtttgcccagctctcgcacctgcagtgc}$ $\verb|ctgcgcctgagccacaactgcatctcgcaggcagtcaatggctcccagttcctgccgctgaccggtctgcaggtg|$ ctagacctgtcccgcaataagctggacctctaccacgagcactcattcacggagctaccgcqactgqagqccctq gaceteagetacaacagecagecetttggcatgcagggcgtgggccacaaettcagettcgtggctcacctqcqc accetgegecaceteageetggeecacaacaacatecacagecaagtgteecageagetetgeagtacgtegetg $\verb|cgggccctggacttcagcggcaatgcactgggccatatgtgggccgagggagacctctatctgcacttcttccaa|\\$ ggcctgagcggtttgatctggctggacttgtcccagaaccgcctgcacaccctcctgccccaaaccctgcgcaac ctccccaagagcctacaggtgctgcgtctccgtgacaattacctggccttctttaagtggtggagcctccacttc ctgcccaaactggaagtcctcgacctggcaggaaaccggctgaaggccctgaccaatqqcaqcctqcctqctqqc acceggeteeggaggetggatgteagetgeaacageateagettegtggeeceeggettetttteeaaggeeaaq gagctgcgagagctcaaccttagcgccaacqccctcaaqacagtqqaccactcctqqtttqqqcccctqqcqagt gccctgcaaatactagatgtaagcgccaaccctctgcactqcqcctqtqqqqcqqcctttatqqacttcctqctq gaggtgcaggctgccgtgcccggtctgcccagccgggtgaagtgtggcagtccgggccagctccagggcctcagc atctttgcacaggacctgcgcctctgcctggatgaggccctctcctgggactgtttcgcc

5

15

20

25

30

35

40

In addition to the foregoing native rat, porcine, bovine, equine, and ovine TLR9 polypeptides and nucleic acid molecules encoding them, chimeric TLR9 polypeptides and nucleic acid molecules encoding them are provided by the invention. The chimeric polypeptides include at least one amino acid substitution based on a comparison of conserved and non-conserved amino acids among at least two of rat, murine, porcine, bovine, equine, ovine, canine, feline, and human TLR9. The information contained in a multiple sequence alignment of these various TLR9 polypeptide sequences, provided for example in Figure 1, can be used to identify and select individual amino acid positions and even individual amino acids to substitute in designing a chimeric TLR9. The substitution or substitutions can be effected using methods known to those of ordinary skill in molecular biology. Nucleic acids encoding the native or chimeric polypeptides of the invention can be inserted into an expression vector and used to express TLR9 polypeptide.

A conservative amino acid substitution shall refer to a substitution of a first amino acid for a second amino acid, wherein side chains of the first amino acid and the second amino acid share similar features in terms of hydrophobicity, size, aromaticity, or tendency to alter conformation. For example, conservative amino acid substitutions generally may be made between members within each of the following groups: hydrophobic (A, I, L, M, V), neutral (C, S, T), acidic (D, E), basic (H, K, N, Q, R), and aromatic (F, W, Y). A non-conservative amino acid substitution refers to any other amino acid substitution.

- 29 -

An expression vector for TLR9 will include at least a nucleotide sequence coding for a TLR9, or a fragment thereof coding for a functional TLR9 polypeptide, operably linked to a gene expression sequence which can direct the expression of the TLR9 nucleic acid within a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked. With respect to TLR9 nucleic acid, the "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the TLR9 nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, β-actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papillomavirus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein (MT) promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

10

15

20

25

30

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid coding sequence for a TLR9 polypeptide. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

Generally a nucleic acid coding sequence and a gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or control of the gene expression sequence. Thus the TLR9 nucleic acid coding sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the TLR9 nucleic acid coding sequence under the influence or control of the gene expression sequence. If it is desired that the TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired TLR9 protein or polypeptide.

10

15

20

25

30

A "TLR9 ligand" as used herein refers to a molecule that specifically binds a TLR9 polypeptide. In one embodiment the TLR9 ligand specifically binds a TLR9 polypeptide corresponding to at least a ligand-binding portion of the extracellular domain of TLR9. In most instances a TLR9 ligand will also induce TLR9 signaling when contacted with TLR9 under suitable conditions. TLR9 signaling refers to TLR/IL-1R signal transduction mediated through the TLR9, as described in further detail elsewhere herein. As mentioned above, CpG nucleic acids have been reported to be TLR9 ligands, but TLR9 ligands may include other entities as well, including, for example, small molecules. As also previously mentioned, there appears to be a species-specific preference for at least certain TLR9s and certain CpG motifs. As used herein, a species-preferred CpG DNA refers to a particular CpG DNA that is optimized for signal induction by a TLR9 of a particular species. A CpG DNA that is optimized for signal induction by a TLR9 of a particular species refers to a CpG DNA having a sequence that preferentially binds to and/or induces signaling by TLR9 of that species. For example, a human-preferred CpG DNA shall refer to a CpG DNA that optimally stimulates human TLR9 to signal through its TIR domain. Likewise, a murine-preferred CpG DNA

shall refer to a CpG DNA that optimally stimulates murine TLR9 to signal through its TIR domain. Examples of human-preferred and murine-preferred CpG DNA are ODN 2006 (SEQ ID NO:58) and 1668 (SEQ ID NO:60), respectively.

The binding and species specificity of TLR9s are believed to be influenced by key amino acids present in the extracellular domain of TLR9. Key amino acids in a TLR9 as used herein refer to those amino acids which contribute significantly to ligand binding and ligand specificity of a particular TLR9 polypeptide.

5

10

15

20

25

30

A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e., "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) which activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

In one embodiment a CpG nucleic acid is represented by at least the formula:

5'-N₁X₁CGX₂N₂-3'

wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

An immunostimulatory nucleic acid molecule, including for example a CpG DNA, may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As

used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

10

15

20

25

30

The substituted purines and pyrimidines of the immunostimulatory nucleic acids include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The immunostimulatory nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' (or equivalent) order from left to right and that "A" denotes adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

5

10

15

20

25

30

The immunostimulatory nucleic acids can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the immunostimulatory nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β-cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Let* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Let* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); Garegg et al., *Tetrahedron Let* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Let* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

The immunostimulatory nucleic acid may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

A "stabilized immunostimulatory nucleic acid" shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an

10

15

20

25

30

oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized immunostimulatory nucleic acids have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the immunostimulatory nucleic acids when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail in U.S. Pat. Nos. 6,194,388 and 6,207,646, the entire contents of which are incorporated herein by reference. It is believed that these modified oligonucleotides may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester nucleic acids are active in immune cells.

Other stabilized immunostimulatory nucleic acids include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

Phosphorothioate nucleic acid molecules may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described. Uhlmann E and Peyman A (1990) Chem Rev 90:544; Goodchild J (1990) Bioconjugate Chem 1:165.

- 35 -

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

Nucleic acid-binding fragments of TLRs are believed to include the extracytoplasmic (extracellular) domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al. (2000) *Mol Cell Biol* 20:5107-18. Both human and mouse TLR9 CXXC domains occur at aa 253-268:

	CXXC motif:	GNCXXCXXXXXCXXC	SEQ ID NO:62
	Human TLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:63
25	Murine TLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:64

An additional motif believed to be involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:53. Fujita, N et al.(2000) *Mol Cell Biol* 20:5107-18; Ohki I et al. (1999) *EMBO J* 18:6653-61. Amino acids 524-554 of hTLR9 and aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

MBD motif:

10

15

20

30

- 36 -	•
--------	---

MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXX-R-S-XXXXXXX-Y	SEQ ID NO:65
hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXX-R-L-XXXXXXX-Y	SEQ ID NO:66
mTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXX-Q-L-XXXXXXX-Y	SEQ ID NO:67
hTLR9	Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:68
mTLR9	O-VLDLSHN-K-L-D-L-Y-HWKSFSELP-Q-L-QALDLS-Y	SEQ ID NO:69

5

10

15

20

25

30

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is conserved and is believed to be involved in CpG binding.

According to another aspect of the invention, a screening method is provided for identifying an immunostimulatory compound. The method according to this aspect of the invention involves contacting a functional TLR9 with a test compound; detecting presence or absence of a response mediated by a TLR9 signal transduction pathway in the presence of the test compound arising as a result of an interaction between the functional TLR9 and the test compound; and determining the test compound is an immunostimulatory compound when the presence of a response mediated by the TLR9 signal transduction pathway is detected.

An immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell. A TLR9 ligand that is an immunostimulatory compound is a natural or synthetic compound that is capable of inducing an immune response when contacted with an immune cell that expresses TLR9. A TLR9 ligand that is an immunostimulatory compound is also a natural or synthetic compound that is capable of inducing a TLR/IL-1R signal transduction pathway when contacted with a TLR9. Immunostimulatory compounds include but are not limited to immunostimulatory nucleic acids. The immunostimulatory compound can be, for example, a nucleic acid molecule, polynucleotide or oligonucleotide, a polypeptide or oligopeptide, a lipid or lipopolysaccharide, a small molecule.

A basis for certain of the screening assays is the presence of a functional TLR9 in a cell. The functional TLR9 in some instances is naturally expressed by a cell. In other instances, expression of the functional TLR9 can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an

immunostimulatory nucleic acid. In yet other instances, expression of the functional TLR9 can involve introduction of a chimeric or modified TLR9 into a cell or cell line that otherwise lacks the TLR9 or lacks responsiveness to immunostimulatory nucleic acid, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an immunostimulatory nucleic acid. Examples of cell lines lacking TLR9 or immunostimulatory nucleic acid responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction of the species-specific, chimeric or modified TLR9 into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a TLR9-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above). Methods for transient and for stable transfection of a cell are well known in the art.

5

10

15

20

25

30

The screening assays can have any of a number of possible readout systems based upon either TLR/IL-1R signaling pathway or other assays useful for assessing response to immunostimulatory nucleic acids. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing.

In certain embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving MyD88, TRAF, p38, and/or ERK. Häcker H et al. (1999) *EMBO J* 18:6973-6982. These pathways activate kinases including κB kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF-κB. Examples of such promoters include, without limitation, those for NF-κB, IL-1β, IL-6, IL-8, IL-12 p40, CD80, CD86, and TNF-α. The reporter gene operatively linked to the TLR-sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β-galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., greenfluorescent protein (GFP, U.S. Pat. No. 5,491,084), blue fluorescent protein, etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF-α). In certain embodiments the reporter is selected from IL-8, TNF-α, NF-κB-luciferase (NF-κB-luc; Häcker H et al. (1999) *EMBO J* 18:6973-6982), IL-12 p40-luc (Murphy TL et al. (1995)

Mol Cell Biol 15:5258-5267), and TNF-luc (Häcker H et al. (1999) EMBO J 18:6973-6982). At least one of these reporter constructs (NF-kB-luc) is commercially available (Stratagene, La Jolla, CA). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

According to one embodiment of this method, comparison can be made to a reference immunostimulatory nucleic acid. The reference immunostimulatory nucleic acid may be any suitably selected immunostimulatory nucleic acid, including a CpG nucleic acid. In certain embodiments the screening method is performed using a plurality of test nucleic acids. In certain embodiments comparison of test and reference responses is based on comparison of quantitative measurements of responses in each instance.

10

15

20

25

30

In another aspect the invention provides a screening method for identifying species specificity of an immunostimulatory nucleic acid. The method involves contacting a TLR9 of a first species with a test immunostimulatory nucleic acid; contacting a TLR9 of a second species with the test immunostimulatory nucleic acid; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the TLR9 of the first species with the test immunostimulatory nucleic acid; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the TLR9 of the second species with the test immunostimulatory nucleic acid; and comparing the two responses. The TLR9 may be expressed by a cell or it may be part of a cell-free system. The TLR9 may be part of a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF, IKB, NF-KB, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of human fibroblast 293 fibroblast cells transfected with TLR9 from various species and optionally cotransfected with a reporter construct sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for screening species selectivity with respect to a given nucleic acid sequence.

Test compounds can include but are not limited to peptide nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test

- 39 **-**

compounds can further include variants of a reference immunostimulatory nucleic acid incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

5

10

15

20

25

30

In preferred embodiments, the screening methods can be performed on a large scale and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiple-well plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate.

Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

The following examples are provided for illustrative purposes and are not meant to be limiting in any way.

Examples

Example 1. Cloning and Sequencing of Rat, Porcine, Bovine, Equine, Ovine, Canine, and Feline TLR9

Cells and Tissues. Lymphoid tissues, primarily spleen or blood mononuclear cells (PBMC) from five mammalian species were collected: mouse, pig, bovine, rat and horse. Spleen samples were collected in RNAlaterTM (Ambion[®], Austin, TX, USA), stabilized at 4°C overnight and stored at -70°C. Blood samples were centrifuged at 500 x g for 25 min at room temperature and the buffy coat, containing enriched PBMC, was then removed and stored at -70°C. The mouse specimen was used as a comparative positive control.

First-strand cDNA synthesis. Total RNA from the spleen and PBMC samples was isolated using a monophasic solution of phenol and guanidine isothiocyanate: TRIzolTM reagent (GIBCO BRL[®], Burlington, ON, Canada) according to the manufacturer's instructions. First-strand cDNA was synthesized from the total RNA using SUPERSCRIPTTM II reverse transcriptase (GIBCO BRL[®], Burlington, ON, Canada). Approximately 3 μg of total RNA was added to 50 pmoles of oligo(dT) primer [poly T₍₁₈₎]; the mixture was heated to 70°C for 10 min and subsequently chilled on ice. The following was added to the cooled reaction mixture: 1 μl of mixed dNTP stock containing 10 mM each dATP, dCTP, dGTP and dTTP (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) at neutral pH, 1X first strand buffer (50 mM Tris-HCl pH 8.3/75 mM KCl/3 mM MgCl₂) and 2 μl of 0.1 M DTT. The mixture was subsequently heated to 42°C for 2 min, followed by addition of 200 units of SUPERSCRIPTTM II reverse transcriptase. The reaction was carried out at 42°C for 50 min, followed by 70°C for 15 min. The first-strand cDNA was used as the template for subsequent polymerase chain reaction (PCR) amplifications.

10

15

20

25

30

PCR amplification. TLR9 gene was PCR amplified from each of the above-mentioned species using primers designed from known mouse and human TLR9 sequence in Genbank: Accession AF314224 and AF259262, respectively. The primers were designed using the primer design software, Clone Manager 5 (Scientific and Educational Software, Durham, NC, USA). TLR9 gene-specific primers used were:

forward primer 5'-ACCTTGCCTGCCTTCCTACCCTGTGA-3' (SEQ ID NO:37) and reverse primer 5'-GTCCGTGTGGGCCAGCACAAA-3' (SEQ ID NO:38).

The 2.7 Kbp fragment was PCR amplified using Advantage[®] 2 DNA polymerase mix (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions.

PCR reaction volumes of 25 μl contained 15 pmoles of each primer, 0.2 mM of dNTP mix and 1 μl of reverse transcription reaction. PCR amplification was conducted by initial denaturation at 94°C for 1 min followed by 30 cycles of 94°C denaturation (15 sec), 65°C annealing (45 sec) and 72°C extensions (2 min), with a final extension at 72°C for 5 min.

Cloning and sequencing. The PCR amplified fragment was treated with 500 units of T4 DNA polymerase (Amersham Pharmacia Biotech Inc., Baie de Urfe, Quebec) for 15 min at room temperature prior to cleaning the reaction with QIAquick PCR purification kit (QIAGEN Inc., Mississauga, ON, Canada). The fragment was then ligated to pZErOTM - 2

- 41 -

vector (Invitrogen[™] Life Technologies, Burlington, ON, Canada), treated with *Eco RV* restriction enzyme, using T4 DNA Ligase (GIBCO BRL[®], Burlington, ON, Canada). *E. coli* TOP 10 chemically competent cells (Invitrogen[™] Life Technologies, Burlington, ON, Canada) were used to transform ligated products. Plasmids containing the 2.7 Kbp fragment were sequenced using an automated DNA sequencer, CEQ[™] 2000XL DNA analysis system (Beckman Coulter Inc., Fullerton, CA, USA).

Sequences of the 2.7 Kbp fragment were derived from three clones of each species selected from independent PCR reactions to account for errors that may have been incurred during the PCR amplifications and to confirm the sequence data.

Nucleotide sequences of the rat, porcine, bovine, equine, ovine, canine, and feline TLR9 were extended and completed using standard 5' and 3' RACE PCR and primers designed using the sequences obtained from the 2.7 Kbp fragments.

10

15

20

25

30

Results. Nucleotide sequences of rat, porcine, bovine, equine, canine, and feline TLR9 cDNA obtained by the methods above are provided as SEQ ID NOs 3, 7, 11, 15, 19, 23, and 27, respectively. Deduced amino acid sequences are provided as SEQ ID NOs 1, 5, 9, 13, 17, 21, and 25, respectively. Deduced amino acid sequences of full-length murine and human TLR9 are provided as SEQ ID NOs 29 and 33, respectively.

Example 2. Comparison of Aligned Sequences for TLR9 from Various Mammalian Species.

Multiple sequence alignment of deduced amino acid sequences for feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 polypeptides was performed using Clustal W 1.82 (see, for example, www.cmbi.kun.nl/bioinf/tools/clustalw.shtml). In addition, paired sequence alignment of deduced amino acid sequences for murine and human TLR9 polypeptides was performed using Clustal W 1.82. The results of the multiple sequence alignment are presented in **Figure 1**. As will be appreciated from Figure 1, certain amino acids are highly conserved across all species examined. Similarly, certain amino acids differ only by conservative amino acid substitutions among the various species. In addition, it is evident that certain amino acids which are conserved between murine and human TLR9 are not conserved in other species. Furthermore, Figure 1 also indicates that certain amino acids are highly divergent across various species. The information provided by the comparison of multiple species adds significantly to the information available by comparison between only murine and human TLR9 sequences.

- 42 -

The putative transmembrane regions of the TLR9 polypeptides are indicated in boxes in Figure 1. Sequence upstream of each transmembrane region is extracellular domain and is believed to include sequence primarily responsible for binding to TLR9 ligands, including CpG DNA. The extracellular domains of feline, canine, bovine, mouse, ovine, porcine, horse, human, and rat TLR9 correspond to amino acids numbered 1-820, 1-822, 1-818, 1-821, 1-819, 1-820, 1-820, and 1-821, respectively, as shown in Figure 1.

Figure 2 presents an evolutionary relatedness tree for six TLR9 polypeptides examined. The cladogram in Figure 2 was prepared using Clustal W (see above). As can be appreciated from this figure, murine and human TLR9 are nearly the most divergent TLR9s in this group. Surprisingly, human and horse TLR9 appear relatively closely related.

Example 3. Reconstitution of TLR9 Signaling in 293 Fibroblasts.

5

10

15

20

25

30

Mouse TLR9 cDNA (SEQ ID NO:31) and human TLR9 cDNA (SEQ ID NO:35) in pT-Adv vector (from Clonetech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

Since NF-κB activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-258; Muzio M et al. (1998) *J Exp Med* 187:2097-101), cells were transfected with hTLR9 or co-transfected with hTLR9 and an NF-κB-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected with hTLR9 and a six-times NF-κB-luciferase reporter plasmid (NF-κB-luc) or with hTLR9 alone. After stimulus with CpG-ODN (2006, 2μM, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:58), GpC-ODN (2006-GC, 2μM, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID NO:59), LPS (100 ng/ml) or media, NF-κB activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results representative of three independent experiments showed that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Independently, human fibroblast 293 cells were transiently transfected with mTLR9 and the NF-κB-luc construct or with mTLR9 alone. After stimulation with CpG-ODN (1668, 2μM; TCCATGACGTTCCTGATGCT, SEQ ID NO:60), GpC-ODN (1668-GC, 2μM;

TCCATGAGCTTCCTGATGCT, SEQ ID NO:61), LPS (100 ng/ml) or media, NF-kB activation by luciferase readout (8h) or IL-8 production by ELISA (48h) were monitored. Results showed that expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation.

To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF-κB-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2x10⁶ cells/plate) with 16 µg of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR. The clones were also screened for IL-8 production or NF-kB-luciferase activity after stimulation with ODN. Four different types of clones were generated.

293-hTLR9-luc:

expressing human TLR9 and 6-fold NF-kB-luciferase reporter

293-mTLR9-luc:

expressing murine TLR9 and 6-fold NF-κB-luciferase reporter

293-hTLR9:

expressing human TLR9

15 293-mTLR9:

5

10

20

25

expressing murine TLR9

Results indicated that stable clones also responded to CpG-ODN.

Example 4. Similar ODN Sequence Specificity of TLR9 of Human and Equine TLR9.

 $3x10^6$ 293T cells were electroporated with $5\mu g$ NF- κB -luc plasmid and $5\mu g$ of either horse TLR9-pcDNA3.1 plasmid or humanTLR9-pcDNA3.1 plasmid at 200V, 975 µF. After the electroporation the cells were plated in 96-well cell culture plates at 2.5x10⁴ cells per well and grown overnight at 37°C. The cells were stimulated with the indicated concentration of ODN for 16h, after which the supernatant was removed and the cells lysed in lysis buffer and frozen for at least 2 hours at -80°C. Luciferase activity was measured by adding Luciferase Assay substrate from Promega. Values are given as fold specific induction over nonstimulated control. Results are shown in Figure 3.

As shown in Figure 3, ODN 2006 (TCGTCGTTTTGTCGTTTTGTCGTT; SEQ ID NO:58) has a strong specificity for human TLR9. ODN 1982

(TCCAGGACTTCTCAGGTT; SEQ ID NO:70) was the negative control ODN. ODN 30 5890 (TCCATGACGTTTTTGATGTT; SEQ ID NO:39) has a strong specificity for mouse

- 44 -

TLR9. This experiment demonstrates the similarity of horse TLR9 to human TLR9 in binding specificity, a result predicted by the evolutionary relatedness of horse TLR9 to human TLR9. Mouse TLR9 is more distant from horse TLR9 and human TLR9 in sequence homology, and ODN 5890 was not detected by either human or horse TLR9.

5

10

15

Example 5. Non-human, Non-murine Native Mammalian TLR9 Useful in Screening for Human-Preferred CpG DNA.

Native rat, porcine, bovine, equine, and ovine TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Rat, porcine, bovine, equine, or ovine TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected native rat, porcine, bovine, equine, or ovine TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

20 I

Example 6. Chimeric TLR9 Useful in Screening for Human-Preferred CpG DNA.

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in this assay are then used as the basis for screening for additional human-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA.

30

25

Example 7. Chimeric TLR9 Responsive to Both Human-Preferred and Murine-Preferred CpG DNA.

- 45 -

Chimeric TLR9 polypeptides are screened for binding or TLR9 signaling activity when contacted with human-preferred CpG DNA (ODN 2006) and also screened for binding or TLR9 signaling activity when contacted with murine-preferred CpG DNA (ODN 1668). Chimeric TLR9 polypeptides which exhibit significant TLR9 binding or TLR9 signaling activity in each of these assays are then used as the basis for screening for additional human-preferred CpG DNA and for screening for additional murine-preferred CpG DNA. An expression vector containing a nucleic acid sequence encoding a selected chimeric TLR9 polypeptide, and optionally a reporter construct, is introduced into cells which do not express TLR9. The cells expressing the selected chimeric TLR9 polypeptide are contacted with candidate human-preferred CpG DNA or candidate murine-preferred CpG DNA. Candidate human-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as human-preferred CpG DNA. Candidate murine-preferred CpG DNA exhibiting significant TLR9 binding or TLR9 signaling activity are selected as murine-preferred CpG DNA.

15

20

25

10

Equivalents

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 46 -

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.

5

- 2. An isolated polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.
- 3. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:17.
 - 4. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:18.
 - 5. A vector comprising the nucleic acid of any of claims 3-4.
 - 6. A cell comprising the vector of claim 5.

20

25

15

- 7. An antibody or fragment thereof that binds specifically to the polypeptide of any of claims 1-2.
- 8. A method for identifying key amino acids in a TLR9 of a first species which confer specificity for CpG DNA optimized for TLR9 of the first species, comprising:

aligning protein sequences of TLR9 of a first species, TLR9 of a second species, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for TLR9 of the first species rather than when contacted with a CpG DNA optimized for TLR9 of the second species;

30

generating an initial set of candidate amino acids in the TLR9 of the first species by excluding each amino acid in the TLR9 of the first species which (a) is identical with the

- 47 -

TLR9 of the second species or (b) differs from the TLR9 of the second species only by conservative amino acid substitution;

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in the TLR9 of the first species which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in the TLR9 of the first species each amino acid in the refined set of candidate amino acids.

9. A method for identifying key amino acids in human TLR9 which confer specificity for CpG DNA optimized for human TLR9, comprising:

10

15

20

25

30

aligning protein sequences of human TLR9, murine TLR9, and TLR9 of a third species, wherein the TLR9 of the third species preferentially generates a signal when contacted with a CpG DNA optimized for human TLR9 rather than when contacted with a CpG DNA optimized for murine TLR9;

generating an initial set of candidate amino acids in human TLR9 by excluding each amino acid in human TLR9 which (a) is identical with murine TLR9 or (b) differs from murine TLR9 only by conservative amino acid substitution;

generating a refined set of candidate amino acids by selecting each amino acid in the initial set of candidate amino acids in human TLR9 which (a) is identical with the TLR9 of the third species or (b) differs from the TLR9 of the third species only by conservative amino acid substitution; and

identifying as key amino acids in human TLR9 each amino acid in the refined set of candidate amino acids.

10. The method according to claim 9, performed iteratively with a plurality of TLR9s derived from different species other than human and mouse, wherein for each TLR9 the refined set of candidate amino acids is assigned a weight, said weight corresponding to a ratio equal to (responsiveness to human-preferred CpG DNA)/(responsiveness to murine-preferred CpG DNA).

- 48 -

- 11. An isolated polypeptide comprising an amino acid sequence identical to SEQ ID NO:30 except for substitution of at least one key amino acid identified according to the method of any of claims 9 or 10.
- 5 12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide according to claim 11.
 - 13. A vector comprising the nucleic acid of claim 12.
- 10 14. A cell comprising the vector of claim 13.
 - 15. An antibody that binds specifically to the polypeptide of claim 14.
 - 16. A screening method to identify a TLR9 ligand, comprising: contacting a polypeptide according to any of claims 1, 2, or 11 with a candidate TLR9 ligand;

measuring a signal in response to the contacting; and identifying the candidate TLR9 ligand as a TLR9 ligand when the signal in response to the contacting is consistent with TLR9 signaling.

20

15

- 17. The method of claim 16, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.
- 18. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF-κB.
 - 19. The method of claim 17, wherein the candidate TLR9 ligand is an immunostimulatory nucleic acid.
- 20. The method of claim 19, wherein the immunostimulatory nucleic acid is CpGDNA.

- 49 -

21. A screening method to identify species-specific CpG-motif preference of an isolated polypeptide of claim 2 or claim 11, comprising:

contacting an isolated polypeptide of claim 2 or claim 11 with a CpG DNA comprising a hexamer sequence selected from the group consisting of GACGTT, AACGTT, CACGTT, TACGTT, GGCGTT, GCCGTT, GTCGTT, GATGTT, GAAGTT, GAGGTT, GACATT, GACCTT, GACGTT, G

measuring a signal in response to the contacting; and

10

15

identifying a species-specific CpG-motif preference when the signal in response to the contacting is consistent with TLR9 signaling.

- 22. The method of claim 21, wherein the signal comprises expression of a reporter gene responsive to TLR/IL-1R signal transduction pathway.
- 23. The method of claim 17, wherein the reporter gene is operatively linked to a promoter sensitive to NF-κB.
 - 24. The method of claim 21, wherein the CpG DNA is an oligodeoxynucleotide having a sequence selected from the group consisting of

```
(SEQ ID NO:39),
         TCCATGACGTTTTTGATGTT
20
                                    (SEQ ID NO:40),
         TCCATAACGTTTTTGATGTT
                                    (SEQ ID NO:41),
         TCCATCACGTTTTTGATGTT
                                    (SEQ ID NO:42),
         TCCATTACGTTTTTGATGTT
         TCCATGGCGTTTTTGATGTT
                                    (SEQ ID NO:43),
         TCCATGCCGTTTTTGATGTT
                                    (SEQ ID NO:44),
25
         TCCATGTCGTTTTTGATGTT
                                    (SEQ ID NO:45),
                                    (SEQ ID NO:46),
         TCCATGATGTTTTTGATGTT
                                    (SEQ ID NO:47),
         TCCATGAAGTTTTTGATGTT
                                    (SEQ ID NO:48),
         TCCATGAGGTTTTTGATGTT
                                    (SEQ ID NO:49),
         TCCATGACATTTTTGATGTT
30
                                    (SEQ ID NO:50),
         TCCATGACCTTTTTGATGTT
                                    (SEQ ID NO:51),
         TCCATGACTTTTTTGATGTT
         TCCATGACGCTTTTGATGTT
                                    (SEQ ID NO:52),
                                    (SEQ ID NO:53),
         TCCATGACGATTTTGATGTT
                                    (SEO ID NO:54),
         TCCATGACGGTTTTGATGTT
35
                                    (SEO ID NO:55),
         TCCATGACGTCTTTGATGTT
                                    (SEQ ID NO:56), and
         TCCATGACGTATTTGATGTT
                                    (SEQ ID NO:57).
         TCCATGACGTGTTTGATGTT
```

Figure 1 (1/3)

feline	MGPCHGALHPLSLLVQAAALAVALAQGTLPAFLPCELQRHGLVNCDWLFLKSVPHFSAAA	60
canine	MGPCRGALHPLSLLVQAAALALALAQGTLPAFLPCELQPHGLVNCNWLFLKSVPRFSAAA	60
bovine	MGP-YCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGQVDCNWLFLKSVPHFSAGA	59
mouse	MGP-YCAPHPLSLLVQAAALAAALAEGTLPAFLPCELQPHGOVDCNWLFLKSVPHFSAGA	59
ovine	MGP-YCAPHPLSLLVQAAALAAALAQGTLPAFLPCELQPRGKVNCNWLFLKSVPRFSAGA	59
porcine	MGP-RCTLHPLSLLVQVTALAAALAQGRLPAFLPCELQPHGLVNCNWLFLKSVPHFSAAA	59
horse	MGPCHGALQPLSLLVQAAMLAVALAQGTLPPFLPCELQPHGLVNCNWLFLKSVPHFSAAA	60
human	MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA	60
rat	MVLCRRTLHPLSLLVQAAVLAEALALGTLPAFLPCELKPHGLVDCNWLFLKSVPHFSAAE	60
	* ::******	
feline	PRGNVTSLSLYSNRIHHLHDSDFVHLSSLRRLNLKWNCPPASLSPMHFPCHMTIEPHTFL	120
canine	PRGNVTSLSLYSNRIHHLHDYDFVHFVHLRRLNLKWNCPPASLSPMHFPCHMTIEPNTFL	120
bovine	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	110
mouse	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	110
ovine	PRANVTSLSLISNRIHHLHDSDFVHLSNLRVLNLKWNCPPAGLSPMHFPCRMTIEPNTFL	110
porcine	PRANVTSLSLLSNRIHHLHDSDFVHLSSLRTLNLKWNCPPAGLSPMHFPCHMTIEPNTFL	110
horse	PRDNVTSLSLLSNRIHHLHDSDFAQLSNLQKLNLKWNCPPAGLSPMHFPCHMTIEPNTFL	120
human	PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL	120
rat	PRSNITSLSLIANRIHHLHNLDFVHLPNVRQLNLKWNCPPPGLSPLHFSCRMTIEPKTFL	
	** *:**** :***** : ** :: : : : : : : :	120
feline	AVPTLEELNLSYNSITTVPALPSSLVSLSLSRTNILVLDPANLAGLHSLRFLFLDGNCYY	100
canine	AVPTLEDLNLSYNSITTVPALPSSLVSLSLSRTNILVLDPATLAGLYALRFLFLDGNCYY	100
bovine	AVPTLEELNLSYNGITTVPALPSSLVSLSLSHTSILVLGPTHFTGLHALRFLYMDGNCYY	170
mouse	AVPTLEELNLSYNGITTVPALPSSLVSLSSHTSILVLGPTHFTGLHALRFLYMDGNCYY	
ovine	AVPTLEELNLSYNGITTVPALPSSLVSLSSRTSILVLGPTHFTGLHALRFLYMDGNCYY	
porcine	AVPTLEELNLSYNSITTVPALPDSLVSLSLSRTNILVLDPTHLTGLHALRYLYMDGNCYY	
horse	AVPTLEELNLSYNGITTVPALPSSLVSLILSRTNILQLDPTSLTGLHALRFLYMDGNCYY	
human	AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY	
rat	AMRMLEELNLSYNGITTVPRLPSSLTNLSLSHTNILVLDASSLAGLHSLRVLFMDGNCYY	
	*: **:***** *** *** ** ** ** ** * * * *	100
	• • • • • • • • • • • • • • • • • • • •	
feline	KNPCPQALQVAPGALLGLGNLTHLSLKYNNLTAVPRGLPPSLEYLLLSYNHIITLAPEDL	240
canine	KNPCQQALQVAPGALLGLGNLTHLSLKYNNLTVVPRGLPPSLEYLLLSYNHIITLAPEDL	
bovine	MNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIVTLAPEDL	
mouse	MNPCPRALEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIVTLAPEDL	
ovine	KNPCQQAVEVAPGALLGLGNLTHLSLKYNNLTEVPRRLPPSLDTLLLSYNHIITLAPEDL	
porcine	KNPCQGALEVVPGALLGLGNLTHLSLKYNNLTEVPRSLPPSLETLLLSYNHIVTLTPEDL	
horse	KNPCGRALEVAPGALLGLGNLTHLSLKYNNLTTVPRSLPPSLEYLLLSYNHIVTLAPEDL	
human	KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL	
rat	KNPCNGAVNVTPDAFLGLSNLTHLSLKYNNLTEVPROLPPSLEYLLLSYNLIVKLGAEDL	
	*** *::*.*.*:*********** *** **: ***** *:.* . ***	240
feline	ANLTALRVLDVGGNCRRCDHARNPCMECPKGFPHLHPDTFSHLNHLEGLVLKDSSLYNLN	300
canine	ANLTALRVLDVGGNCRRCDHARNPCRECPKGFPQLHPNTFGHLSHLEGLVLRDSSLYSLD	300
bovine	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
mouse	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
ovine	ANLTALRVLDVGGNCRRCDHARNPCRECPKNFPKLHPDTFSHLSRLEGLVLKDSSLYKLE	299
porcine	ANLTALRVLDVGGNCRRCDHARNPCRECPKDHPKLHSDTFSHLSRLEGLVLKDSSLYNLD	299
horse	ANLTALRVLDVGGNCRRCDHARNPCVECPHKFPQLHSDTFSHLSRLEGLVLKDSSLYQLN	300
human	ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN	
rat	ANLTSLRMLDVGGNCRRCDHAPDLCTECROKSLDLHPOTFHHLSHLEGLVLKDSSLHSLN	
	****:**:*********** : * ** : .**.:** **.:***** *:	
feline	PRWFHALGNLMVLDLSENFLYDCITKTTAFQGLAQLRRLNLSFNYHKKVSFAHLHLAPSF	360
canine	PRWFHGLGNLMVLDLSENFLYDCITKTKAFYGLARLRRLNLSFNYHKKVSFAHLHLASSF	
bovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSF	
mouse	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLHLASSF	
ovine	KDWFRGLGRLQVLDLSENFLYDYITKTTIFNDLTQLRRLNLSFNYHKKVSFAHLALASSF	
porcine	TRWFRGLDRLQVLDLSENFLYDCITKTTTFKNLTQLRKLNLSFNYHKKVSFAHLQLAFSF	
horse	PRWFRGLGNLTVLDLSENFLYDCITKTKAFQGLAQLRRLNLSFNYHKKVSFAHLTLAPSF	
human	ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF	
rat		
	SKWFQGLANLSVLDLSENFLYESINKTSAFQNLTRLRKLDLSFNYCKKVSFARLHLASSF **:.* .* ******** . * .**. * .*:.** *:**** *:********	200
	······································	

2/4

Figure 1 (2/3)

feline	GSLLSLQQLDMHGIFFRSLSETTLRSLVHLPMLQSLHLQMNFINQAQLSIFGAFPGLRYV	420
canine	GSLLSLQELDIHGIFFRSLSKTTLQSLAHLPMLQRLHLQLNFISQAQLSIFGAFPGLRYV	420
bovine	GSLVSLEKLDMHGIFFRSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFV	419
mouse	GSLVSLEKLDMHGIFFRSLTNITLQSLTRLPKLQSLHLQLNFINQAQLSIFGAFPSLLFV	419
ovine	GGLVSLEKLDMHGIFFRSLTNTTLRPLTQLPKLQSLSLQLNFINQAELSIFGAFPSLLFV	419
porcine	CHECK TO THE TENT OF THE TENT	419
horse	GSLLSLQELDMHGIFFRSLSQKTLQPLARLPMLQRLYLQMNFINQAQLGIFKDFPGLRYI	420
human	GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV	420
rat	KSLVSLQELNMNGIFFRLLNKNTLRWLAGLPKLHTLHLQMNFINQAQLSVFSTFRALRFV	420
	* :*::*::**** * : **: *. ** *: * **:**.**:* * .* ::	
- 11	DI COMPTEGRADI ANTICCIONE CERTIFIC CONTRA CONCENTRA CONTRA DE CONT	170
feline	DLSDNRISGAMELAAATGEVDGGERVRLPSGDLALGPPGTPSSEGFMPGCKTLNFTLD	
canine	Digotifico de Las Las Constantes de la Constante de la Constan	480 476
bovine	2202111203121212121212121212121212121212	476
mouse	BBBBMCCOMMITTER BBCBC FOR THE STATE OF THE S	476
ovine		477
porcine		478
horse		478
human	DEDDMIKEDGREDELITATION COLUMN	479
rat		4/3
	:**	
feline	LSRNNLVTIQPEMFARLSRLQCLLLSRNSISQAVNGSQFMPLTSLQVLDLSHNKLDLYHG	538
canine	LSRNNLYTVQPEMFYRLARLQCLGLSHNSISQAVNGSQFVPLSNLRVLDLSHNKLDLYHG	540
bovine	LSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLDLSHNKLDLYHG	536
mouse	LSRNNLVTIQQEMFTRLSRLQCLRLSHNSISQAVNGSQFVPLTSLRVLDLSHNKLDLYHG	
ovine		536
porcine	LSRNNLVTIQSEMFARLSRLECLRLSHNSISQAVNGSQFVPLTSLRVLDLSHNKLDLYHG	537
horse	LSRNNLVTVQPEMFAQLSRLQCLRLSHNSISQAVNGSQFVPLTSLQVLDLSHNKLDLYHG	538
human	LSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHE	538
rat	I.SBNNOVTIKPEMFVNI.SHI.OCLSI.SHNCIAOAVNGSOFLPLTNLKVLDLSYNKLDLYHS	539
146	**** **: ***. *: ** ** ** ** ** ** ** * * *	
6-14	RSFTELPRLEALDLSYNSQPFSMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSA	598
feline	RSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPALRYLSLAHNGIHSRVSQQLRSA	600
canine	RSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSA	596
bovine	RSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSA	596
mouse	RSFTELPQLEALDLSYNSQPFSMQGVGHNLSFVAQLPSLRYLSLAHNGIHSRVSQKLSSA	596
ovine	RSFTELPRLEALDLSYNSQPFTMQGVGHNLSFVAQLPALRYLSLAHNDIHSRVSQQLCSA	597
porcine	RSFTELPRLEALDLSYNSQPFSMRGVGHNLSFVAQLPTLRYLSLAHNGIHSRVSQQLCST	598
horse	HSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCST	598
human	KSFSELPQLQALDLSYNSQPFSMQGIGHNFSFLANLSRLQNLSLAHNDIHSRVSSRLYST	599
rat	**:**:**:*****************************	
feline	SLRALDFSGNALSRMWAEGDLYLHFFRGLRSLVRLDLSQNRLHTLLPRTLDNLPKSLRLL	658
canine	SLRALDFSGNTLSOMWAEGDLYLRFFQGLRSLVQLDLSQNRLHTLLPRNLDNLPKSLRLL	660
bovine	SLRALDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQL	656
mouse	SLRALDFSGNSLSQMWAEGDLYLCFFKGLRNLVQLDLSENHLHTLLPRHLDNLPKSLRQL	656
ovine	SLRALDFSGNSLSOMWAEGDLYLCFFKGLRNLVQLDLSKNHLHTLLPRHLDNLPKSLRQL	656
porcine	SLCALDFSGNDLSRMWAEGDLYLRFFQGLRSLVWLDLSQNHLHTLLPRALDNLPKSLKHL	657
horse	SLWALDFSGNSLSQMWAEGDLYLRFFQGLRSLIRLDLSQNRLHTLLPCTLGNLPKSLQLL	658
human	SLRALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVL	658
rat	SVEYLDFSGNGVGRMWDEEDLYLYFFQDLRSLIHLDLSQNKLHILRPQNLNYLPKSLTKL	659
	*: ***** :::** * **** **:.* .*: ****:** * * *	
feline	RLRDNYLAFFNWSSLVLLPRLEALDLAGNQLKALSNGSLPNGTQLQRLDLSSNSISFVAS	718
canine	RIRDNYLAFFNWSSLALLPKLEALDLAGNOLKALSNGSLPNGTQLQRLDLSGNSIGFVVP	720
bovine	RI.RDNNI.AFFNWSSLTVLPRLEALDLAGNOLKALSNGSLPPGIRLQKLDVSSNSIGFVIP	716
mouse	RI.RDNNI.AFFNWSSLTVLPRLEALDLAGNOLKALSNGSLPPGIRLQKLDVSSNSIGFVIP	716
ovine	RI.RDNNI.AFFNWSSLTVLPOLEALDLAGNOLKALSNGSLPPGTRLQKLDVSSNSIGFVTF	716
porcine	HI.R DNNI.AFFNWSSLTLLPKLETLDLAGNOLKALSNGSLPSGTQLRRLDLSGNSIGFVNF	717
horse	RIRNNYLAFFNWSSLTLLPNLETLDLAGNOLKALSNGSLPSGTQLQRLDVSRNSIIFVVF	718
human	RIRDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAF	718
rat	SERONHI SEFNWSSLAFL PNLR DLDLAGNLLKALTNGTL PNGTLLQKLDVSSNSIV FVVF	719
- 	*** * *** ** ** ** ** *** **** *** * * *	

WO 2004/026888 PCT/US2003/029577 3/4

Figure 1 (3/3)

feline	SFFALATRLRELNLSANALKTVEPSWFGSLAGTLKVLDVTGNPLHCACGAAFVDFLLEVQ	778
canine	SFFALAVRLRELNLSANALKTVEPSWFGSLAGALKVLDVTANPLHCACGATFVDFLLEVQ	780
bovine	GFFVRATRLIELNLSANALKTVDPSWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
mouse	GFFVRATRLIELNLSANALKTVDPSWFGSLAGTLKILDVSANPLHCACGAAFVDFLLERQ	776
ovine	GFFVLANRLKELNLSANALKTVDPFWFGRLTETLNILDVSANPLHCACGAAFVDFLLEMQ	776
porcine	GFFALAKQLEELNLSANALKTVEPSWFGSMVGNLKVLDVSANPLHCACGATFVGFLLEVQ	777
horse		778
human	GFFSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQ	778
rat	AFFALAVELKEVNLSHNILKTVDRSWFGPIVMNLTVLDVSSNPLHCACGAPFVDLLLEVQ	779
	.** * ,* *:*** * *:* : *** : . * :**********	
feline	AAVPGLPGHVKCGSPGQLQGRSIFAQDLRLCLDEALSWDCFGLSLLTVALGLAVPMLHHL	838
canine	AAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDEALSWVCFSLSLLAVALSLAVPMLHQL	840
bovine	EAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVALGLAVPMLHHL	836
mouse	EAVPGLSRRVTCGSPGQLQGRSIFTQDLRLCLDETLSLDCFGLSLLMVALGLAVPMLHHL	836
ovine	AAVPGLSRRVTCGSPGQLQGRSIFAQDLRLCLDETLSLDCFGFSLLMVALGLAVPMLHHL	836
porcine	AAVPGLPSRVKCGSPGQLQGHSIFAQDLRLCLDETLSWNCFGISLLAMALGLVVPMLHHL	837
horse	AAVPGLPSRVKCGSPGQLQGRSIFAQDLRLCLDKSLSWDCFGLSLLVVALGLAMPMLHHL	838
human	AAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHL	838
rat	TKVPGLANGVKCGSPRQLQGRSIFAQDLRLCLDDVLSRDCFGLSLLAVAVGTVLPLLQHL	839

feline	CGWDLWYCFHLCLAWLPRRGRRRGADALPYDAFVVFDKAQSAVADWVYNELRVRLEER	896
canine	CGWDLWYCFHLCLAWLPRRGRRRGVDALAYDAFVVFDKAQSSVADWVYNELRVQLEER	898
bovine	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEER	894
mouse	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAVVVFDKVQSAVADWVYNELRVQLEER	
ovine	CGWDLWYCFHLCLAHLPRRRRQRGEDTLLYDAFVVFDKAQSAVADWVYNELRVQLEER	894
porcine	CGWDLWYCFHLCLAWLPHRGQRRGADALFYDAFVVFDKAQSAVADWVYNELRVQLEER	
horse	CGWDLWYCFHLGLAWLPRRGWQRGADALSYDAFVVFDKAQSAVADWVYNELRVRLEER	896
human	CGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEEC	
rat	CGWDVWYCFHLCLAWLPLLTRGR-RSAQALPYDAFVVFDKAQSAVADWVYNELRVRLEER	898
	****:***** ** ** ** ** ** ** **********	
	DODD S D V OF DED DATE DOWN THAT HAS ALMORDING THE AUMODISCOTED A CELL A CODE	056
feline	1.0144111111111111111111111111111111111	956
canine	RGRRALRLCLEERDWVPGKTLFENLWASVYSSRKTLFVLARTDRVSGLLRASFLLAQQRL	958 954
bovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL	954 954
mouse	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL	954
ovine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTMFVLDHTDRVSGLLRASFLLAQQRL RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKTLFVLAHTDRVSGLLRASFLLAQQRL	955
porcine	RGRRALRLCLEERDWLPGKTLFENLWASVYSSRKMLFVLAHTDQVSGLLRASFLLAQQRL	
horse	RGRWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRL	
human	RGRWALKLCLEERDWLPGGTLFENLWASIYGSRKTLFVLAHTDKVSGLLRTSFLLAQQRL	
rat	*** ******:**:**:*********** :*** :**: ***:******	230
feline	LEDRKDVVVLVILRPDAHRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNQ	1016
canine	LEDRKDVVVLVILCPDAHRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGTALTRDNR	
bovine	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNR	
mouse	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGIALTRDNR	
ovine	LEDRKDVVVLVILRPAAYRSRYVRLRQRLCRQSVLLWPHQPSGQGSFWANLGMALTRDNR	1014
porcine	LEDRKDVVVLVILRPDAYRSRYVRLRQRLCRQSVLLWPHQPRGQGSFWAQLGTALTRDNH	1015
horse	LEDRKDVVVLVILSPDARRSRYVRLRQRLCRQSVLFWPHQPSGQRSFWAQLGMALTRDNR	1016
human	LEDRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNH	1018
rat	LEDRKDVVVLVILRPDAHRSRYVRLRORLCROSVLFWPHQPNGQGSFWAQLSTALTRDNH	1018
	********* * . ************** ** ** **** * *****	
		40
feline	HFYNQNFCRGPTTAE	1031
canine	HFYNQNFCRGPTTA	1032
bovine	HFYNRNFCRGPTTAE	1029
mouse	HFYNRNFCRGPTTAE	1032
ovine	HFYNRNFCRGPTTAE	1029
porcine	HFYNRNFCRGPTTAE	1030
horse	HFYNONFCRGPTMAE	1031
human	HFYNRNFCQGPTAE	1032
rat	HFYNRNFCRGPTAE	1032

Figure 2





Figure 3



SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH
 University of Saskatchewan
 Qiagen GmbH

- <120> TOLL-LIKE RECEPTOR 9 (TLR9) FROM VARIOUS MAMMALIAN SPECIES
- <130> C1041.70040WO00
- <150> US 60/412,479
- <151> 2002-09-19
- <160> 70
- <170> PatentIn version 3.1
- <210> 1
- <211> 1032
- <212> PRT
- <213> Rattus norvegicus
- <400> 1

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn 50 55

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn 65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp
85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met 100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 135 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro 180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser 260 265 270

Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe 290 295 300

Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335

Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala 340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu 355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu 370 375 380

Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400

- Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala
 405 410 415
- Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr 420 425 430
- Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val 435 440 445
- Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser 450 455 460
- Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu 465 470 480
- Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495
- Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala 500 505 510
- Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp 515 520 525
- Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu 530 540
- Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 560
- Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser 565 570 575
- Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val 580 585 590
- Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly 595 600 605
- Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe

610 615 620

Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys 625 630 635

Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu 645 650 655

Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser 660 665 670

Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn 675 680 685

Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala 705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn 725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly 755 760 765

Ala Pro Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly 770 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg 785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser 805 810 815

Arg Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Thr Val 820 825 830

Leu Pro Leu Leu Gln His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe 835 840 845

-4-

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Thr Arg Gly Arg Arg Ser 850 855 860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu 885 890 895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp 900 905 910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Lys Val Ser 930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Phe Trp Pro His Gln Pro Asn Gly Gln Gly Ser Phe Trp Ala Gln 995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg 1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu 1025 1030

<210> 2

<211> 821

<212> PRT

<213> Rattus norvegicus

<400> 2

Met Val Leu Cys Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Val Leu Ala Glu Ala Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Glu Pro Arg Ser Asn 50 55 60

Ile Thr Ser Leu Ser Leu Ile Ala Asn Arg Ile His His Leu His Asn 65 70 75 80

Leu Asp Phe Val His Leu Pro Asn Val Arg Gln Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Pro Gly Leu Ser Pro Leu His Phe Ser Cys Arg Met
100 105 110

Thr Ile Glu Pro Lys Thr Phe Leu Ala Met Arg Met Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 140

Leu Thr Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 155 160

Ser Ser Leu Ala Gly Leu His Ser Leu Arg Val Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Asn Gly Ala Val Asn Val Thr Pro 180 185 190

Asp Ala Phe Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Glu Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn Leu Ile Val Lys Leu Gly Ala Glu Asp Leu 225 235 240

Ala Asn Leu Thr Ser Leu Arg Met Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asp Leu Cys Thr Glu Cys Arg Gln Lys Ser 260 265 270

- Leu Asp Leu His Pro Gln Thr Phe His His Leu Ser His Leu Glu Gly 275 280 285
- Leu Val Leu Lys Asp Ser Ser Leu His Ser Leu Asn Ser Lys Trp Phe 290 295 300
- Gln Gly Leu Ala Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320
- Tyr Glu Ser Ile Asn Lys Thr Ser Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335
- Arg Lys Leu Asp Leu Ser Phe Asn Tyr Cys Lys Lys Val Ser Phe Ala 340 345
- Arg Leu His Leu Ala Ser Ser Phe Lys Ser Leu Val Ser Leu Gln Glu 355 360 365
- Leu Asn Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Asn Thr Leu 370 375 380
- Arg Trp Leu Ala Gly Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400
- Asn Phe Ile Asn Gln Ala Gln Leu Ser Val Phe Ser Thr Phe Arg Ala 405 410 415
- Leu Arg Phe Val Asp Leu Ser Asn Asn Arg Ile Ser Gly Pro Pro Thr 420 425 430
- Leu Ser Arg Val Ala Pro Glu Lys Ala Asp Glu Ala Glu Lys Gly Val 435 440 445
- Pro Trp Pro Ala Ser Leu Thr Pro Ala Leu Pro Ser Thr Pro Val Ser 450 455 460 '
- Lys Asn Phe Met Val Arg Cys Lys Asn Leu Arg Phe Thr Met Asp Leu 465 470 475 480
- Ser Arg Asn Asn Gln Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495

Ser His Leu Gln Cys Leu Ser Leu Ser His Asn Cys Ile Ala Gln Ala 500 505 510

- Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Lys Val Leu Asp 515 520 525
- Leu Ser Tyr Asn Lys Leu Asp Leu Tyr His Ser Lys Ser Phe Ser Glu 530 540
- Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 555
- Ser Met Gln Gly Ile Gly His Asn Phe Ser Phe Leu Ala Asn Leu Ser 565 570 575
- Arg Leu Gln Asn Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val 580 585 590
- Ser Ser Arg Leu Tyr Ser Thr Ser Val Glu Tyr Leu Asp Phe Ser Gly 595 600 605
- Asn Gly Val Gly Arg Met Trp Asp Glu Glu Asp Leu Tyr Leu Tyr Phe 610 615 620
- Phe Gln Asp Leu Arg Ser Leu Ile His Leu Asp Leu Ser Gln Asn Lys 625 630 635
- Leu His Ile Leu Arg Pro Gln Asn Leu Asn Tyr Leu Pro Lys Ser Leu 645 650 655
- Thr Lys Leu Ser Phe Arg Asp Asn His Leu Ser Phe Phe Asn Trp Ser 660 665 670
- Ser Leu Ala Phe Leu Pro Asn Leu Arg Asp Leu Asp Leu Ala Gly Asn 675 680 685
- Leu Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 695 700
- Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Phe Val Val Pro Ala 705 710 715 720
- Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn

725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn $740 \hspace{1.5cm} 745 \hspace{1.5cm} 750 \hspace{1.5cm}$

Leu Thr Val Leu Asp Val Ser Ser Asn Pro Leu His Cys Ala Cys Gly 755 760 765

Ala Pro Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Arg Gln Leu Gln Gly Arg
785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Asp Val Leu Ser 805 810 815

Arg Asp Cys Phe Gly 820

<210> 3

<211> 3099

<212> DNA

<213> Rattus norvegicus

<400> 3

atggttetet gtegeaggae eetgeaceee ttgtetetee tggtacagge egcagtgetg 60 getgaggete tggeeetggg taccetgeet geetteetae cetgtgaact gaageeteat 120 ggcctggtag actgcaactg gctcttcctg aagtctgtgc ctcacttctc tgccgcagaa 180 coccepticca acateaceag cetticetty ategecaace geatecacea cetgeacaac 240 ctcgactttg tccacctgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc 300 cctggcctca gccccttgca cttctcctgc cgcatgacca ttgagcccaa aaccttcctg 360 gctatgcgca tgctggaaga gctgaacctg agctataacg gtatcaccac tgtgccccgc 420 ctgcccagct ccctgacgaa tctgagccta agccacacca acatcctggt actcgatgcc 480 agcagceteg etggeetgea cageetgega gttetettea tggaegggaa etgetaetae aagaacccct gcaacgggc ggtgaacgtg accccggacg ccttcctggg cttgagcaac 600 ctcacccact tgtcccttaa gtataacaac ctcacagagg tgccccgcca actgcccccc 660 agectggagt acctectgct gtectataac ctcategtca agetggggge cgaagaceta 720 gccaacctga cctcccttcg aatgcttgat gtgggtggga attgccgtcg ctgtgatcac 780

gcccccgacc tctgtacaga	atgccggcag	aagtcccttg	atctgcaccc	tcagactttc	840
catcacctga gccaccttga	aggcctggtg	ctgaaggaca	gttctctcca	ctcgctgaac	900
tccaagtggt tccagggtct	ggcgaacctc	teggtgetgg	acctaagcga	gaactttctc	960
tacgagagca tcaacaaaac	cagcgccttt	cagaacctga	cccgtctgcg	caagctcgac	1020
ctgtccttca attactgcaa	gaaggtatcg	ttcgcccgcc	tccacctggc	aagttccttc	1080
aagagcctgg tgtcgctgca	ggagctgaac	atgaacggca	tcttcttccg	cttactcaac	1140
aagaacacgc tcaggtggct	ggctggtctg	cccaagctcc	acacgctgca	ccttcaaatg	1200
aatttcatca accaggcgca	gctcagcgtc	tttagtacct	tccgagccct	tcgctttgtg	1260
gacctgtcca ataatcgcat	cagegggeet	ccaacgctgt	ccagagtcgc	ccccgaaaag	1320
gcagacgagg cggagaaggg	ggttccatgg	cctgcaagtc	tcaccccagc	tctcccgagc	1380
actcccgtct caaagaactt	catggtcagg	tgtaagaacc	tcagattcac	catggacctg	1440
tctcggaaca accaggtgac	tatcaagcca	gagatgttcg	tcaacctctc	ccatctccag	1500
tgtctgagcc tgagccacaa	ctgcatcgcg	caggctgtca	atggctctca	gttcctgccg	1560
ctgaccaacc tgaaggtgct	ggacctgtcc	tataacaagc	tggacctgta	ccattcgaaa	1620
tegtteagtg ageteceaca	gttgcaggcc	ctggacctga	gctacaacag	ccagccattc	1680
agcatgcagg ggataggcca	caacttcagt	tttctggcca	atctgtccag	gttacagaac	1740
cttagcctgg cacacaatga	cattcacage	cgcgtgtcct	cacgcctcta	cagcacctca	1800
gtggagtatc tggacttcag	cggcaacggt	gtgggccgca	tgtgggacga	ggaggacctt	1860
tacctctatt tcttccaaga	cctgagaagc	ctgattcatc	tggacctgtc	tcagaataag	1920
ctgcacatcc tccggcccca	gaacctcaac	tacctcccca	agagcctgac	gaagctgagt	1980
ttccgtgaca atcacctctc	tttctttaac	tggagcagtc	tggccttcct	gcccaatctg	2040
cgagacctgg acctggcagg	caatctacta	aaggccctga	ccaacggcac	cctgcctaat	2100
ggcacgctcc tccagaaact	ggatgtcagt	agcaacagta	tegtetttgt	ggtcccagcc	2160
ttetttgete tggcggtaga	. gctaaaagag	gtcaacctca	gccataacat	cctcaagact	2220
gtggatcgct cctggtttgg	gcccattgtg	atgaacctga	cggttctaga	cgtgagcagc	2280
aaccetetge attgtgeetg	cggtgcaccc	tttgtagact	tactgctgga	agtgcagacc	2340
aaggtgcctg gcctggctaa	cggtgtgaag	tgtggcagtc	cccgccagct	gcagggccgc	2400
agcatctttg cgcaagacct	gcggctgtgc	ctggatgacg	tcctttctcg	ggactgcttt	2460
ggcctttcac tcctggctgt	ggccgtgggc	acggtgttgc	ctttactgca	gcatctctgc	2520
ggctgggacg tctggtactg	tttccatctg	tgcctggcat	ggctaccttt	gctgacccgt	2580

2640 ggccggcgca gcgcccaagc tctcccttat gatgccttcg tggtgttcga taaggcgcag 2700 agegeggttg etgaetgggt gtataaegag ettegagtge ggetagagga geggegeggt 2760 egeegageee taegettgtg tetggaggae egagattgge tgeetggeea gaeactette gagaacctct gggcctccat ctatggcagc cgcaagactc tgtttgtgct ggcccacacg 2820 gacaaggtca gtggcctcct gcgcaccagc ttcctgctgg ctcagcagcg cctgctggag 2880 gaccgcaagg acgtggtggt gttggtgatc ctgcgccctg atgcccaccg ctcccgctac 2940 gtgcgactgc gccagcgcct ctgccgccag agtgtgctct tctggcccca tcagcccaac 3000 3060 gggcagggca gcttctgggc ccagctgagt acagccctga ctagggacaa ccaccacttc tataaccgga acttctgccg gggacctaca gcagaatag 3099

<210> 4

<211> 2463

<212> DNA

<213> Rattus norvegicus

<400> 4

60 atggttctct gtcgcaggac cctgcacccc ttgtctctcc tggtacaggc cgcagtgctg gctgaggctc tggccctggg taccctgcct gccttcctac cctgtgaact gaagcctcat 120 ggcctggtag actgcaactg gctcttcctg aagtctgtgc ctcacttctc tgccgcagaa 180 ccccgttcca acatcaccag cctttccttg atcgccaacc gcatccacca cctgcacaac 240 ctcgactttg tccacctgcc caacgtgcga cagctgaacc tcaagtggaa ctgtccgccc 300 cetggeetea geceettgea etteteetge egeatgacea ttgageecaa aacetteetg 360 gctatgcgca tgctggaaga gctgaacctg agctataacg gtatcaccac tgtgccccgc 420 ctqcccagct ccctgacgaa tctgagccta agccacacca acatcctggt actcgatgcc 480 ageageeteg etggeetgea eageetgega gttetettea tggaegggaa etgetaetae 540 aagaacccct gcaacggggc ggtgaacgtg accccggacg ccttcctggg cttgagcaac 600 ctcacccact tgtcccttaa gtataacaac ctcacagagg tgccccgcca actgcccccc 660 agectggagt acctectget gteetataac eteategtea agetggggge egaagaceta 720 gccaacctga cctcccttcg aatgcttgat gtgggtggga attgccgtcg ctgtgatcac 780 geoceegace tetgtacaga atgeeggeag aagteeettg atetgeacee teagaettte 840 catcacctga gccaccttga aggcctggtg ctgaaggaca gttctctcca ctcgctgaac 900 tecaagtggt tecagggtet ggegaacete teggtgetgg acetaagega gaactttete 960 tacgagagca tcaacaaaac cagcgccttt cagaacctga cccgtctgcg caagctcgac 1020

PCT/US2003/029577 WO 2004/026888

ctgtccttca	attactgcaa	gaaggtatcg	ttcgcccgcc	tccacctggc	aagttccttc	1080
aagagcctgg	tgtcgctgca	ggagctgaac	atgaacggca	tcttcttccg	cttactcaac	1140
aagaacacgc	tcaggtggct	ggctggtctg	cccaagctcc	acacgctgca	ccttcaaatg	1200
aatttcatca	accaggcgca	gctcagcgtc	tttagtacct	tecgageeet	tcgctttgtg	1260
gacctgtcca	ataatcgcat	cagcgggcct	ccaacgctgt	ccagagtcgc	ccccgaaaag	1320
gcagacgagg	cggagaaggg	ggttccatgg	cctgcaagtc	teaccceage	tctcccgagc	1380
actcccgtct	caaagaactt	catggtcagg	tgtaagaacc	tcagattcac	catggacctg	1440
tctcggaaca	accaggtgac	tatcaagcca	gagatgttcg	tcaacctctc	ccatctccag	1500
tgtctgagcc	tgagccacaa	ctgcatcgcg	caggctgtca	atggctctca	gttcctgccg	1560
ctgaccaacc	tgaaggtgct	ggacctgtcc	tataacaagc	tggacctgta	ccattcgaaa	1620
tcgttcagtg	agctcccaca	gttgcaggcc	ctggacctga	gctacaacag	ccagccattc	1680
agcatgcagg	ggataggcca	caacttcagt	tttctggcca	atctgtccag	gttacagaac	1740
cttagcctgg	cacacaatga	cattcacage	cgcgtgtcct	cacgcctcta	cagcacctca	1800
gtggagtatc	tggacttcag	cggcaacggt	gtgggccgca	tgtgggacga	ggaggacctt	1860
tacctctatt	tcttccaaga	cctgagaagc	ctgattcatc	tggacctgtc	tcagaataag	1920
ctgcacatcc	tccggcccca	gaacctcaac	tacctcccca	agagcctgac	gaagctgagt	1980
ttccgtgaca	atcacctctc	tttctttaac	tggagcagtc	tggccttcct	gcccaatctg	2040
cgagacctgg	acctggcagg	caatctacta	aaggccctga	ccaacggcac	cctgcctaat	2100
ggcacgctcc	tccagaaact	ggatgtcagt	agcaacagta	tegtetttgt	ggtcccagcc	2160
ttctttgctc	tggcggtaga	gctaaaagag	gtcaacctca	gccataacat	cctcaagact	2220
gtggatcgct	cctggtttgg	gcccattgtg	atgaacctga	cggttctaga	cgtgagcagc	2280
aaccctctgc	attgtgcctg	cggtgcaccc	tttgtagact	tactgctgga	agtgcagacc	2340
aaggtgcctg	gcctggctaa	cggtgtgaag	tgtggcagtc	cecgccaget	gcagggccgc	2400
agcatctttg	cgcaagacct	gcggctgtgc	ctggatgacg	tecttteteg	ggactgcttt	2460
ggc						2463
			ı			

<210> 5
<211> 1030
<212> PRT
<213> Sus scrofa

<400> 5

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val 1 5 10 15

- Thr Ala Leu Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu 20 25 30
- Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe 35 40 45
- Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Ala Asn Val 50 55 60
- Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80
- Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn 85 90 95
- Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr 100 105 110
- Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125
- Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu 130 135 140
- Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr 145 150 155 160
- His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn 165 170 175
- Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly 180 185 190
- Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205
- Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu 210 215 220
- Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala 225 230 235 235

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 245 250 255

- Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro 260 265 270
- Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285
- Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg 290 295 300
- Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315
- Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg 325 330 335
- Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350
- Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu 355 360 365
- Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln 370 375 380
- Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn 385 390 395 400
- Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu 405 410 415
- Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro
 420 425 430
- Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro 435 440 445
- Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp 450 455 460
- Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg 465 470 475 480

Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg 485 490 495

- Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn 500 505 510
- Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser 515 520 525
- His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro 530 540
- Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met 545 550 555 560
- Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu 565 570 575
- Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln 580 585 590
- Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp 595 600 605
- Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln 610 615 620
- Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His 625 630 635 640
- Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His 645 650 655
- Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu 660 665 670
- Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu 675 680 685
- Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg 690 695 700
- Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe

705					710					715					720
Ala	Leu	Ala	Lys	Gln 725	Leu	Glu	Glu	Leu	Asn 730	Leu	Ser	Ala	Asn	Ala 735	Leu
Lys	Thr	Val	Glu 740	Pro	Ser	Trp	Phe	Gly 745	Ser	Met	Val	Gly	Asn 750	Leu	Lys
Val	Leu	Asp 755	Val	Ser	Ala	Asn	Pro 760	Leu	His	Cys	Ala	Cys 765	Gly	Ala	Thr
Phe	Val 770	Gly	Phe	Leu	Leu	Glu 775	Val	Gln	Ala	Ala	Val 780	Pro	Gly	Leu	Pro
Ser 785	Arg	Val	Lys	Cys	Gly 790	Ser	Pro	Gly	Gln	Leu 795	Gln	Gly	His	Ser	Ile 800
Phe	Ala	Gln	Asp	Leu 805	Arg	Leu	Cys	Leu	Asp 810	Glu	Thr	Leu	Ser	Trp 815	Asn
Cys	Phe	Gly	Ile 820	Ser	Leu	Leu	Ala	Met 825	Ala	Leu	Gly	Leu	Val 830	Val	Pro
Met	Leu	His 835	His	Leu	Cys	Gly	Trp 840	Asp	Leu	Trp	Tyr	Cys 845	Phe	His	Leu
Cys	Leu 850	Ala	Trp	Leu	Pro	His 855	Arg	Gly	Gln	Arg	Arg 860	Gly	Ala	Asp	Ala
Leu 865	Phe	Tyr	Asp	Ala	Phe 870	Val	Val	Phe	Asp	Lys 875	Ala	Gln	Ser	Ala	Val 880
Ala	Asp	Trp	Val	Tyr 885	Asn	Glu	Leu	Arg	Val 890	Gln	Leu	Glu	Glu	Arg 895	Arg
Gly	Arg	Arg	Ala 900	Leu	Arg	Leu	Cys	Leu 905	Glu	Glu	Arg	Asp	Trp 910	Leu	Pro
Gly	ГÀЗ	Thr 915	Leu	Phe	Glu	Asn	Leu 920	Trp	Ala	Ser	Val	Tyr 925	Ser	Ser	Arc
Lys	Thr 930	Leu	Phe	Val	Leu	Ala 935	His	Thr	Asp	Arg	Val 940	Ser	Gly	Leu	Leu

- 16 -

Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys

Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala Tyr Arg Ser Arg 970

Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp

Pro His Gln Pro Arg Gly Gln Gly Ser Phe Trp Ala Gln Leu Gly Thr 995 1000 1005

Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg Asn Phe Cys 1010 1015 1020

Arg Gly Pro Thr Thr Ala Glu 1025 1030

<210> 6 <211> 819 <212> PRT

<213> Sus scrofa

<400> 6

Met Gly Pro Arg Cys Thr Leu His Pro Leu Ser Leu Leu Val Gln Val

Į

Thr Ala Leu Ala Ala Leu Ala Gln Gly Arg Leu Pro Ala Phe Leu 25

Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu Phe

Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Ala Asn Val

Thr Ser Leu Ser Leu Ser Asn Arg Ile His His Leu His Asp Ser 70 75

Asp Phe Val His Leu Ser Ser Leu Arg Thr Leu Asn Leu Lys Trp Asn 90

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met Thr 105

- 17 -

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

- Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Asp Ser Leu 130 135 140
- Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro Thr 145 150 155 160
- His Leu Thr Gly Leu His Ala Leu Arg Tyr Leu Tyr Met Asp Gly Asn 165 170 175
- Cys Tyr Tyr Lys Asn Pro Cys Gln Gly Ala Leu Glu Val Val Pro Gly 180 185 190
- Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205
- Asn Leu Thr Glu Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Thr Leu 210 215 220
- Leu Leu Ser Tyr Asn His Ile Val Thr Leu Thr Pro Glu Asp Leu Ala 225 230 235 240
- Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Asn Cys Arg Arg 245 250 255
- Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asp His Pro 260 265 270
- Lys Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285
- Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asp Thr Arg Trp Phe Arg 290 295 300
- Gly Leu Asp Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315
- Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Arg Leu Arg 325 330 335
- Ser Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu His Leu Ala Pro Ser Phe Gly His Leu Arg Ser Leu Lys Glu Leu 355 360 365

- Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu Gln 370 380
- Pro Leu Val Gln Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn 385 390 395 400
- Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly Leu 405 410 415
- Leu Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430
- Val Ala Ile Thr Arg Glu Val Asp Gly Arg Glu Arg Val Trp Leu Pro 435 440 445
- Ser Arg Asn Leu Ala Pro Arg Pro Leu Asp Thr Leu Arg Ser Glu Asp 450 455 460
- Phe Met Pro Asn Cys Lys Ala Phe Ser Phe Thr Leu Asp Leu Ser Arg 465 470 475 480
- Asn Asn Leu Val Thr Ile Gln Ser Glu Met Phe Ala Arg Leu Ser Arg
 485
 490
 495
- Leu Glu Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn 500 505 510
- Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser 515 520 525
- His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro 530 535 540
- Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Thr Met 545 550 555 560
- Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala Leu 565 570 575
- Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln 580 585 590

Gln Leu Cys Ser Ala Ser Leu Cys Ala Leu Asp Phe Ser Gly Asn Asp 595 600 605

Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe Gln 610 615 620

Gly Leu Arg Ser Leu Val Trp Leu Asp Leu Ser Gln Asn His Leu His 625 630 635

Thr Leu Leu Pro Arg Ala Leu Asp Asn Leu Pro Lys Ser Leu Lys His 645 650 655

Leu His Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu 660 665 670

Thr Leu Leu Pro Lys Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln Leu 675 680 685

Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Arg Arg 690 695 700

Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Asn Pro Gly Phe Phe 705 710 715 720

Ala Leu Ala Lys Gln Leu Glu Glu Leu Asn Leu Ser Ala Asn Ala Leu 725 730 735

Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Met Val Gly Asn Leu Lys 740 745 750

Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Thr 755 760 765

Phe Val Gly Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro 770 780

Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly His Ser Ile 785 790 795 800

Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Trp Asn 805 810 810

Cys Phe Gly

<210> 7 <211> 3352 <212> DNA <213> Sus scrofa

<400> 7 gagcacgaac atcettcact gtagctgetg cccggtctgc cagccagacc ctttggagaa 60 gaccccactc cctgtcatgg gcccccgctg caccctgcac cccctttctc tcctggtgca 120 ggtgacagcg ctggctgegg ctctggccca gggcaggctg cctgccttcc tgccctgtga 180 gctccagccc cacggcctgg tgaactgcaa ctggctcttc ctgaagtccg tgccccactt 240 300 cteggeggea gegeeeggg ceaaegteac cageetetee ttaeteteea acegeateea ccacctgeac gactccgact tegtecacct gtccagecta cgaactetea aceteaagtg 360 gaactgeceg ceggetggee teagececat geactteece tgccacatga ceategagee 420 480 caacacette etggeegtge ceaccetgga ggagetgaac etgagetaca acageateac gaccgtgcct gccctgcccg actccctcgt gtccctgtcg ctgagccgca ccaacatcct 540 600 ggtgctagac cccaccacc tcactggcct acatgccctg cgctacctgt acatggatgg 660 caactgctac tacaagaacc cctgccaggg ggcgctggag gtggtgccgg gtgccctcct 720 cggcctgggc aacctcacac atctctcact caagtacaac aatctcacgg aggtgccccg 780 cageetgeec eccageetgg agaeeetget gttgteetae aaceaeattg teaceetgae gcctgaggac ctggccaatc tgactgccct gcgcgtgctt gatgtggggg ggaactgccg 840 900 ccqctgtqac catgcccgca acccctgcag ggagtgccca aaggaccacc ccaagctgca 960 ctctgacacc ttcagccacc tgagccgcct cgaaggcctg gtgttgaaag acagttctct 1020 ctacaacctg gacaccaggt ggttccgagg cctggacagg ctccaagtgc tggacctgag tgagaacttc ctctacgact gcatcaccaa gaccacggcc ttccagggcc tggcccgact 1080 gcgcagcctc aacctgtcct tcaattacca caagaaggtg tcctttgccc acctgcacct 1140 1200 ggcaccetce titgggcace teeggteeet gaaggagetg gacatgcatg geatettett 1260 ccqctcqctc agtqaqacca cgctccaacc tctggtccaa ctgcctatgc tccagaccct 1320 qcqcctgcag atgaacttca ttaaccagge ccagetcage atetttgggg cettecetgg 1380 cctgctgtac gtggacctat cggacaaccg catcagcgga gctgcaaggc cagtggccat tactagggag gtggatggta gggagagggt ctggctgcct tccaggaacc tcgctccacg 1440 tocactggae actotocgot cagaggaett catgocaaac tgcaaggeet teagetteac 1500

1560 cttggacctg tctcggaaca acctggtgac aatccagtcg gagatgtttg ctcgcctctc acgcctcgag tgcctgcgcc tgagccacaa cagcatctcc caggcggtca atggctctca 1620 qtttqtqccg ctgaccagcc tgcgggtgct ggacctgtcc cacaacaagc tggacctgta 1680 1740 teaeggege tegtteaegg agetgeegeg cetggaagea etggaeetea getacaatag 1800 ccagecettt accatgeagg gtgtgggeca caaceteage ttegtggeec agetgeeege 1860 cctgcgctac ctcagcctgg cgcacaatga catccatagc cgagtgtccc agcagctctg tagogoctca ctgtgcgccc tggactttag cggcaacgat ctgagccgga tgtgggctga 1920 1980 gggagacete tateteeget tettecaagg cetaagaage etagtetgge tggacetgte 2040 ccagaaccac ctgcacaccc tcctgccacg tgccctggac aacctcccca aaagcctgaa 2100 gcatctgcat ctccgtgaca ataacctggc cttcttcaac tggagcagcc tgaccctcct gcccaagctg gaaaccctgg acttggctgg aaaccagctg aaggccctaa gcaatggcag 2160 2220 cetqccatet qqcacccage tgcggagget ggacctcagt ggcaacagca tcggctttgt quaccetgge ttetttgeee tggeeaagea gttagaagag etcaacetea gegeeaatge 2280 cctcaagaca gtggagccct cctggtttgg ctcgatggtg ggcaacctga aagtcctaga 2340 cgtgagegec aaccetetge actgtgeetg tggggegace ttegtggget teetgetgga 2400 ggtacagget geogtgeetg ggetgeecag eegegteaag tgtggeagte eggggeaget 2460 2520 ccagggccat agcatctttg cgcaagacct gegeetetge etggatgaga ecetetegtg 2580 gaactgtttt ggcatctcgc tgctggccat ggccctgggc ctggttgtgc ccatgctgca 2640 ccacctetge ggetgggace tetggtactg ettecacetg tgeetggeet ggetgeecea 2700 ccqaqqqcaq cqqcqqqqc cagacqccct gttctatgat gccttcqtgg tctttgacaa 2760 ageteagagt getgtggeeg aetgggtgta caacgagetg egggtgeage tggaggageg 2820 ccgtgggcgc cgcgcactgc gcctgtgcct ggaggagcga gactggttac ctggcaagac gctcttcgag aacctgtggg cctcagtcta cagcagccgc aagaccctgt ttgtgctggc 2880 ccacacggac cgtgtcagcg gcctcttgcg tgccagtttc ctgctggccc agcagcgcct 2940 3000 qctggaggac cgcaaggacg ttgtagtgct ggtgatcctg cgccccgatg cctaccgctc ccgctacgtg cggctgcgcc agcgcctctg ccgccagagt gtcctcctct ggccccacca 3060 gccccgtggg cagggcagct tctgggccca gctgggcaca gccctgacca gggacaacca 3120 ccacttctat aaccqgaact tctgccgggg ccccacgaca gccgaatagc actgagtgac 3180 ageceagttg ecceageece eetggatttg ectetetgee tggggtgeec caacetgett 3240 tgctcagcca caccactgct ctgctccctg ttccccaccc cacccccag cctggcatgt 3300 -

aacatgtgc	c caataaatgo	: taccggaggg	g ccaagaaaaa	aaaaaaaaaa	a aa	3352
<210> 8 <211> 245 <212> DN7 <213> Sus						
<400> 8	getgeaccet	gcaccccctt	teteteetaa	tacaaataa	: agcgctggct	60
					gccccacggc	120
					: ggcagcgccc	180
cgggccaacg	tcaccagcct	ctccttactc	tccaaccgca	tccaccacct	gcacgactcc	240
gacttcgtcc	acctgtccag	cctacgaact	ctcaacctca	agtggaactg	cccgccggct	300
ggcctcagcc	ccatgcactt	cccctgccac	atgaccatcg	agcccaacac	cttcctggcc	360
gtgcccaccc	tggaggagct	gaacctgagc	tacaacagca	tcacgaccgt	gcctgccctg	420
cccgactccc	tegtgteect	gtcgctgagc	cgcaccaaca	tcctggtgct	agaccccacc	480
cacctcactg	gcctacatgc	cctgcgctac	ctgtacatgg	atggcaactg	ctactacaag	540
aacccctgcc	agggggcgct	ggaggtggtg	ccgggtgccc	tcctcggcct	gggcaacctc	600
acacatctct	cactcaagta	caacaatctc	acggaggtgc	cccgcagcct	gcccccagc	660
ctggagaccc	tgctgttgtc	ctacaaccac	attgtcaccc	tgacgcctga	ggacctggcc	720
aatctgactg	ccctgcgcgt	gcttgatgtg	gggggaact	gccgccgctg	tgaccatgcc	780
cgcaacccct	gcagggagtg	cccaaaggac	caccccaagc	tgcactctga	caccttcagc	840
cacctgagcc	gcctcgaagg	cctggtgttg	aaagacagtt	ctctctacaa	cctggacacc	900
aggtggttcc	gaggcctgga	caggetecaa	gtgctggacc	tgagtgagaa	cttcctctac	960
gactgcatca	ccaagaccac	ggccttccag	ggcctggccc	gactgcgcag	cctcaacctg	1020
tccttcaatt	accacaagaa	ggtgtccttt	gcccacctgc	acctggcacc	ctcctttggg	1080
cacctccggt	ccctgaagga	gctggacatg	catggcatct	tcttccgctc	gctcagtgag	1140
accacgetee	aacctctggt	ccaactgcct	atgctccaga	ccctgcgcct	gcagatgaac	1200
ttcattaacc	aggcccagct	cagcatcttt	ggggccttcc	ctggcctgct	gtacgtggac	1260
ctatcggaca	accgcatcag	cggagctgca	aggccagtgg	ccattactag	ggaggtggat	1320
ggtagggaga	gggtctggct	gccttccagg	aacctcgctc	cacgtccact	ggacactctc	1380
cgctcagagg	acttcatgcc	aaactgcaag	gccttcagct	tcaccttgga	cctgtctcgg	1440
aacaacctgg	tgacaatcca	gtcggagatg	tttgctcgcc	tctcacgcct	cgagtgcctg	1500

PCT/US2003/029577 WO 2004/026888

cgcctgagcc	acaacagcat	ctcccaggcg	gtcaatggct	ctcagtttgt	gccgctgacc	1560
agcctgcggg	tgctggacct	gtcccacaac	aagctggacc	tgtatcacgg	gcgctcgttc	1620
acggagctgc	cgcgcctgga	agcactggac	ctcagctaca	atagccagcc	ctttaccatg	1680
cagggtgtgg	gccacaacct	cagcttcgtg	gcccagctgc	ccgccctgcg	ctacctcagc	1740
ctggcgcaca	atgacatcca	tagccgagtg	tcccagcagc	tctgtagcgc	ctcactgtgc	1800
gccctggact	ttagcggcaa	cgatctgagc	cggatgtggg	ctgagggaga	cctctatctc	1860
cgcttcttcc	aaggcctaag	aagcctagtc	tggctggacc	tgtcccagaa	ccacctgcac	1920
accctcctgc	cacgtgccct	ggacaacctc	cccaaaagcc	tgaagcatct	gcatctccgt	1980
gacaataacc	tggccttctt	caactggagc	agcctgaccc	tectgeccaa	gctggaaacc	2040
ctggacttgg	ctggaaacca	gctgaaggcc	ctaagcaatg	gcagcctgcc	atctggcacc	2100
cagctgcgga	ggctggacct	cagtggcaac	agcatcggct	ttgtgaaccc	tggcttcttt	2160
gccctggcca	agcagttaga	agagctcaac	ctcagcgcca	atgccctcaa	gacagtggag	2220
ccctcctggt	ttggctcgat	ggtgggcaac	ctgaaagtcc	tagacgtgag	cgccaaccct	2280
ctgcactgtg	cctgtggggc	gaccttcgtg	ggetteetge	tggaggtaca	ggctgccgtg	2340
cctgggctgc	ccagccgcgt	caagtgtggc	agtccggggc	agctccaggg	ccatagcatc	2400
tttgcgcaag	acctgcgcct	ctgcctggat	gagaccctct	cgtggaactg	ttttggc	2457

<210> 9 <211> 1029 <212> PRT <213> Bos taurus

<400> 9

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala

Ala Ala Leu Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

- Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr 100 105 110
- Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125
- Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140
- Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160
- His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175
- Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly 180 185 190
- Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205
- Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 215 220
- Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240
- Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Asn Cys Arg Arg 245 250 255
- Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 . 270
- Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285
- Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300
- Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr

305					310					315					320	
Asp	Tyr	Ile	Thr	Lys 325	Thr	Thr	Ile	Phe	Asn 330	Asp	Leu	Thr	Gln	Leu 335	Arg	
Arg	Leu	Asn	Leu 340	Ser	Phe	Asn	Tyr	His 345	Lys	Lys	Val	Ser	Phe 350	Ala	His	
Leu	His	Leu 355	Ala	Ser	Ser	Phe	Gly 360	ser	Leu	Val	Ser	Leu 365	Glu	ГЛа	Leu	
Asp	Met 370	His	Gly	Ile	Phe	Phe 375	Arg	Ser	Leu	Thr	Asn 380	Ile	Thr	Leu	Gln	
Ser 385	Leu	Thr	Arg	Leu	Pro 390	Lys	Leu	Gln	Ser	Leu 395	His	Leu	Gln	Leu	Asn 400	
Phe	Ile	Asn	Gln	Ala 405	Ġln	Leu	Ser	Ile	Phe 410	Gly	Ala	Phe	Pro	Ser 415	Leu	
Leu	Phe	Val	Asp 420	Leu	Ser	Asp	Asn	Arg 425	Ile	Ser	Gly	Ala	Ala 430	Thr	Pro	
Ala	Ala	Ala 435	Leu	Gly	Glu	Val	Asp 440	Ser	Arg	Val	Glu	Val 445	Trp	Arg	Leu	
Pro	Arg 450	Gly	Leu	Ala	Pro	Gly 455	Pro	Leu	Asp	Ala	Val 460	Ser	Ser	Lys	Asp	
Phe 465	Met	Pro	Ser	Суз	Asn 470	Leu	Asn	Phe	Thr	Leu 475	Asp	Leu	Ser	Arg	Asn 480	
Asn	Leu	Val	Thr	Ile 485	Gln	Gln	Glu	Met	Phe 490	Thr	Arg	Leu	Ser	Arg 495	Leu	
Gln	Cys	Leu	Arg 500	Leu	Ser	His	Asn	Ser 505	Ile	Ser	Gln	Ala	Val 510	Asn	Gly	
Ser	Gln	Phe 515	Val	Pro	Leu	Thr	Ser 520	Leu	Arg	Val	Leu	Asp 525	Leu	Ser	His	
Asn	L ув 530	Leu	Asp	Leu	Tyr	His 535	Gly	Arg	Ser	Phe	Thr 540	Glu	Leu	Pro	Gln	

- 26 -

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 555 556

- Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575
- Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys 580 585 590
- Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605
- Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 615 620
- Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr 625 630 635 640
- Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 645 650 655
- Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr 660 665 670
- Val Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys 675 680 685
- Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Ile Arg Leu Gln Lys Leu 690 695 700
- Asp Val Ser Ser Asn Ser Ile Gly Phe Val Ile Pro Gly Phe Phe Val 705 710 715 720
- Arg Ala Thr Arg Leu Ile Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys 725 730 735
- Thr Val Asp Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu Lys Ile 740 745 750
- Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe
 755 760 765
- Val Asp Phe Leu Leu Glu Arg Gln Glu Ala Val Pro Gly Leu Ser Arg 770 780

Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe 785 790 795 800

Thr Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys 805 810 815

Phe Gly Leu Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met 820 825 830

Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys 835 840 845

Leu Ala His Leu Pro Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu 850 855 860

Leu Tyr Asp Ala Val Val Val Phe Asp Lys Val Gln Ser Ala Val Ala 865 870 875 880

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly 885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly 900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys 915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg 930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp 945 950 955 960

Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr 965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro 980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Ile Ala 995 1000 1005

Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Arg Asn Phe Cys Arg 1010 1015 1020

Gly Pro Thr Thr Ala Glu 1025

<210> 10 <211> 818

<212> PRT

<213> Bos taurus

<400> 10

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala

Ala Ala Leu Ala Ala Leu Ala Glu Gly Thr Leu Pro Ala Phe Leu

Pro Cys Glu Leu Gln Pro His Gly Gln Val Asp Cys Asn Trp Leu Phe

Leu Lys Ser Val Pro His Phe Ser Ala Gly Ala Pro Arg Ala Asn Val

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr 105

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu

Val Ser Leu Ser Leu Ser His Thr Ser Ile Leu Val Leu Gly Pro Thr

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 170

Cys Tyr Tyr Met Asn Pro Cys Pro Arg Ala Leu Glu Val Ala Pro Gly 185

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 215 220

Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Asn Cys Arg Arg 245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Asn Asp Leu Thr Gln Leu Arg 325 330 335

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

Leu His Leu Ala Ser Ser Phe Gly Ser Leu Val Ser Leu Glu Lys Leu 355 360 365

Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Ile Thr Leu Gln 370 375 380

Ser Leu Thr Arg Leu Pro Lys Leu Gln Ser Leu His Leu Gln Leu Asn 385 390 395 400

Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415

Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Thr Pro

420 425 430

Ala Ala Leu Gly Glu Val Asp Ser Arg Val Glu Val Trp Arg Leu
435 440 445

Pro Arg Gly Leu Ala Pro Gly Pro Leu Asp Ala Val Ser Ser Lys Asp 450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 470 475 480

Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu 485 490 495

Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly 500 505 510

Ser Gln Phe Val Pro Leu Thr Ser Leu Arg Val Leu Asp Leu Ser His 515 520 525

Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 540

Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 555 560

Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys 580 585 590

Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605

Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 615 620

Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Glu Asn His Leu His Thr 625 630 635 640

Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 645 650 655

Arg	Leu	Arg	Asp 660	Asn	Asn	Leu	Ala	Phe 665	Phe	Asn	Trp	Ser	Ser 670	Leu	Thr	
Val	Leu	Pro 675	Arg	Leu	Glu	Ala	Leu 680	Asp	Leu	Ala	Gly	Asn 685	Gln	Leu	Lys	
Ala	Leu 690	Ser	Asn	Gly	Ser	Leu 695	Pro	Pro	Gly	Ile	Arg 700	Leu	Gln	Lys	Leu	
Asp 705	Val	Ser	Ser	Asn	Ser 710	Ile	Gly	Phe	Val	Ile 715	Pro	Gly	Phe	Phe	Val 720	
Arg	Ala	Thr	Arg	Leu 725	Ile	Glu	Leu	Asn	Leu 730	Ser	Ala	Asn	Ala	Leu 735	Lys	
Thr	Val	Asp	Pro 740	Ser	Trp	Phe	Gly	Ser 745	Leu	Ala	Gly	Thr	Leu 750	Lys	Ile	<u>-</u>
Leu	Asp	Val 755	Ser	Ala	Asn	Pro	Leu 760	His	Cys	Ala	Cys	Gly 765	Ala	Ala	Phe	
Val	Asp 770	Phe	Leu	Leu	Glu	Arg 775	Gln	Glu	Ala.	Val	Pro 780	Gly	Leu	Ser	Arg	
Arg 785	Val	Thr	Cys	Gly	Ser 790	Pro	Gly	Gln	Leu	Gln 795	Gly	Arg	Ser	Ile	Phe 800	
Thr	Gln	Asp	Leu	Arg 805	Leu	Cys	Leu	Asp	Glu 810	Thr	Leu	Ser	Leu	Asp 815	Cys	
Phe	Gly															
<210 <211		.1 191													-	
<212 <213		NA os t	auru	s												
<400 ggga		1 gg c	gcca	agca	t cc	ttcc	ctgc	agc	tgcc	tcc	caac	ctgc	cc g	ccag	accct	: 60
ctgg	agaa	gc c	gcat	tccc	t gt	catg	ggcc	cct	actg	tgc	cccg	cacc	cc c	tttc	tctcc	: 120
tggt	gcag	gc g	gcgg	cact	g gc	agcg	gccc	tgg	ccga	a aa	cacc	ctgc	ct g	cctt	cctgo	: 180
cctg	tgag	ct c	cagc	ccca	t gg	tcag	gtgg	act	gcaa	ctg	gctg	ttcc	tg a	agtc	tgtgc	240
cgca	cttt	tc g	gctg	gagc	c cc	ccgg	gcca	atg	tcac	cag	cctc	tcct	ta a	tctc	caacc	300

gcatccacca cttgcatgac tctgacttcg tccacctgtc caacctgcgg gtcctcaacc 360 420 tcaagtggaa ctgcccgccg gccggcctca gccccatgca cttcccctgc cgtatgacca 480 togagoccaa cacottoctg gotgtgocca cootggagga gotgaacotg agotacaacg quateacqae eqtqeetqee etgeceagtt ecetegtgte ectgtegetg agceacacea 540 gcatcctggt gctaggcccc acccacttca ccggcctgca cgccctgcgc tttctgtaca 600 tggacggcaa ctgctactac atgaacccct gcccgcgggc cctggaggtg gccccaggcg 660 ccctcctcgg cctgggcaac ctcacgcacc tgtcgctcaa gtacaacaac ctcacggagg 720 tgccccgccg cctgcccccc agcctggaca ccctgctgct gtcctacaac cacattgtca 780 840 ccctqqcacc cqaqqacctq gccaacctga ctgccctgcg cgtgcttgac gtgggtggga 900 actqccqccq ctqcqaccat gcccgcaacc cctgcaggga gtgcccaaag aacttcccca 960 agetgeacce tgacacette agteacetga geegeetega aggeetggtg ttgaaggaca gttctctcta caaactagag aaagattggt tccgcggcct gggcaggctc caagtgctcg 1020 1080 acctgagtga gaacttcctc tatgactaca tcaccaagac caccatcttc aacgacctga cccagctgcg cagactcaac ctgtccttca attaccacaa gaaggtgtcc ttcgcccacc 1140 1200 tgcacctage gtecteettt gggagtetgg tgteeetgga gaagetggae atgcaeggea tettetteeg eteceteace aacateaege tecagteget gaceeggetg eccaagetee 1260 1320 agagtetgea tetgeagetg aactteatea accaggeeca geteageate tttggggeet 1380 teceqageet getettegtg gaeetgtegg acaacegeat cageggagee gegaegeeag eggeegeet gggggaggtg gacageaggg tggaagtetg gegattgeee aggggeeteg 1440 1500 ctccaqqccc qctqqacqcc gtcaqctcaa aggacttcat gccaagctgc aacctcaact 1560 tcaccttgga cctgtcacgg aacaacctgg tgacaatcca gcaagagatg tttacccgcc totcccgcct ccagtgcctg cgcctgagcc acaacagcat ctcgcaggcg gttaatggct 1620 1680 cccagttcgt gccgctgacc agcctgcgag tgctcgacct gtcccacaac aagctggacc tgtaccatgg gcgctcattc acggagctgc cgcagctgga ggcactggac ctcagctaca 1740 acagecagee etteageatg cagggegtgg gecacaacet cagettegtg geecagetge 1800 1860 cctccctqcq ctacctcagc cttgcgcaca atggcatcca cagccgcgtg tcacagaagc 1920 tcaqcagcgc ctcgttgcgc gccctggact tcagcggcaa ctccctgagc cagatgtggg 1980 ccqaqqqaga cctctatctc tgctttttca aaggcttgag gaacctggtc cagctggacc 2040 tqtccqaqaa ccatctgcac accetectge etegteacet ggacaacetg cccaagagee

tgcggcagct gcgtctccgg	gacaataacc	tggccttctt	caactggagc	agcctgaccg	2100
tectgeeceg getggaagee	ctggatctgg	caggaaacca	gctgaaggcc	ctgagcaacg	2160
gcagcctgcc gcctggcatc	cggctccaga	agctggacgt	gagcagcaac	agcatcggct	2220
tegtgatece eggettette	gteegegega	ctcggctgat	agagcttaac	ctcagcgcca	2280
atgccctgaa gacagtggat	ccctcctggt	teggtteett	agcagggacc	ctgaaaatcc	2340
tagacgtgag cgccaacccg	ctccactgcg	cctgcggggc	ggcctttgtg	gacttcctgc	2400
tggagagaca ggaggccgtg	cccgggctgt	ccaggcgcgt	cacatgtggc	agtccgggcc	2460
agetecaggg cegeageate	ttcacacagg	acctgcgcct	ctgcctggat	gagaccctct	2520
ccttggactg ctttggcctc	tcactgctaa	tggtggcgct	gggcctggca	gtgcccatgc	2580
tgcaccacct ctgtggctgg	gacctctggt	actgcttcca	cctgtgtctg	gcccatttgc	2640
cccgacggcg gcggcagcgg	ggcgaggaca	ccctgctcta	tgatgccgtc	gtggtcttcg	2700
acaaggtgca gagtgcagtg	gctgattggg	tgtacaacga	geteegegtg	cagctggagg	2760
agegeegggg gegeegggeg	ctccgcctct	gcctggagga	gcgagactgg	ctccctggta	2820
agacgctctt cgagaacctg	tgggcctcgg	tctacagcag	ccgcaagacc	atgttcgtgc	2880
tggaccacac ggaccgggtc	ageggeetee	tgcgcgccag	cttcctgctg	gcccagcagc	2940
gcctgttgga ggaccgcaag	gacgtcgtag	tgctggtgat	cctgcgcccc	gccgcctatc	3000
ggtcccgcta cgtgcggctg	cgccagcgcc	tctgccgcca	gagcgtcctc	ctctggcccc	3060
accagcccag tggccagggt	agtttctggg	ccaacctggg	catagecetg	accagggaca	3120
accgtcactt ctataaccgg	aacttctgcc	ggggccccac	gacagccgaa	tagcacagag	3180
tgactgccca g					3191

<210> 12 <211> 2454

<212> DNA

<213> Bos taurus

<400> 12

atgggccct actgtgccc gcacccctt tetetectgg tgcaggcggc ggcactggca 60
gcggccctgg ccgagggcac cctgcctgcc ttcctgccct gtgagctcca gccccatggt 120
caggtggact gcaactggct gttcctgaag tctgtgccgc acttttcggc tggagccccc 180
cgggccaatg tcaccagcct ctccttaatc tccaaccgca tccaccactt gcatgactct 240
gacttcgtcc acctgtccaa cctgcgggtc ctcaacctca agtggaactg cccgccggcc 300
ggcctcagcc ccatgcactt cccctgccgt atgaccatcg agcccaacac cttcctggct 360

420 gtgcccaccc tggaggagct gaacctgagc tacaacggca tcacgaccgt gcctgccctg cccagttccc tcgtgtccct gtcgctgagc cacaccagca tcctggtgct aggccccacc 480 cacttcaccg gcctgcacgc cctgcgcttt ctgtacatgg acggcaactg ctactacatg 540 600 aaccectgce egegggeest ggaggtggce ccaggegese testeggest gggsaacste acgeacetgt egeteaagta caacaacete acggaggtge ecegeegeet geececeage 660 ctggacaccc tgctgctgtc ctacaaccac attgtcaccc tggcacccga ggacctggcc 720 aacctgactg ccctgcgcgt gcttgacgtg ggtgggaact gccgccgctg cgaccatgcc 780 cgcaacccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccttcagt 840 cacctgagcc gcctcgaagg cctggtgttg aaggacagtt ctctctacaa actagagaaa 900 gattggttcc gcggcctggg caggctccaa gtgctcgacc tgagtgagaa cttcctctat 960 gactacatca ccaagaccac catcttcaac gacctgaccc agctgcgcag actcaacctg 1020 1080 teetteaatt accacaagaa ggtgteette geecacetge acctagegte eteetttggg agtotggtgt cootggagaa gotggacatg cacggcatct tottcogctc cotcaccaac 1140 atcacgetec agtegetgac eeggetgeec aagetecaga gtetgeatet geagetgaac 1200 ttcatcaacc aggcccagct cagcatcttt ggggccttcc cgagcctgct cttcgtggac 1260 ctgtcggaca accgcatcag cggagccgcg acgccagcgg ccgccctggg ggaggtggac 1320 ageagggtgg aagtetggeg attgeecagg ggeetegete caggeeeget ggaegeegte 1380 ageteaaagg actteatgee aagetgeaac eteaacttea cettggacet gteaeggaac 1440 aacctggtga caatccagca agagatgttt acccgcctct cccgcctcca gtgcctgcgc 1500 ctgagccaca acagcatete gcaggeggtt aatggeteee agttegtgee gctgaccage 1560 ctgcgagtgc tcgacctgtc ccacaacaag ctggacctgt accatgggcg ctcattcacg 1620 1680 gagetgeege agetggagge actggacete agetacaaca gecageeett cageatgeag 1740 ggegtgggee acaaceteag ettegtggee cagetgeeet eeetgegeta eeteageett 1800 gegeacaatg geateeacag eegegtgtea eagaagetea geagegeete gttgegegee ctggacttca geggcaactc cctgagecag atgtgggeeg agggagacet ctatetetge 1860 tttttcaaag gcttgaggaa cctggtccag ctggacctgt ccgagaacca tctgcacacc 1920 ctcctgcctc gtcacctgga caacctgccc aagagcctgc ggcagctgcg tctccgggac 1980 aataacctgg ccttcttcaa ctggagcagc ctgaccgtcc tgccccggct ggaagccctg 2040 gatctggcag gaaaccagct gaaggccctg agcaacggca gcctgccgcc tggcatccgg 2100 ctccagaagc tggacgtgag cagcaacagc atcggcttcg tgatccccgg cttcttcgtc 2160

cgcgcgactc ggctgataga gcttaacctc agcgccaatg ccctgaagac agtggatccc 2220
tcctggttcg gttccttagc agggaccctg aaaatcctag acgtgagcgc caacccgctc 2280
cactgcgcct gcggggcggc ctttgtggac ttcctgctgg agagacagga ggccgtgccc 2340
gggctgtcca ggcgcgtcac atgtggcagt ccgggccagc tccagggccg cagcatcttc 2400
acacaggacc tgcgcctctg cctggatgag accctctcct tggactgctt tggc 2454

<210> 13

<211> 1031

<212> PRT

<213> Equus caballus

<400> 13

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 . 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Asp Asn 50 55 60

Val Thr Ser Leu Ser Leu Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro 145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly 165 170 175

- Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro 180 185 190
- Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205
- Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr 210 215 220
- Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu 225 230 235 240
- Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 250
- Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe 260 265 270
- Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285
- Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe 290 295 300
- Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315
- Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335
- Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350
- His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365
- Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu 370 375 380
- Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly 405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu 420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu 435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu 450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser 465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser 485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val 500 505 510

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu 515 520 525

Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 545 550 555 560

Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr
565 570 575

Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser 580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe 610 615 620

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln 645 650 655

- Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 665 670
- Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln 675 680 685
- Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln 690 695 700
- Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe 705 710 715 720
- Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735
- Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu 740 745 750
- Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala 755 . 760 . 765
- Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu 770 775 780
- Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800
- Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp 805 810 815
- Asp Cys Phe Gly Leu Ser Leu Leu Val Val Ala Leu Gly Leu Ala Met 820 825 830
- Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845
- Leu Gly Leu Ala Trp Leu Pro Arg Gly Trp Gln Arg Gly Ala Asp 850 855 860
- Ala Leu Ser Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala

865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu 900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Gln Val Ser Gly Leu 930 935 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg 945 950 955 960

Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Ala Arg Arg Ser 965 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Phe 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly 995 1000 1005

Met Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln Asn Phe 1010 1015 1020

Cys Arg Gly Pro Thr Met Ala Glu 1025 1030

<210> 14

<211> 820

<212> PRT

<213> Equus caballus

<400> 14

Met Gly Pro Cys His Gly Ala Leu Gln Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Met Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Pro Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu

35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Asp Asn 50 55 60

Val Thr Ser Leu Ser Leu Leu Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Ser Asp Phe Ala Gln Leu Ser Asn Leu Gln Lys Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ile Leu Ser Arg Thr Asn Ile Leu Gln Leu Asp Pro 145 150 155 160

Thr Ser Leu Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gly Arg Ala Leu Glu Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Thr Val Pro Arg Ser Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Leu Ser Tyr Asn His Ile Val Thr Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 250

Arg Cys Asp His Ala Arg Asn Pro Cys Val Glu Cys Pro His Lys Phe 260 265 270

Pro Gln Leu His Ser Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Tyr Gln Leu Asn Pro Arg Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Thr Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335

Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350

His Leu Thr Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Gln Lys Thr Leu 370 375 380

Gln Pro Leu Ala Arg Leu Pro Met Leu Gln Arg Leu Tyr Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Lys Asp Phe Pro Gly 405 410 415

Leu Arg Tyr Ile Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Val Glu 420 425 430

Pro Val Ala Thr Thr Gly Glu Val Asp Gly Gly Lys Lys Val Trp Leu 435 440 445

Thr Ser Arg Asp Leu Thr Pro Gly Pro Leu Asp Thr Pro Ser Ser Glu 450 455 460

Asp Phe Met Pro Ser Cys Lys Asn Leu Ser Phe Thr Leu Asp Leu Ser 465 470 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser 485 490 495

Arg Leu Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val 500 505 510

- 42 -

PCT/US2003/029577 WO 2004/026888

Asn Gly Ser Gln Phe Val Pro Leu Thr Ser Leu Gln Val Leu Asp Leu 520 Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 535 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 550 555 Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Thr 570 Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser 585

Gln Gln Leu Cys Ser Thr Ser Leu Trp Ala Leu Asp Phe Ser Gly Asn 600

Ser Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg Phe Phe

Gln Gly Leu Arg Ser Leu Ile Arg Leu Asp Leu Ser Gln Asn Arg Leu 635 625 630

His Thr Leu Leu Pro Cys Thr Leu Gly Asn Leu Pro Lys Ser Leu Gln 645 650

Leu Leu Arg Leu Arg Asn Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 665

Leu Thr Leu Leu Pro Asn Leu Glu Thr Leu Asp Leu Ala Gly Asn Gln 680

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Ser Gly Thr Gln Leu Gln

Arg Leu Asp Val Ser Arg Asn Ser Ile Ile Phe Val Val Pro Gly Phe 710 715

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730

Leu Arg Thr Glu Glu Pro Ser Trp Phe Gly Phe Leu Ala Gly Ser Leu 740 745

Glu Val Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala 755 760 765

Ala Phe Val Asp Phe Leu Leu Gln Val Gln Ala Ala Val Pro Gly Leu
770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Lys Ser Leu Ser Trp 805 810 815

Asp Cys Phe Gly 820

<210> 15

<211> 3391

<212> DNA

<213> Equus caballus

<400> 15

ctctqttctc tqaqctqttg ccgcqtqaag ggactgcgag cacaaagcat cctcctctgc agetgetgee cagtgtgeca getggaceet etggateate teccaeteee tgteatggge 120 180 cettgccatg gtgccctgca gcccctgtct ctcctggtgc aggcggccat gctggccgtg getetggece aaggeaceet geéteeette etgecetgtg ageteeagee ceaeggeetg 240 gtgaactgca actggctgtt cctgaagtcc gtgccccact tctcagcagc agcaccccgg 300 gacaatgtca ccagecttte ettgetetee aacegcatee accaecteea egacteegac 360 tttgcccaac tgtccaacct gcagaaactc aacctcaaat ggaactgccc gccagccggc 420 ctcagcccca tgcacttccc ctgccacatg accatcgagc ccaacacttt cctggctgta 480 540 ageteceteg tgtecetgat cetgageege accaacatee tgeagetaga ecceaceage 600 ctcacgggcc tgcatgccct gcgcttccta tacatggatg gcaactgcta ctacaagaac 660 ccctgcgggc gggccctgga ggtggcccca ggcgccctcc ttggcctggg caacctcacc 720 cacctgtcac tcaagtacaa caacctcaca acggtgcccc gcagcctgcc ccctagcctg 780 qaqtacctqc tqttqtccta caaccacatt gtcaccctgg cacctgagga cctggccaat 840 ctgactgccc tgcqtgtgct cgatgtgggt ggaaactgcc gccgctgtga ccatgcacgc 900 aacccctgcg tggagtgccc acataaattc ccccagctgc actccgacac cttcagccac 960

ctaagccgcc tagaaggcct cgtgttgaag gatagttctc tctaccagct gaaccccaga 1020 tggttccgtg gcctgggcaa cctcacagtg ctcgacctga gtgagaactt cctctacgac 1080 1140 tgcatcacca aaaccaaggc attccagggc ctggcccagc tgcgaagact caacttgtcc 1200 ttcaattacc ataagaaggt gtccttcgcc cacctgacgc tggcaccctc cttcgggagc ctgctctccc tgcaggaact ggacatgcat ggcatcttct tccgctcact cagccagaag 1260 acgetecage cactggeeeg cetgeeeatg etecagegte tgtatetgea gatgaaette 1320 atcaaccagg cccagctcgg catcttcaag gacttccctg gtctgcgcta catagacctg 1380 tcagacaacc gcatcagtgg agctgtggag ccggtggcca ccacagggga ggtggatggt 1440 gggaagaagg tetggetgae atecagggae etcaetecag geceaetgga caececeage 1500 1560 tctgaggact tcatgccaag ctgcaagaac ctcagcttca ccttggacct gtcacggaac 1620 aacctggtaa cagtccagcc agagatgttt gcccagctct cgcgcctcca gtgcctgcgc 1680 ctgagccaca acagcatete geaggeggte aatggeteae agttegtgee actgaecage ctgcaggtgc tggacctgtc ccataacaaa ctggacctgt accatgggcg ctcgtttacg 1740 1800 gagetgeege gaetggagge cetggacete agetacaaca gecagecett cageatgegg ggtgtgggcc acaacctcag ctttgtggcc cagctgccca ccctgcgcta cctcagcctg 1860 1920 gcacacaatg gcatccacag ccgtgtgtcc cagcagctct gcagcacctc gctgtgggcc 1980 ctggacttca gcggcaattc cctgagccag atgtgggctg agggagacct ctatctccgc ttcttccaag gcctgagaag cctaatccgg ctagacctgt cccagaatcg tctgcatacc 2040 2100 ctcctgccat gcaccctggg caacctcccc aagagettge agetgctgcg tetecgtaac aattacctgg ccttcttcaa ttggagcagc ctgaccctcc tgcccaacct ggaaaccctg 2160 gacctggctg gaaaccagct gaaggctctg agcaatggca gcctgccttc tggcacccag 2220 2280 ctccagaggc tggacgtcag caggaacagc atcatcttcg tggtccctgg cttctttgct ctggccacga ggctgcgaga gctcaacctc agtgccaacg ccctcaggac agaggagccc 2340 tootggtttg gtttcctagc aggctccctt gaagtcctag atgtgagcgc caaccctctg 2400 cactgcgcct gtggggcagc ctttgtggac ttcctgctgc aggttcaggc tgccgtgcct 2460 2520 ggtctgccca gccgcgtcaa gtgtggcagt ccgggccagc tccagggccg cagcatcttc gcacaagacc tgcgcctctg cctggacaag tccctctcct gggactgttt tggtctctca 2580 ttgctggttg tggccctggg cctggccatg cctatgttgc accacctctg cggctgggac 2640 2700 ctctggtact gcttccacct gggcctggcc tggctgcccc ggcgggggtg gcagcggggc

gcggatgccc tgagctatga	tgcctttgtg	gtcttcgaca	aggcacagag	cgcagtggcc	2760
gactgggtgt acaatgaact	gcgggtgcgg	ctagaggagc	gccgtgggcg	cegggegete	2820
cgcctgtgtc tggaggagcg	tgactggcta	cctggcaaga	cgctgttcga	aaacctgtgg	2880
gcctcagtct acagcagccg	caagatgctg	tttgtgctgg	cccacacgga	ccaggtcagt	2940
ggcctcttgc gtgccagctt	cctgctggcc	cagcagcgtc	tgctggagga	ccgcaaggac	3000
gttgtggtgc tggtaatcct	gagecetgae	gcccgccgtt	cccgttacgt	geggetgege	3060
cagcgcctct gccgccagag	tgtcctcttc	tggccccacc	agcctagtgg	ccagcgcagc	3120
ttctgggccc agctaggcat	ggccctgacc	agggacaacc	gccacttcta	taaccagaac	3180
ttctgccggg gcccgacgat	ggctgagtag	cacagagtga	cagcctggca	tgtacaaccc	3240
ccagccctga ccttgcctct	ctgcctatga	tgcccagtct	gcctcactct	gtgacgcccc	3300
tgctctgcct ccgccaccct	cacccctggc	atacagcagg	cactcaataa	atgccactgg	3360
caggccaaac agccaaaaaa	aaaaaaaaa	a			3391

<210> 16

<211> 2460 <212> DNA

<213> Equus caballus

<400> 16

atgggccctt gccatggtgc cctgcagccc ctgtctctcc tggtgcaggc ggccatgctg 60 120 geogtggete tggcccaagg caccetgeet ceetteetge cetgtgaget ceagecceae ggcctggtga actgcaactg gctgttcctg aagtccgtgc cccacttctc agcagcagca 180 ccccgggaca atgtcaccag cettteettg etetecaacc geatecacca cetecacgae 240 tccgactttg cccaactgtc caacctgcag aaactcaacc tcaaatggaa ctgcccgcca 300 360 gccggcctca gccccatgca ettcccctgc cacatgacca tcgagcccaa cactttcctg 420 gctgtaccca ccctggagga gctgaacctg agctacaacg gcatcacgac tgtgcctgcc 480 etgeccaget ecetegtgte cetgatectg agecgeacea acatectgea getagacee accagoetea egggeetgea tgecetgege tteetataca tggatggeaa etgetaetae 540 aagaacccct gcgggcgggc cctggaggtg gccccaggcg ccctccttgg cctgggcaac 600 660 ctcacccacc tgtcactcaa gtacaacaac ctcacaacgg tgccccgcag cctgccccct agcctggagt acctgctgtt gtcctacaac cacattgtca ccctggcacc tgaggacctg 720 gecaatetga etgeeetgeg tgtgetegat gtgggtggaa aetgeegeeg etgtgaeeat 780 gcacgcaacc cctgcgtgga gtgcccacat aaattccccc agctgcactc cgacaccttc 840

PCT/US2003/029577 WO 2004/026888

agccacctaa	gccgcctaga	aggcctcgtg	ttgaaggata	gttctctcta	ccagctgaac	900
cccagatggt	tccgtggcct	gggcaacctc	acagtgctcg	a cctgagtga	gaacttcctc	960
tacgactgca	tcaccaaaac	caaggcattc	cagggcctgg	cccagctgcg	aagactcaac	1020
ttgtccttca	attaccataa	gaaggtgtcc	ttcgcccacc	tgacgctggc	accetectte	1080
gggagcctgc	tctccctgca	ggaactggac	atgcatggca	tcttcttccg	ctcactcagc	1140
cagaagacgc	tccagccact	ggcccgcctg	cccatgctcc	agcgtctgta	tctgcagatg	1200
aacttcatca	accaggccca	gctcggcatc	ttcaaggact	tecetggtet	gcgctacata	1260
gacctgtcag	acaaccgcat	cagtggagct	gtggagccgg	tggccaccac	aggggaggtg	1320
gatggtggga	agaaggtctg	gctgacatcc	agggacctca	ctccaggccc	actggacacc	1380
cccagctctg	aggacttcat	gccaagctgc	aagaacctca	gcttcacctt	ggacctgtca	1440
cggaacaacc	tggtaacagt	ccagccagag	atgtttgccc	agctctcgcg	cctccagtgc	1500
ctgcgcctga	gccacaacag	catctcgcag	gcggtcaatg	gctcacagtt	cgtgccactg	1560
accagcctgc	aggtgctgga	cctgtcccat	aacaaactgg	acctgtacca	tgggegeteg	1620
tttacggagc	tgccgcgact	ggaggccctg	gacctcagct	acaacagcca	gcccttcagc	1680
atgcggggtg	tgggccacaa	cctcagcttt	gtggcccagc	tgcccaccct	gcgctacctc	1740
agcctggcac	acaatggcat	ccacagccgt	gtgtcccagc	agctctgcag	cacctcgctg	1800
tgggccctgg	acttcagcgg	caattccctg	agccagatgt	gggctgaggg	agacctctat	1860
ctccgcttct	tccaaggcct	gagaagccta	atccggctag	acctgtccca	gaatcgtctg	1920
cataccctcc	tgccatgcac	cctgggcaac	ctccccaaga	gcttgcagct	gctgcgtctc	1980
cgtaacaatt	acctggcctt	cttcaattgg	agcagcctga	ccctcctgcc	caacctggaa	2040
accetggace	tggctggaaa	ccagctgaag	gctctgagca	atggcagcct	gccttctggc	2100
acccagctcc	agaggctgga	cgtcagcagg	aacagcatca	tcttcgtggt	ccctggcttc	2160
tttgctctgg	ccacgagget	gcgagagctc	aacctcagtg	ccaacgccct	caggacagag	2220
gagccctcct	ggtttggttt	cctagcaggc	tcccttgaag	tcctagatgt	gagcgccaac	2280
cctctgcact	gegeetgtgg	ggcagccttt	gtggacttcc	tgctgcaggt	tcaggctgcc	2340
gtgcctggtc	tgcccagccg	cgtcaagtgt	ggcagtccgg	gccagctcca	gggccgcagc	2400
atcttcgcac	aagacctgcg	cctctgcctg	gacaagtccc	tctcctggga	ctgttttggt	2460

<210> 17 <211> 1029 <212> PRT <213> Ovis aries

<400> 17

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 55

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr 100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly 180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

- Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 245 250 255
- Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270
- Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285
- Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300
- Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320
- Asp Tyr Ile Thr Lys Thr Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg 325 330 335
- Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350
- Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu 355 360 365
- Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg 370 375 380
- Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn 385 390 395 400
- Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415
- Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430
- Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp 435 440 445
- Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp 450 455 460

Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 470 475 480

- Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu .485 490 495
- Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly . $500 \hspace{1.5cm} 505 \hspace{1.5cm} 510 \hspace{1.5cm}$
- Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr 515 520 525
- Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 535 540
- Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 550
- Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575
- Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys 580 585 590
- Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605
- Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 615 620
- Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr 625 630 635 640
- Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 645 650 655
- Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr 660 665 670
- Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys 675 680 685
- Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu 690 695 700

715 Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys 730 Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile 745 740 Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe 790 Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys 815 805 Phe Gly Phe Ser Leu Leu Met Val Ala Leu Gly Leu Ala Val Pro Met 825 830 820 Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His Leu Cys 840 835 Leu Ala His Leu Pro Arg Arg Arg Gln Arg Gly Glu Asp Thr Leu 850

Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val

Leu Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala Val Ala

870

Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu Glu Arg Arg Gly 885 890 895

Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu Pro Gly 900 905 910

Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser Arg Lys 915 920 925

Thr Met Phe Val Leu Asp His Thr Asp Arg Val Ser Gly Leu Leu Arg

930 935 940

Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg Lys Asp 945 950 955 960

Val Val Leu Val Ile Leu Arg Pro Ala Ala Tyr Arg Ser Arg Tyr 965 970 975

Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu Trp Pro 980 985 990

His Gln Pro Ser Gly Gln Gly Ser Phe Trp Ala Asn Leu Gly Met Ala 995 1000 1005

Gly Pro Thr Thr Ala Glu 1025

<210> 18

<211> 818

<212> PRT

<213> Ovis aries

<400> 18

Met Gly Pro Tyr Cys Ala Pro His Pro Leu Ser Leu Leu Val Gln Ala 1 5 10 15

Ala Ala Leu Ala Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe Leu 20 25 30

Pro Cys Glu Leu Gln Pro Arg Gly Lys Val Asn Cys Asn Trp Leu Phe 35 40 45

Leu Lys Ser Val Pro Arg Phe Ser Ala Gly Ala Pro Arg Ala Asn Val 50 55 60

Thr Ser Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asp Ser 65 70 75 80

Asp Phe Val His Leu Ser Asn Leu Arg Val Leu Asn Leu Lys Trp Asn 85 90 95

Cys Pro Pro Ala Gly Leu Ser Pro Met His Phe Pro Cys Arg Met Thr

100 105 110

Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu Asn 115 120 125

Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu 130 135 140

Val Ser Leu Ser Leu Ser Arg Thr Ser Ile Leu Val Leu Gly Pro Thr 145 150 155 160

His Phe Thr Gly Leu His Ala Leu Arg Phe Leu Tyr Met Asp Gly Asn 165 170 175

Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Val Glu Val Ala Pro Gly
180 185 190

Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr Asn 195 200 205

Asn Leu Thr Glu Val Pro Arg Arg Leu Pro Pro Ser Leu Asp Thr Leu 210 215 220

Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu Ala 225 230 235 240

Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg Arg 245 250 255

Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Asn Phe Pro 260 265 270

Lys Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly Leu 275 280 285

Val Leu Lys Asp Ser Ser Leu Tyr Lys Leu Glu Lys Asp Trp Phe Arg 290 295 300

Gly Leu Gly Arg Leu Gln Val Leu Asp Leu Ser Glu Asn Phe Leu Tyr 305 310 315 320

Asp Tyr Ile Thr Lys Thr Thr Ile Phe Arg Asn Leu Thr Gln Leu Arg

Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His 340 345 350

- Leu Gln Leu Ala Pro Ser Phe Gly Gly Leu Val Ser Leu Glu Lys Leu 355 360 365
- Asp Met His Gly Ile Phe Phe Arg Ser Leu Thr Asn Thr Thr Leu Arg 370 375 380
- Pro Leu Thr Gln Leu Pro Lys Leu Gln Ser Leu Ser Leu Gln Leu Asn 385 390 395 400
- Phe Ile Asn Gln Ala Glu Leu Ser Ile Phe Gly Ala Phe Pro Ser Leu 405 410 415
- Leu Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Arg Pro 420 425 430
- Val Ala Ala Leu Gly Glu Val Asp Ser Gly Val Glu Val Trp Arg Trp 435 440 445
- Pro Arg Gly Leu Ala Pro Gly Pro Leu Ala Ala Val Ser Ala Lys Asp 450 455 460
- Phe Met Pro Ser Cys Asn Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn 465 470 475 480
- Asn Leu Val Thr Ile Gln Gln Glu Met Phe Thr Arg Leu Ser Arg Leu 485 490 490
- Gln Cys Leu Arg Leu Ser His Asn Ser Ile Ser Gln Ala Val Asn Gly 500 505 510
- Ser Gln Phe Val Pro Leu Thr Arg Leu Arg Val Leu Asp Leu Ser Tyr 515 520 525
- Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu Pro Gln 530 540
- Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln 545 550 555 560
- Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ser Leu Arg 565 570 575

- 54 -

Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg Val Ser Gln Lys 580 585 590

- Leu Ser Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn Ser Leu 595 600 605
- Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Cys Phe Phe Lys Gly 610 615
- Leu Arg Asn Leu Val Gln Leu Asp Leu Ser Lys Asn His Leu His Thr 625 630 635 640
- Leu Leu Pro Arg His Leu Asp Asn Leu Pro Lys Ser Leu Arg Gln Leu 645 650 655
- Arg Leu Arg Asp Asn Asn Leu Ala Phe Phe Asn Trp Ser Ser Leu Thr
 660 665 670
- Val Leu Pro Gln Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln Leu Lys 675 680 685
- Ala Leu Ser Asn Gly Ser Leu Pro Pro Gly Thr Arg Leu Gln Lys Leu 690 695 700
- Asp Val Ser Ser Asn Ser Ile Gly Phe Val Thr Pro Gly Phe Phe Val 705 710 715 720
- Leu Ala Asn Arg Leu Lys Glu Leu Asn Leu Ser Ala Asn Ala Leu Lys 725 730 735
- Thr Val Asp Pro Phe Trp Phe Gly Arg Leu Thr Glu Thr Leu Asn Ile 740 745 750
- Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala Ala Phe 755 760 765
- Val Asp Phe Leu Leu Glu Met Gln Ala Ala Val Pro Gly Leu Ser Arg 770 775 780
- Arg Val Thr Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser Ile Phe 785 790 795 800
- Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Thr Leu Ser Leu Asp Cys 805 810 815

Phe Gly

<210> 19 <211> 3199 <212> DNA <213> Ovis aries

<400> 19 gtcggcaegg gaagtgageg ccaagcatcc ttccctgcag ctgccgccca acttgcccgc 60 cagaccetet ggagaageeg catteeetge catgggeece tactgtgeec egeaceeeet 120 ttctctcctg gtgcaggegg cggcgctggc agcagccctg gcccagggca ccctgcctgc 180 cttcctgccc tgtgagctcc agccccgggg taaggtgaac tgcaactggc tgttcctgaa 240 300 gtctgtgccg cgcttttcgg ccggagcccc ccgggccaat gtcaccagcc tctccttaat ctccaaccgc atccaccact tgcacgactc tgacttcgtc cacctgtcca acctgcgggt 360 cctcaacctc aagtggaact gcccgccggc cggcctcagc cccatgcact tcccctgccg catgaccatc gagcccaaca cottcctggc tgtgcccacc ctggaggagc tgaacctgag 480 540 ctacaatggc atcacgaccg tgcctgccct gcccagttct ctcgtatccc tgtcgctgag ccgcaccagc atcctggtgc taggccccac ccacttcacc ggcctgcacg ccctgcgctt 600 tctgtacatg gacggcaact gctactataa gaacccctgc cagcaggccg tggaggtggc cccaggcgcc ctccttggcc tgggcaacct cacgcacctg tcgctcaagt acaacaacct 720 cacggaggtg ccccgccgcc tgcccccag cctggacacc ctgctgctgt cctacaacca 780 840 catcatcacc ctggcacccg aggacctggc caatctgact gccctgcgtg tgcttgatgt gggcgggaac tgccgccgct gcgaccacgc ccgcaacccc tgcagggagt gcccaaagaa 900 cttccccaag ctgcaccctg acaccttcag ccacctgage cgcctcgaag gcctggtgtt 960 gaaggacagt tetetetaca aactagagaa agactggtte egeggeetgg geaggeteea 1020 agtgetegae etgagtgaga actteeteta tgactacate accaagacea ceatetteag 1080 quacctgace cagetgegea gaeteaacet gteetteaat taccacaaga aggtgteett 1140 1200 egeceacety caactygeac ecteettigg gggeetggtg teeetggaga agetggacat 1260 geacggeate ttetteeget ceeteaceaa caccaegete eggeegetga eecagetgee caagetecag agtetgagte tgcagetgaa etteateaae caggeegage teageatett 1320 1380 tqqqqccttc ccgagcctgc tcttcgtgga cctgtcggac aaccgcatca gcggagctgc gaggccggtg gccgccctcg gggaggtgga cagcggggtg gaagtctggc ggtggcccag 1440

gggcctcgct	ccaggcccgc	tggccgccgt	cagcgcaaag	gacttcatgc	caagctgcaa	1500
cctcaacttc	accttggacc	tgtcacggaa	caacctggtg	acgatccagc	aggagatgtt	1560
tacccgcctc	tecegeetee	agtgcctgcg	cctgagccac	aacagcatct	cgcaggcggt	1620
taatggctcg	cagttcgtgc	cgctgacccg	cctgcgagtg	ctcgacctgt	cctacaacaa	1680
gctggacctg	taccatgggc	gctcgttcac	ggagctgccg	cagctggagg	cactggacct	1740
cagctacaac	agccagccct	tcagcatgca	gggcgtgggc	cacaacctca	gcttcgtggc	1800
ccagctgccg	tccctgcgct	acctcagcct	tgcgcacaac	ggcatccaca	gccgcgtgtc	1860
acagaagctc	agcagcgcct	cgctgcgcgc	cctggacttc	agcggcaact	ccctgagcca	1920
gatgtgggcc	gagggagacc	tctatctctg	cttcttcaaa	ggcttgagga	acctggtcca	1980
gctggacctg	tccaagaacc	acctgcacac	cctcctgcct	cgtcacctgg	ataacctgcc	2040
caagagcctg	cggcagctgc	gtctccggga	caataacctg	gecttettea	actggagcag	2100
cctgactgtt	ctgccccagc	tggaagccct	ggatctggcg	ggaaaccagc	tgaaggccct	2160
gagcaacggc	agcctgccac	ctggcacccg	gctccagaag	ctggacgtga	gcagcaacag	2220
catcggcttt	gtgacccctg	gcttctttgt	ccttgccaac	cggctgaaag	agcttaacct	2280
cagegeeaae	gccctgaaga	cagtggatcc	cttctggttc	ggtcgcttaa	cagagaccct	2340
gaatatccta	gacgtgagcg	ccaacccgct	ccactgtgcc	tgcggggcgg	cctttgtgga	2400
cttcctgctg	gagatgcagg	cggccgtgcc	tgggctgtcc	aggcgcgtca	cgtgtggcag	2460
tccgggccag	ctccagggcc	gcagcatctt	cgcacaggac	ctgcgcctct	gcctggatga	2520
gaccctctcc	ttggactgct	ttggcttctc	gctgctaatg	gtggcgctgg	gcctggcggt	2580
gcccatgctg	caccacctct	gtggctggga	cctgtggtac	tgcttccacc	tgtgtctggc	2640
ccatttgccc	cgacggcggc	ggcagcgggg	cgaggacacc	ctgctctacg	atgccttcgt	2700
ggtcttcgac	aaggegeaga	gtgcagtggc	cgactgggtg	tacaacgagc	tccgcgtgca	2760
gctggaggag	cgccgcgggc	gccgggcgct	cegcetetge	ctggaggagc	gagactggct	2820
ccctggcaag	acgctcttcg	agaacctgtg	ggcctcggtc	tacagcagcc	gtaagaccat	2880
gttcgtgctg	gaccacacgg	accgggtcag	tggcctcctg	cgcgccagct	tcctgctggc	2940
ccagcagcgc	ctgttggagg	accgcaagga	tgtcgtggtg	ctggtgatcc	tgcgccccgc	3000
cgcctaccgg	tcccgctacg	tgcggctgcg	ccagcgcctc	tgccgccaga	gcgtcctcct	3060
ctggccccac	cagcccagtg	gccagggtag	cttctgggcc	aacctgggca	tggccctgac	3120
cagggacaac	cgccacttct	ataaccggaa	cttctgccgg	ggccccacga	cagccgaata	3180

gcacagagtg actgcccag	3199

<210> 20 <211> 2454

<212> DNA

<213> Ovis aries

<400> 20 atgggccct actgtgcccc gcaccccctt tctctcctgg tgcaggcggc ggcgctggca 60 120 geagecetgg ceeagggeae cetgeetgee tteetgeeet gtgageteea geeeeggggt aaqqtqaact gcaactggct gttcctgaag tctgtgccgc gcttttcggc cggagccccc 180 egggecaatg teaceageet etecttaate tecaacegea tecaceaett geacgaetet 240 300 qacttcqtcc acctqtccaa cctqcgggtc ctcaacctca agtggaactg cccgccggcc 360 qqcctcaqcc ccatgcactt cccctgccgc atgaccatcg agcccaacac cttcctggct gtgcccaccc tggaggagct gaacctgagc tacaatggca tcacgaccgt gcctgccctg 420 cccagttctc tegtatecct gtegetgage egeaceagea teetggtget aggeeecace cacttcaccg gcctgcacgc cctgcgcttt ctgtacatgg acggcaactg ctactataag 540 600 aaccectgee ageaggeegt ggaggtggee ceaggegeee teettggeet gggeaacete acgcacctgt cgctcaagta caacaacctc acggaggtgc cccgccgcct gccccccagc 660 ctggacaccc tgctgctgtc ctacaaccac atcatcaccc tggcacccga ggacctggcc 720 aatctgactg ccctgcgtgt gcttgatgtg ggcgggaact gccgccgctg cgaccacgcc 780 840 cgcaaccct gcagggagtg cccaaagaac ttccccaagc tgcaccctga caccttcagc 900 cacctgagec gcctcgaagg cctggtgttg aaggacagtt ctctctacaa actagagaaa gactggttcc gcggcctggg caggctccaa gtgctcgacc tgagtgagaa cttcctctat 960 gactacatca ccaagaccac catcttcagg aacctgaccc agctgcgcag actcaacctg 1020 1080 tccttcaatt accacaagaa ggtgtccttc gcccacctgc aactggcacc ctcctttggg qgcctggtgt ccctggagaa gctggacatg cacggcatct tcttccgctc cctcaccaac 1140 1200 accacqctcc ggccgctgac ccagctgccc aagctccaga gtctgagtct gcagctgaac ttcatcaacc aggccgagct cagcatcttt ggggccttcc cgagcctgct cttcgtggac 1260 ctgtcggaca accgcatcag cggagctgcg aggccggtgg ccgccctcgg ggaggtggac 1320 ageggggtgg aagtetggeg gtggeecagg ggeetegete caggeeeget ggeegeegte 1380 agcgcaaagg acttcatgcc aagctgcaac ctcaacttca ccttggacct gtcacggaac 1440 aacctggtga cgatccagca ggagatgttt acccgcctct cccgcctcca gtgcctgcgc 1500

ctgagccaca acagcatete geaggegett aatggetege agttegtgee getgaeeege 1560 ctgcgagtgc tcgacctgtc ctacaacaag ctggacctgt accatgggcg ctcgttcacg 1620 gagetgeege agetggagge aetggaeete agetaeaaca geeageeett eageatgeag 1680 ggcgtgggcc acaacctcag cttcgtggcc cagctgccgt ccctgcgcta cctcagcctt 1740 gegeacaaeg geatecaeag eegegtgtea eagaagetea geagegeete getgegegee 1800 ctggacttca geggeaacte eetgageeag atgtgggeeg agggagacet etatetetge 1860 ttcttcaaag gcttgaggaa cctggtccag ctggacctgt ccaagaacca cctgcacacc 1920 ctectgeetc gteacetgga taacetgeec aagageetge ggeagetgeg teteegggae 1980 aataacctgg cettetteaa etggageage etgactgtte tgeeceaget ggaageeetg 2040 gatetggegg gaaaccaget gaaggeeetg ageaacggea geetgeeaec tggeaccegg 2100 ctccagaagc tggacgtgag cagcaacagc ateggetttg tgacccetgg ettetttgte 2160 cttgccaacc ggctgaaaga gcttaacctc agcgccaacg ccctgaagac agtggatccc 2220 ttctggttcg gtcgcttaac agagaccctg aatatcctag acgtgagcgc caacccgctc 2280 cactgtgcct gcggggcggc ctttgtggac ttcctgctgg agatgcaggc ggccgtgcct 2340 gggctgtcca ggcgcgtcac gtgtggcagt ccgggccagc tccagggccg cagcatcttc 2400 gcacaggacc tgcgcctctg cctggatgag accetetect tggactgett tggc 2454

<210> 21

<211> 1032

<212> PRT

<213> Canis familiaris

<400> 21

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Leu Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
70 75 80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp 90 Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 105 Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu 120 115 Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 155 145 150 Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly 170 165 Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 200 Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 230 235 225 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe

Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly
275 280 285

Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe 290 295 300

His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu 325 330 335

- Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350
- His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365
- Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu 370 375 380
- Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu 385 390 395 400
- Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 410 415
- Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu 420 425 430
- Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val 435 440 445
- Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly 450 455 460
- Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp 465 470 475 480
- Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
 485 490 495
- Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln 500 505 510
- Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu 515 520 525
- Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr 530 540
- Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro

545 550 . 555 560

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu 565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg 580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser 595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg 610 615 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn 625 630 635 640

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser 645 650 655

Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp 660 665 670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly 675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln 690 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro 705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala 725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly 740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys
755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro
770 775 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly 785 790 795 800

- Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu 805 810 815
- Ser Trp Val Cys Phe Ser Leu Ser Leu Leu Ala Val Ala Leu Ser Leu 820 825 830
- Ala Val Pro Met Leu His Gln Leu Cys Gly Trp Asp Leu Trp Tyr Cys 835 840 845
- Phe His Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Gly 850 855 860
- Val Asp Ala Leu Ala Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln 865 870 875
- Ser Ser Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Gln Leu Glu 885 890 895
- Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp 900 905 910
- Trp Val Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr 915 920 925
- Ser Ser Arg Lys Thr Leu Phe Val Leu Ala Arg Thr Asp Arg Val Ser 930 935 940
- Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960
- Asp Arg Lys Asp Val Val Leu Val Ile Leu Cys Pro Asp Ala His 965 970 975
- Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990
- Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln 995 1000 1005
- Leu Gly Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln 1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Thr Ala 1025 1030

<210> 22

<211> 822

<212> PRT

<213> Canis familiaris

<400> 22

Met Gly Pro Cys Arg Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Leu Ala Leu Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Tyr Asp Phe Val His Phe Val His Leu Arg Arg Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Asn Thr Phe Leu Ala Val Pro Thr Leu Glu Asp Leu 115 120 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140

Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160

Ala Thr Leu Ala Gly Leu Tyr Ala Leu Arg Phe Leu Phe Leu Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Gln Gln Ala Leu Gln Val Ala Pro 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

- Asn Asn Leu Thr Val Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220
- Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240
- Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255
- Arg Cys Asp His Ala Arg Asn Pro Cys Arg Glu Cys Pro Lys Gly Phe 260 265 270
- Pro Gln Leu His Pro Asn Thr Phe Gly His Leu Ser His Leu Glu Gly 275 280 285
- Leu Val Leu Arg Asp Ser Ser Leu Tyr Ser Leu Asp Pro Arg Trp Phe 290 295 300
- His Gly Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315
- Tyr Asp Cys Ile Thr Lys Thr Lys Ala Phe Tyr Gly Leu Ala Arg Leu 325 330 335
- Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350
- His Leu His Leu Ala Ser Ser Phe Gly Ser Leu Leu Ser Leu Gln Glu 355 360 365
- Leu Asp Ile His Gly Ile Phe Phe Arg Ser Leu Ser Lys Thr Thr Leu 370 375 380
- Gln Ser Leu Ala His Leu Pro Met Leu Gln Arg Leu His Leu Gln Leu 385 390 395 400
- Asn Phe Ile Ser Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly
 405 410 415
- Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ala Glu 420 425 430

Pro Ala Ala Ala Thr Gly Glu Val Glu Ala Asp Cys Gly Glu Arg Val 435 440 445

Trp Pro Gln Ser Arg Asp Leu Ala Leu Gly Pro Leu Gly Thr Pro Gly 450 455 460

Ser Glu Ala Phe Met Pro Ser Cys Arg Thr Leu Asn Phe Thr Leu Asp 465 470 480

Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Val Arg
485 490 495

Leu Ala Arg Leu Gln Cys Leu Gly Leu Ser His Asn Ser Ile Ser Gln 500 505 510

Ala Val Asn Gly Ser Gln Phe Val Pro Leu Ser Asn Leu Arg Val Leu 515 520 525

Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr 530 540

Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro 545 550 555

Phe Ser Met Arg Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu \cdot 565 570 575

Pro Ala Leu Arg Tyr Leu Ser Leu Ala His Asn Gly Ile His Ser Arg 580 585 590

Val Ser Gln Gln Leu Arg Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser 595 600 605

Gly Asn Thr Leu Ser Gln Met Trp Ala Glu Gly Asp Leu Tyr Leu Arg 610 615 620

Phe Phe Gln Gly Leu Arg Ser Leu Val Gln Leu Asp Leu Ser Gln Asn 625 630 635 640

Arg Leu His Thr Leu Leu Pro Arg Asn Leu Asp Asn Leu Pro Lys Ser 645 650 655

Leu Arg Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp

660	665	670
660	665	670

Ser Ser Leu Ala Leu Leu Pro Lys Leu Glu Ala Leu Asp Leu Ala Gly 675 680 685

Asn Gln Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln 690 695 700

Leu Gln Arg Leu Asp Leu Ser Gly Asn Ser Ile Gly Phe Val Val Pro 705 710 715 720

Ser Phe Phe Ala Leu Ala Val Arg Leu Arg Glu Leu Asn Leu Ser Ala
725 730 735

Asn Ala Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly 740 745 750

Ala Leu Lys Val Leu Asp Val Thr Ala Asn Pro Leu His Cys Ala Cys 755 760 765

Gly Ala Thr Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro 770 780

Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly 785 790 795 800

Arg Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu 805 810 815

Ser Trp Val Cys Phe Ser 820

<210> 23

<211> 3334

<212> DNA

<213> Canis familiaris

<400> 23

aggaaggggc tgtgagctcc aagcatectt teetgeaget getgeecage etgeeageea 60
gaeeetetgg agaageecee geteeetgte atgggeeeet geegtggege eetgeaceec 120
etgtetetee tggtgeagge tgeegegeta geeetggeee tggeecaggg caeeetgget 180
geetteetge eetgtgaget eeageeeat ggeetggtga aetgeaactg getgtteete 240
aagteegtge eeegettete ggeagetgea eeeegggta aegteaceag eettteettg 300

tactccaacc	gcatccacca	cctccatgac	tatgactttg	tccacttcgt	ccacctgcgg	360
cgtctcaatc	tcaagtggaa	ctgcccgccc	gccagcctca	gccccatgca	ctttccctgt	420
cacatgacca	ttgagcccaa	caccttcctg	gctgtgccca	ccctagagga	cctgaatctg	480
agctataaca	gcatcacgac	tgtgcccgcc	ctgcccagtt	cgcttgtgtc	cctgtccctg	540
agccgcacca	acatcctggt	gctggaccct	gccaccctgg	caggccttta	tgccctgcgc	600
ttcctgttcc	tggatggcaa	ctgctactac	aagaacccct	gccagcaggc	cctgcaggtg	660
gccccaggtg	ccctcctggg	cctgggcaac	ctcacacacc	tgtcactcaa	gtacaacaac	720
ctcaccgtgg	tgccgcgggg	cctgccccc	agcctggagt	acctgctctt	gtcctacaac	780
cacatcatca	ccctggcacc	tgaggacctg	gccaatctga	ctgccctgcg	tgtcctcgat	840
gtgggtggga	actgtcgccg	ctgtgaccat	gcccgtaacc	cctgcaggga	gtgccccaag	900
ggcttccccc	agctgcaccc	caacaccttc	ggccacctga	gccacctcga	aggcctggtg	960
ttgagggaca	gctctctcta	cagcctggac	cccaggtggt	tccatggcct	gggcaacctc	1020
atggtgctgg	acctgagtga	gaacttcctg	tatgactgca	tcaccaaaac	caaagccttc	1080
tacggcctgg	cceggetgeg	cagactcaac	ctgtccttca	attatcataa	gaaggtgtcc	1140
tttgcccacc	tgcatctggc	atcctccttc	gggagcctac	tgtccctgca	ggagctggac	1200
atacatggca	tettetteeg	ctcgctcagc	aagaccacgc	tccagtcgct	ggcccacctg	1260
cccatgctcc	agcgtctgca	tctgcagttg	aactttatca	gccaggccca	gctcagcatc	1320
ttcggcgcct	tccctggact	gcggtacgtg	gacttgtcag	acaaccgcat	cagtggagct	1380
gcagagcccg	cggctgccac	aggggaggta	gaggcagact	gtggggagag	agtctggcca	1440
cagtcccggg	accttgctct	gggcccactg	ggcacccccg	gctcagaggc	cttcatgccg	1500
agctgcagga	ccctcaactt	caccttggac	ctgtctcgga	acaacctagt	gactgttcag	1560
ccggagatgt	ttgtccggct	ggcgcgcctc	cagtgcctgg	gcctgagcca	caacagcatc	1620
tcgcaggcgg	tcaatggctc	gcagttcgtg	cctctgagca	acctgcgggt	gctggacctg	1680
tcccataaca	agctggacct	gtaccacggg	cgctcgttca	cggagctgcc	gcggctggag	1740
gccttggacc	tcagctacaa	cagccagccc	ttcagcatgc	ggggcgtggg	ccacaatctc	1800
agctttgtgg	cacagctgcc	agccctgcgc	tacctcagcc	tggcgcacaa	tggcatccac	1860
agccgcgtgt	cccagcagct	ccgcagcgcc	tegeteeggg	ccctggactt	cagtggcaat	1920
accctgagcc	agatgtgggc	cgagggagac	ctctatctcc	gcttcttcca	aggcctgaga	1980
agcctggttc	agctggacct	gtcccagaat	cgcctgcata	ccctcctgcc	acgcaacctg	2040
gacaacctcc	ccaagagcct	geggeteetg	cggctccgtg	acaattacct	ggctttcttc	2100

aactggagca	gcctggccct	cctacccaag	ctggaagccc	tggacctggc	gggaaaccag	2160
ctgaaggccc	tgagcaatgg	cagcttgccc	aacggcaccc	agctccagag	gctggacctc	2220
agcggcaaca	gcatcggctt	cgtggtcccc	agcttttttg	ccctggccgt	gaggcttcga	2280
gagctcaacc	tcagcgccaa	cgccctcaag	acggtggagc	cctcctggtt	tggttccctg	2340
gcgggtgccc	tgaaagtcct	agacgtgacc	gccaacccct	tgcattgcgc	ttgcggcgca	2400
accttcgtgg	acttcttgct	ggaggtgcag	gctgcggtgc	ccggcctgcc	tagccgtgtc	2460
aagtgcggca	gcccgggcca	gctccagggc	cgcagcatct	tegcacagga	cctgcgcctc	2520
tgcctggacg	aagcgctctc	ctgggtctgt	ttcagcctct	cgctgctggc	tgtggccctg	2580
agcctggctg	tgcccatgct	gcaccagctc	tgtggctggg	acctctggta	ctgcttccac	2640
ctgtgcctgg	cctggctgcc	ccggcggggg	cggcggcggg	gtgtggatgc	cctggcctat	2700
gacgccttcg	tggtcttcga	caaggcgcag	agctcggtgg	cggactgggt	gtacaatgag	2760
ctgcgggtac	agctagagga	gcgccgtggg	cgccgggcgc	tacgcctgtg	tctggaggaa	2820
cgtgactggg	tacccggcaa	aaccctcttc	gagaacctct	gggcctcagt	ttacagcagc	2880
cgcaagacgc	tgtttgtgct	ggcccgcacg	gacagagtca	gcggcctcct	gcgtgccagc	2940
ttectgctgg	cccaacagcg	cctgctggag	gaccgcaagg	acgtcgtggt	gctggtgatc	3000
ctgtgccccg	acgcccaccg	ctcccgctat	gtgcggctgc	gccagcgcct	ctgccgccag	3060
agtgtcctcc	tctggcccca	ccagcccagt	ggccagcgca	gcttctgggc	ccagctgggc	3120
acggccctga	ccagggacaa	ccgccacttc	tacaaccaga	acttctgccg	gggccccacg	3180
acagcctgat	aggcagacag	cccagcacct	tegegeeeet	acaccctgcc	tgtctgtctg	3240
ggatgcccga	cctgctggct	ctacaccgcc	gctctgtctc	ccctacaccc	agccctggca	3300
taaagcgacc	gctcaataaa	tgctgctggt	agac			3334

<210> 24

<211> 2466

<212> DNA

<213> Canis familiaris

<400> 24

atgggccct gccgtggcgc cctgcaccc ctgtctctc tggtgcaggc tgccgcgcta 60 gccctggccc tggcccaggg caccctgcct gccttcctgc cctgtgagct ccagccccat 120 ggcctggtga actgcaactg gctgttcctc aagtccgtgc cccgcttctc ggcagctgca 180 ccccgcggta acgtcaccag cctttccttg tactccaacc gcatccacca cctccatgac 240 tatgactttg tccacttcgt ccacctgcgg cgtctcaatc tcaagtggaa ctgcccgccc 300

gccagcctca	gccccatgca	ctttccctgt	cacatgacca	ttgagcccaa	caccttcctg	360
gctgtgccca	ccctagagga	cctgaatctg	agctataaca	gcatcacgac	tgtgcccgcc	420
ctgcccagtt	cgcttgtgtc	cctgtccctg	agccgcacca	acatcctggt	gctggaccct	480
gccaccctgg	caggccttta	tgccctgcgc	ttcctgttcc	tggatggcaa	ctgctactac	540
aagaacccct	gccagcaggc	cctgcaggtg	gccccaggtg	ccctcctggg	cctgggcaac	600
ctcacacacc	tgtcactcaa	gtacaacaac	ctcaccgtgg	tgccgcgggg	catgaacaa	660
agcctggagt	acctgctctt	gtcctacaac	cacatcatca	ccctggcacc	tgaggacctg	720
gccaatctga	ctgccctgcg	tgtcctcgat	gtgggtggga	actgtcgccg	ctgtgaccat	780
gcccgtaacc	cctgcaggga	gtgccccaag	ggcttccccc	agctgcaccc	caacaccttc	840
ggccacctga	gccacctcga	aggcctggtg	ttgagggaca	gctctctcta	cagcctggac	900
cccaggtggt	tccatggcct	gggcaacctc	atggtgctgg	acctgagtga	gaacttcctg	960
tatgactgca	tcaccaaaac	caaagccttc	tacggcctgg	cccggctgcg	cagactcaac	1020
ctgtccttca	attatcataa	gaaggtgtcc	tttgcccacc	tgcatctggc	atcctccttc	1080
gggagcctac	tgtccctgca	ggagetggae	atacatggca	tettetteeg	ctcgctcagc	1140
aagaccacgc	tccagtcgct	ggcccacctg	cccatgetee	agcgtctgca	tctgcagttg	1200
aactttatca	gccaggccca	gctcagcatc	tteggegeet	tecetggaet	gcggtacgtg	1260
gacttgtcag	acaaccgcat	cagtggagct	gcagagcccg	cggctgccac	aggggaggta	1320
gaggcagact	gtggggagag	agtctggcca	cagtcccggg	accttgctct	gggcccactg	1380
ggcacccccg	gctcagaggc	cttcatgccg	agctgcagga	ccctcaactt	caccttggac	1440
ctgtctcgga	acaacctagt	gactgttcag	ccggagatgt	ttgtccggct	ggcgcgcctc	1500
cagtgcctgg	gcctgagcca	caacagcatc	tcgcaggcgg	tcaatggctc	gcagttcgtg	1560
cctctgagca	acctgcgggt	gctggacctg	tcccataaca	agctggacct	gtaccacggg	1620
cgctcgttca	cggagctgcc	gcggctggag	gccttggacc	tcagctacaa	cagccagccc	1680
ttcagcatgc	ggggcgtggg	ccacaatctc	agctttgtgg	cacagetgee	agccctgcgc	1740
tacctcagcc	tggcgcacaa	tggcatccac	agccgcgtgt	cccagcagct	ccgcagcgcc	1800
tcgctccggg	ccctggactt	cagtggcaat	accctgagcc	agatgtgggc	cgagggagac	1860
ctctatctcc	gcttcttcca	aggcctgaga	agcctggttc	agctggacct	gtcccagaat	1920
cgcctgcata	ccctcctgcc	acgcaacctg	gacaacctcc	ccaagagcct	gcggctcctg	1980
cggctccgtg	acaattacct	ggctttcttc	aactggagca	gcctggccct	cctacccaag	2040

ctggaagccc	tggacctggc	gggaaaccag	ctgaaggccc	tgagcaatgg	cagcttgccc	2100
aacggcaccc	agctccagag	gctggacctc	agcggcaaca	gcatcggctt	cgtggtcccc	2160
agcttttttg	ccctggccgt	gaggettega	gagctcaacc	tcagcgccaa	cgccctcaag	2220
acggtggagc	cctcctggtt	tggttccctg	gcgggtgccc	tgaaagtcct	agacgtgacc	2280
gccaacccct	tgcattgcgc	ttgcggcgca	accttcgtgg	acttcttgct	ggaggtgcag	2340
gctgcggtgc	ccggcctgcc	tagccgtgtc	aagtgcggca	gcccgggcca	gctccagggc	2400
cgcagcatct	tcgcacagga	cctgcgcctc	tgcctggacg	aagcgctctc	ctgggtctgt	2460
ttcagc						2466

<210> 25

<211> 1031

<212> PRT

<213> Felis catus

<400> 25

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp
65 70 75 80

Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 . 125

Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 135 140 Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160

- Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly
 165 170 175
- Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro 180 185 190
- Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205
- Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220
- Leu Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 235 240
- Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 250
- Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe 260 265 270
- Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly 275 280 285
- Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe 290 295 300
- His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315 320
- Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu 325 330 335
- Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala 340 345 350
- His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln 355
- Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu 370 375 380

Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met 385 390 395 400

- Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 410 415
- Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu 420 425 430
- Leu Ala Ala Thr Gly Glu Val Asp Gly Glu Arg Val Arg Leu
 435
 440
 445
- Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu 450 455 460
- Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser 465 470 475 480
- Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser 485 490 495
- Arg Leu Gln Cys Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val 500 505 510
- Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu
 515 520 525
- Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 530 540
- Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser 545 550 555
- Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala 565 570 575
- Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser 580 585 590
- Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605
- Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe

610 615 620

Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg 645 650 655

Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser 660 665 670

Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln 675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln 690 695 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe 705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala 755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 775 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Gly Leu Ser Leu Leu Thr Val Ala Leu Gly Leu Ala Val 820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845

Leu Cys Leu Ala Trp Leu Pro Arg Arg Gly Arg Arg Gly Ala Asp 850 855 860

Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln Ser Ala 865 870 875 880

Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu Glu Arg 885 890 895

Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp Trp Leu-900 905 910

Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr Ser Ser 915 920 925

Arg Lys Met Leu Phe Val Leu Ala His Thr Asp Arg Val Ser Gly Leu 930 935 940

Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu Asp Arg 945 950 955 960

Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His Arg Ser 965 970 975

Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val Leu Leu 980 985 990

Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln Leu Gly 995 1000 1005

Thr Ala Leu Thr Arg Asp Asn Gln His Phe Tyr Asn Gln Asn Phe 1010 1015 1020

Cys Arg Gly Pro Thr Thr Ala Glu 1025 1030

<210> 26

<211> 820

<212> PRT

<213> Felis catus

<400> 26

Met Gly Pro Cys His Gly Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ala Ala Leu Ala Val Ala Leu Ala Gln Gly Thr Leu Pro Ala Phe 20 25 30

- Leu Pro Cys Glu Leu Gln Arg His Gly Leu Val Asn Cys Asp Trp Leu 35 40 45
- Phe Leu Lys Ser Val Pro His Phe Ser Ala Ala Pro Arg Gly Asn 50 55 60
- Val Thr Ser Leu Ser Leu Tyr Ser Asn Arg Ile His His Leu His Asp 65 70 75 80
- Ser Asp Phe Val His Leu Ser Ser Leu Arg Arg Leu Asn Leu Lys Trp 85 90 95
- Asn Cys Pro Pro Ala Ser Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110
- Thr Ile Glu Pro His Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125
- Asn Leu Ser Tyr Asn Ser Ile Thr Thr Val Pro Ala Leu Pro Ser Ser 130 140
- Leu Val Ser Leu Ser Leu Ser Arg Thr Asn Ile Leu Val Leu Asp Pro 145 150 155 160
- Ala Asn Leu Ala Gly Leu His Ser Leu Arg Phe Leu Phe Leu Asp Gly 165 170 175
- Asn Cys Tyr Tyr Lys Asn Pro Cys Pro Gln Ala Leu Gln Val Ala Pro 180 185 190
- Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205
- Asn Asn Leu Thr Ala Val Pro Arg Gly Leu Pro Pro Ser Leu Glu Tyr 210 215 220
- Leu Leu Ser Tyr Asn His Ile Ile Thr Leu Ala Pro Glu Asp Leu 225 230 235 240
- Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Arg Asn Pro Cys Met Glu Cys Pro Lys Gly Phe 260 Pro His Leu His Pro Asp Thr Phe Ser His Leu Asn His Leu Glu Gly 275 280 Leu Val Leu Lys Asp Ser Ser Leu Tyr Asn Leu Asn Pro Arg Trp Phe 295 His Ala Leu Gly Asn Leu Met Val Leu Asp Leu Ser Glu Asn Phe Leu 315 310 Tyr Asp Cys Ile Thr Lys Thr Thr Ala Phe Gln Gly Leu Ala Gln Leu Arg Arg Leu Asn Leu Ser Phe Asn Tyr His Lys Lys Val Ser Phe Ala His Leu His Leu Ala Pro Ser Phe Gly Ser Leu Leu Ser Leu Gln Gln 360 355 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Ser Glu Thr Thr Leu 375 Arg Ser Leu Val His Leu Pro Met Leu Gln Ser Leu His Leu Gln Met 395 385 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Ala Phe Pro Gly 405 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Met Glu

Leu Ala Ala Thr Gly Glu Val Asp Gly Glu Arg Val Arg Leu
435 440 445

Pro Ser Gly Asp Leu Ala Leu Gly Pro Pro Gly Thr Pro Ser Ser Glu 450 455 460

Gly Phe Met Pro Gly Cys Lys Thr Leu Asn Phe Thr Leu Asp Leu Ser 465 470 475 480

Arg Asn Asn Leu Val Thr Ile Gln Pro Glu Met Phe Ala Arg Leu Ser 485 490 495

Arg Leu Gln Cys Leu Leu Ser Arg Asn Ser Ile Ser Gln Ala Val 500 505 Asn Gly Ser Gln Phe Met Pro Leu Thr Ser Leu Gln Val Leu Asp Leu 515 520 525 Ser His Asn Lys Leu Asp Leu Tyr His Gly Arg Ser Phe Thr Glu Leu 535 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Ser Met Gln Gly Val Gly His Asn Leu Ser Phe Val Ala Gln Leu Pro Ala 570 565 Leu Arg Tyr Leu Ser Leu Ala His Asn Asp Ile His Ser Arg Val Ser Gln Gln Leu Cys Ser Ala Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 600 Ala Leu Ser Arg Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe 615 Arg Gly Leu Arg Ser Leu Val Arg Leu Asp Leu Ser Gln Asn Arg Leu 635 His Thr Leu Leu Pro Arg Thr Leu Asp Asn Leu Pro Lys Ser Leu Arg 650 Leu Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Asn Trp Ser Ser Leu Val Leu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ala Gly Asn Gln 675 680 685

Leu Lys Ala Leu Ser Asn Gly Ser Leu Pro Asn Gly Thr Gln Leu Gln 690 695 700

Arg Leu Asp Leu Ser Ser Asn Ser Ile Ser Phe Val Ala Ser Ser Phe 705 710 715 720

Phe Ala Leu Ala Thr Arg Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala

725 730 735

Leu Lys Thr Val Glu Pro Ser Trp Phe Gly Ser Leu Ala Gly Thr Leu 740 745 750

Lys Val Leu Asp Val Thr Gly Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Val Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Gly His Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg Ser 785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815

Asp Cys Phe Gly 820

<210> 27

<211> 3235

<212> DNA

<213> Felis catus

<400> 27

agggtctgcg agctccaggc attcttctct gccatcgctg cccagtctgc catccagacc 60 ctctggagaa gccccactc cctgtcatgg gcccctgcca tggcgccctg caccccctgt 120 ctctcctggt gcaggctgcc gcgctggccg tggccctggc ccagggcacc ctgcctgcct 180 ttctgccctg tgagctccag cgccacggcc tggtgaattg cgactggctg ttcctcaagt 240 ccgtgcccca cttctcggcg gcagcgcccc gtggtaacgt caccagcctt tccctgtact 300 ccaacegcat ccaccacete cacgacteeg actttgtcca cctgtccage ctgcggcgte 360 tcaacctcaa atggaactgc ccacccgcca gcctcagccc catgcacttc ccctgtcaca 420 tgaccattga gccccacacc ttcctggccg tgcccaccct ggaggagctg aacctgagct 480 acaacagcat cacgacagta cccgccctgc ccagttccct cgtgtccctg tccttgagcc 540 gtaccaacat cctggtgctg gaccctgcca acctcgcagg gctgcactcc ctgcgctttc 600 tgttcctgga tggcaactgc tactacaaga acccctgccc gcaggccctg caggtggccc 660 egggegeest cettggeetg ggcaacetta egcaeetgte acteaagtae aacaacetea 720 ctgcggtgcc ccgcggcctg ccccccagcc tggagtacct gctattgtcc tacaaccaca 780

tcatcaccct ggcacctgag gacctggcca acctgaccgc cctgcgtgtg ctcgatgtgg 840 gtgggaactg ccgtcgctgt gaccacgccc gcaacccctg tatggagtgc cccaagggct 900 960 tcccgcacct gcaccctgac accttcagcc acctgaacca cctcgaaggc ctggtgttga aggacagete tetetacaae etgaaceeea gatggtteea tgeeetggge aaceteatgg 1020 tgctggacct gagtgagaac ttcctatatg actgcatcac caaaaccaca gccttccagg 1080 gcctggccca gctgcgcaga ctcaacttgt ctttcaatta ccacaagaag gtgtcctttg 1140 cccacctgca tctggcgccc tccttcggga gcctgctctc cctgcagcag ctggacatgc 1200 1260 atggcatctt cttccgctcg ctcagcgaga ccacgctccg gtcgctggtc cacctgccca tgctccagag tctgcacctg cagatgaact tcatcaatca ggcccagctc agcatcttcg 1320 gggccttccc tggcctgcga tacgtggacc tgtcagacaa ccgcataagt ggagccatgg 1380 agctggcggc tgccacgggg gaggtggatg gtggggagag agtccggctg ccatctgggg 1440 acctagetet gggeecaceg ggeaceceta geteegaggg etteatgeea ggetgeaaga 1500 ccctcaactt caccttggac ctgtcacgga acaacctagt gacaatccag ccagagatgt 1560 ttgcccggct ctcgcgcctc cagtgcctgc tcctgagccg caacagcatc tcgcaggcag 1620 tcaacggctc acaatttatg ccgctgacca gcctgcaggt gctggacctg tcccataaca 1680 1740 agetggacet gtaccatggg egetetttea eggagetgee geggetggag geeetggace tcagctacaa cagccagccc ttcagcatgc agggcgtggg tcacaacctc agctttgtgg 1800 cacagetgee ggeeetgege tateteagee tggegeacaa egacateeae ageegtgtgt 1860 cccagcaget ctgcagegec tegetgeggg cettggaett cageggeaat geettgagee 1920 ggatgtgggc cgagggagac ctgtatctcc acttcttccg aggcctgagg agcctggtcc 1980 ggttggatet gteccagaat egeetgeata ecetettgee aegeaceetg gacaacetee 2040 ccaagagcct gcggctgctg cgtctccgtg acaattatct ggctttcttc aactggagca 2100 gcctggtcct cctccccagg ctggaagccc tggacctggc gggaaaccag ctgaaggccc 2160 tgagcaacgg cagcttgcct aatggaaccc agctccagag gctggacctc agcagcaaca 2220 2280 gtatcagett egtggeetee agettttttg etetggeeae eaggetgega gageteaaee tcagtgccaa cgccctcaag acggtggagc cctcctggtt cggttctcta gcgggcaccc 2340 tgaaagtcct agatgtgact ggcaaccccc tgcactgcgc ctgtgggggg gccttcgtgg 2400 acttettget ggaggtgeag getgeagtge eeggeetgee aggeeaegte aagtgtggea 2460 gtccaggtca gctccagggc cgcagcatct ttgcgcagga tctgcgcctc tgcctggatg 2520 aggccetete etgggaetgt tttggcetet egetgetgae egtggeeetg ggcetggeeg 2580

2640 tgcccatgct gcaccacctc tgtggctggg acctctggta ctgcttccac ctgtgcctgg cctggctgcc ccggcggggg cggcggcggg gcgcggatgc cctgccctac gatgcctttg 2700 2760 tggtcttcga caaggcacag agcgcggtgg ccgactgggt gtacaacgag ctgcgggtac 2820 ggctagagga gcgccgtgga cgccgagcgc tccgcctgtg cctggaggaa cgtgactggc taccoggtaa aacgotottt gagaacotgt gggootcagt ttacagcago cgcaagatgo 2880 2940 tgtttgtgct ggcccacaca gacagggtca gcggcctctt gcgcgccagc tttctgctgg 3000 cccagcagcg cctgctggag gaccgcaagg acgttgtggt gctggtgatc ctgcgccccg acgeccaceg etecegetat gtgeggetge gecagegeet etgeegeeag agegteetee 3060 tetggeeeca ecageecagt ggeeagegea gettetggge ceagetggge aeggeeetga 3120 ccaqqqacaa ccaqcacttc tataaccaga acttctgccg gggccccacg acggcagagt 3180 3235 gaccgcccag caccccaagc ctcctacacc ttgcctgtct gcctgggatg ccggg

<210> 28

<211> 2460

<212> DNA

<213> Felis catus

<400> 28

atgggccct gccatggcgc cctgcacccc ctgtctctcc tggtgcaggc tgccgcgctg 60 geogtggece tggcccaggg caccetgect geetttetge cetgtgaget ccagegecae 120 180 ggcctggtga attgcgactg gctgttcctc aagtccgtgc cccacttctc ggcggcagcg cccegtggta acgteaccag cetttecctg tactccaacc geatecacca cetecacgae tecgaetttg tecaeetgte eageetgegg egteteaace teaaatggaa etgeeeacee 300 gccagcctca gccccatgca etteccctgt cacatgacca ttgagcccca caccttcctg 360 gccgtgccca ccctggagga gctgaacctg agctacaaca gcatcacgac agtacccgcc 420 ctgcccagtt ccctcgtgtc cctgtccttg agccgtacca acatcctggt gctggaccct 480 gccaacctcg cagggctgca ctccctgcgc tttctgttcc tggatggcaa ctgctactac 540 600 aagaacccet geeegeagge eetgeaggtg geeeegggeg eeeteettgg eetgggeaae cttacgcacc tgtcactcaa gtacaacaac ctcactgcgg tgccccgcgg cctgccccc 660 agectggagt acctgetatt gtectacaac cacateatea ceetggeace tgaggacetg 720 780 gecaacetga eegeeetgeg tgtgetegat gtgggtggga aetgeegteg etgtgaeeae gcccgcaacc cctgtatgga gtgccccaag ggcttcccgc acctgcaccc tgacaccttc 840 agccacctga accacctega aggcetggtg ttgaaggaca geteteteta caacetgaac 900

cccagatggt	tccatgccct	gggcaacctc	atggtgctgg	acctgagtga	gaacttccta	960
tatgactgca	tcaccaaaac	cacagccttc	cagggcctgg	cccagctgcg	cagactcaac	1020
ttgtctttca	attaccacaa	gaaggtgtcc	tttgcccacc	tgcatctggc	gccctccttc	1080
gggagcctgc	tetecetgea	gcagctggac	atgcatggca	tcttcttccg	ctcgctcagc	1140
gagaccacgc	tccggtcgct	ggtccacctg	cccatgctcc	agagtctgca	cctgcagatg	1200
aacttcatca	atcaggccca	gctcagcatc	ttcggggcct	tccctggcct	gcgatacgtg	1260
gacctgtcag	acaaccgcat	aagtggagcc	atggagctgg	cggctgccac	gggggaggtg	1320
gatggtgggg	agagagtccg	gctgccatct	ggggacctag	ctctgggccc	accgggcacc	1380
cctagctccg	agggcttcat	gccaggctgc	aagaccctca	acțtcacctt	ggacctgtca	1440
cggaacaacc	tagtgacaat	ccagccagag	atgtttgccc	ggctctcgcg	cctccagtgc	1500
ctgctcctga	gccgcaacag	catctcgcag	gcagtcaacg	gctcacaatt	tatgccgctg	1560
accagcctgc	aggtgctgga	cctgtcccat	aacaagctgg	acctgtacca	tgggcgctct	1620
ttcacggagc	tgccgcggct	ggaggccctg	gacctcagct	acaacagcca	gcccttcagc	1680
atgcagggcg	tgggtcacaa	cctcagcttt	gtggcacagc	tgccggccct	gcgctatctc	1740
agcctggcgc	acaacgacat	ccacageegt	gtgtcccagc	agctctgcag	cgcctcgctg	1800
cgggccttgg	acttcagcgg	caatgccttg	agccggatgt	gggccgaggg	agacctgtat	1860
ctccacttct	tccgaggcct	gaggageetg	gtccggttgg	atctgtccca	gaatcgcctg	1920
cataccctct	tgccacgcac	cctggacaac	ctccccaaga	gcctgcggct	gctgcgtctc	1980
cgtgacaatt	atctggcttt	cttcaactgg	agcagcctgg	tectectece	caggctggaa	2040
gccctggacc	tggcgggaaa	ccagctgaag	gccctgagca	acggcagctt	gcctaatgga	2100
acccagetee	agaggctgga	cctcagcagc	aacagtatca	gcttcgtggc	ctccagcttt	2160
tttgctctgg	ccaccagget	gcgagagctc	aacctcagtg	ccaacgccct	caagacggtg	2220
gagccctcct	ggttcggttc	tctagcgggc	accctgaaag	tcctagatgt	gactggcaac	2280
cccctgcact	gcgcctgtgg	ggcggccttc	gtggacttct	tgctggaggt	gcaggctgca	2340
gtgcccggcc	tgccaggcca	cgtcaagtgt	ggcagtccag	gtcagctcca	gggccgcagc	2400
atctttgcgc	aggatctgcg	cctctgcctg	gatgaggccc	tctcctggga	ctgttttggc	2460

<210> 29 <211> 1032 <212> PRT

<213> Mus musculus

<400> 29

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala 145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro 180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu

225					230					235					240
Ala	Asn	Leu	Thr	Ser 245	Leu	Arg	Val	Leu	Asp 250	Val	Gly	Gly	Asn	Cys 255	Arg
Arg	Cys	Asp	His 260	Ala	Pro	Asn	Pro	Cys 265	Ile	Glu	Cys	Gly	Gln 270	Lys	Ser
Leu	His	Leu 275	His	Pro	Glu	Thr	Phe 280	Hìs	His	Leu	Ser	His 285	Leu	Glu	Gly
Leu	Val 290	Leu	Lys	Asp	Ser	Ser 295	Leu	His	Thr	Leu	Asn 300	Ser	Ser	Trp	Phe
G1n 305	Gly	Leu	Val	Asn	Leu 310	Ser	Val	Leu	Asp	Leu 315	Ser	Glu	Asn	Phe	Leu 320
Tyr	Glu	Ser	Ile	Asn 325	His	Thr	Asn	Ala	Phe 330	Gln	Asn	Leu	Thr	Arg 335	Leu
Arg	Lys	Leu	Asn 340	Leu	Ser	Phe		Tyr 345	Arg	Lys	Lys	Val	Ser 350	Phe	Ala
Arg	Leu	His 355	Leu	Ala	Ser	Ser	Phe 360	Lys	Asn	Leu	Val	Ser 365	Leu	Gln	Glu
Leu	Asn 370	Met	Asn	Gly	Ile	Phe 375	Phe	Arg	Ser	Leu	Asn 380	Lys	Tyr	Thr	Leu
Arg 385	Trp	Leu	Ala	Asp	Leu 390	Pro	Lys	Leu	His	Thr 395	Leu	His	Leu	Gln	Met 400
Asn	Phe	Ile	Asn	Gln 405	Ala	Gln	Leu	Ser	Ile 410	Phe	Gly	Thr	Phe	Arg 415	Ala
Leu	Arg	Phe	Val 420	Asp	Leu	Ser	Asp	Asn 425	Arg	Ile	Ser	Gly	Pro 430	Ser	Thr
Leu	Ser	Glu 435	Ala	Thr	Pro	Glu	Glu 440	Ala	Asp	Asp	Ala	Glu 445	Gln	Glu	Glu
Leu	Leu 450	Ser	Ala	Asp	Pro	His 455	Pro	Ala	Pro	Leu	Ser 460	Thr	Pro	Ala	Ser

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu 465 470 475 480

- Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495
- Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala 500 505 510
- Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp 515 520 525
- Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu 530 535 540
- Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 555
- Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser 565 570 575
- Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val
- Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly 595 600 605
- Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe 610 615 620
- Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn 625 635 640
- Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu 645 650 655
- Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr 660 665 670
- Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn 675 680 685
- Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 695 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala 705 710 715 720

- Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn 725 730 735
- Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750
- Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly 755 760 765
- Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
 770 780
- Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
 785 790 795 800
- Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser 805 810 815
- Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val 820 825 830
- Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe 835 840 845
- His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser 850 860
- Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln 865 870 875 888
- Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu 885 890 895
- Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp 900 905 910
- Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr 915 920 925
- Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser 930 935 940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln 995 1000 1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln 1010 1015 1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu 1025 1030

<210> 30

<211> 821

<212> PRT

<213> Mus musculus

<400> 30

Met Val Leu Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu 115 120 125

- Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser 130 135 140
- Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly 165 170 175
- Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro 180 185 190
- Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205
- Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr 210 215 220
- Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu 225 230 235 240
- Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
 245 250 255
- Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser 260 265 270
- Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly 275 280 285
- Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe 290 295 300
- Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315
- Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu 325 330 335
- Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala

340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu 355' 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu 370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala 405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr 420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Glu Glu 435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser 450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu 465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu 485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala 500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp 515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu 530 535

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe 545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser 565 570 575

Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val 580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly 595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe 610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn 625 630 635

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu
. 645 650 655

Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr 660 665 670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn 675 680 685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu 690 700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala 705 710 715 720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn 725 730 735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn 740 745 750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
755 760 765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly
770 775 780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg 785 790 795 800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser 805 810 815

Trp Asp Cys Phe Gly 820

<210> 31 <211> 3200 <212> DNA

<213> Mus musculus

<400> 31

tgtcagaggg agcctcggga gaatcctcca tctcccaaca tggttctccg tcgaaggact 60 ctgcacccct tgtccctcct ggtacaggct gcagtgctgg ctgagactct ggccctqqqt 120 accetgeetg cettectace etgtgagetg aagceteatg geetggtgga etgcaattgg 180 ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgctccaa catcacccgc 240 ctctccttga tctccaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc 300 aacctgcggc agctgaacct caagtggaac tgtccaccca ctggccttag ccccctgcac 360 ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag 420 ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtgaat 480 ctgagcctga gccacaccaa catcctggtt ctagatgcta acagcctcgc cggcctatac 540 agcctgcgcg ttctcttcat ggacgggaac tgctactaca agaacccctg cacaggagcg 600 gtgaaggtga ccccaggcgc cctcctgggc ctgagcaatc tcacccatct gtctctgaag 660 tataacaacc tcacaaaggt gccccgccaa ctgcccccca gcctggagta cctcctggtg 720 tectataace teattgteaa getggggeet gaagacetgg ceaatetgae etecettega 780 gtacttgatg tgggtgggaa ttgccgtcgc tgcgaccatg cccccaatcc ctgtatagaa 840 tgtggccaaa agtccctcca cctgcaccct gagaccttcc atcacctgag ccatctggaa 900 ggcctggtgc tgaaggacag ctctctccat acactgaact cttcctggtt ccaaggtctg 960 gtcaacctct cggtgctgga cctaagcgag aactttctct atgaaagcat caaccacacc 1020 aatgeettte agaacetaac eegeetgege aageteaace tgteetteaa ttacegeaag 1080 aaggtateet ttgeeegeet eeacetggea agtteettea agaacetggt gteaetgeag 1140 gagetgaaca tgaaeggeat ettetteege tegeteaaca agtacaeget cagatggetg 1200 geogatetge ecaaacteca caetetgeat etteaaatga aetteateaa ecaggeacag 1260 ctcagcatct ttggtacctt ccgagccctt cgctttgtgg acttgtcaga caatcgcatc 1320 agtgggcctt caacgctgtc agaagccacc cctgaagagg cagatgatgc agagcaggag 1380 gagetgttgt etgeggatee teacceaget ceaetgagea eccetgette taagaaette 1440

atggacaggt	gtaagaactt	caagttcacc	atggacctgt	ctcggaacaa	cctggtgact	1500
atcaagccag	agatgtttgt	caatctctca	cgcctccagt	gtcttagcct	gagccacaac	1560
tccattgcac	aggctgtcaa	tggctctcag	ttcctgccgc	tgactaatct	gcaggtgctg	1620
gacctgtccc	ataacaaact	ggacttgtac	cactggaaat	cgttcagtga	gctaccacag	1680
ttgcaggccc	tggacctgag	ctacaacagc	cagcccttta	gcatgaaggg	tataggccac	1740
aatttcagtt	ttgtggccca	tctgtccatg	ctacacagcc	ttagcctggc	acacaatgac	1800
attcataccc	gtgtgtcctc	acatctcaac	agcaactcag	tgaggtttct	tgacttcagc	1860
ggcaacggta	tgggccgcat	gtgggatgag	gggggccttt	atctccattt	cttccaaggc	1920
ctgagtggcc	tgctgaagct	ggacctgtct	caaaataacc	tgcatatcct	ccggccccag	1980
aaccttgaca	acctccccaa	gagcctgaag	ctgctgagcc	tccgagacaa	ctacctatct	2040
ttctttaact	ggaccagtct	gtccttcctg	cccaacctgg	aagtcctaga	cctggcaggc	2100
aaccagctaa	aggccctgac	caatggcacc	ctgcctaatg	gcaccctcct	ccagaaactg	2160
gatgtcagca	gcaacagtat	cgtctctgtg	gtcccagcct	tattagatat	ggcggtcgag	2220
ctgaaagagg	tcaacctcag	ccacaacatt	ctcaagacgg	tggatcgctc	ctggtttggg	2280
cccattgtga	tgaacctgac	agttctagac	gtgagaagca	accetetgea	ctgtgcctgt	2340
ggggcagcct	tcgtagactt	actgttggag	gtgcagacca	aggtgcctgg	cctggctaat	2400
ggtgtgaagt	gtggcagccc	cggccagctg	cagggccgta	gcatcttcgc	acaggacctg	2460
cggctgtgcc	tggatgaggt	cctctcttgg	gactgctttg	gcctttcact	cttggctgtg	2520
gccgtgggca	tggtggtgcc	tatactgcac	catctctgcg	gctgggacgt	ctggtactgt	2580
tttcatctgt	gcctggcatg	gctacctttg	ctggcccgca	gccgacgcag	cgcccaagct	2640
ctcccctatg	atgccttcgt	ggtgttcgat	aaggcacaga	gcgcagttgc	ggactgggtg	2700
tataacgagc	tgcgggtgcg	gctggaggag	cggcgcggtc	gccgagccct	acgcttgtgt	2760
ctggaggacc	gagattggct	gcctggccag	acgctcttcg	agaacctctg	ggcttccatc	2820
tatgggagcc	gcaagactct	atttgtgctg	gcccacacgg	accgcgtcag	tggcctcctg	2880
cgcaccagct	tcctgctggc	tcagcagcgc	ctgttggaag	accgcaagga	cgtggtggtg	2940
ttggtgatcc	tgcgtccgga	tgcccaccgc	tcccgctatg	tgcgactgcg	ccagcgtctc	3000
tgccgccaga	gtgtgctctt	ctggccccag	cagcccaacg	ggcagggggg	cttctgggcc	3060
cagctgagta	cagecetgae	tagggacaac	cgccacttct	ataaccagaa	cttctgccgg	3120
ggacctacag	cagaatagct	cagagcaaca	gctggaaaca	gctgcatctt	catgcctggt	3180
tcccgagttg	ctctgcctgc					3200

<210> 32 <211> 2463 <212> DNA

<213> Mus musculus

<400> 32 60 atggttetee gtegaaggae tetgeaeeee ttgteeetee tggtaeagge tgeagtgetg gctgagactc tggccctggg taccctgcct gccttcctac cctgtgagct gaagcctcat 120 180 ggcctggtgg actgcaattg gctgttcctg aagtctgtac cccgtttctc tgcggcagca tectgeteea acateaceeg ceteteettg atetecaace gtatecacea cetgeacaac 240 teegaetteg teeacetgte caacetgegg cagetgaace teaagtggaa etgteeacee 300 360 actggeetta geceeetgea ettetettge cacatgacca ttgageecag aacetteetg getatgegta cactggagga getgaacetg agetataatg gtatcaccac tgtgeecega 420 ctgcccagct ccctggtgaa tctgagcctg agccacacca acatcctggt tctagatgct 480 aacageeteg eeggeetata eageetgege gttetettea tggaegggaa etgetaetae 540 aagaacccct gcacaggagc ggtgaaggtg accccaggeg ccctcctggg cctgagcaat 600 ctcacccatc tgtctctgaa gtataacaac ctcacaaagg tgccccgcca actgcccccc 660 720 agectggagt acctectggt gtectataac eteattgtea agetggggee tgaagacetg gccaatctga cetecetteg agtacttgat gtgggtggga attgeegteg etgegaccat 780 840 gcccccaatc cctgtataga atgtggccaa aagtccctcc acctgcaccc tgagaccttc 900 catcacctga gccatctgga aggcctggtg ctgaaggaca gctctctcca tacactgaac 960 tetteetggt tecaaggtet ggteaacete teggtgetgg acetaagega gaactttete tatgaaagca tcaaccacac caatgccttt cagaacctaa cccgcctgcg caagctcaac 1020 etgteettea attacegeaa gaaggtatee tttgeeegee teeacetgge aagtteette 1080 aagaacctgg tgtcactgca ggagctgaac atgaacggca tcttcttccg ctcgctcaac 1140 aagtacacgc teagatggct ggccgatctg cccaaactcc acactctgca tcttcaaatg 1200 aacttcatca accaggcaca gctcagcatc tttggtacct tccgagccct tcgctttgtg 1260 1320 gacttgtcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac ccctgaagag gcagatgatg cagagcagga ggagctgttg tetgcggate etcacecage tecactgage 1380 accectgett etaagaaett catggaeagg tgtaagaaet teaagtteae eatggaeetg 1440 teteggaaca acetggtgae tateaageea gagatgtttg teaatetete aegeeteeag 1500

1560

tgtcttagcc tgagccacaa ctccattgca caggctgtca atggctctca gttcctgccg

ctgactaatc tgcaggtgct ggacctgtcc cataacaaac tggacttgta ccactggaaa 1620 tegtteagtg agetaceaca gttgcaggee etggaeetga getacaacag ecagecettt 1680 agcatgaagg gtataggcca caatttcagt tttgtggccc atctgtccat gctacacagc 1740 cttagcctgg cacacaatga cattcatacc cqtqtqtcct cacatctcaa cagcaactca 1800 gtgaggtttc ttgacttcag cggcaacggt atgggccgca tgtgggatga ggggggcctt 1860 tateteeatt tetteeaagg eetgagtgge etgetgaage tggaeetgte teaaaataae 1920 ctgcatatcc tccggcccca gaaccttgac aacctcccca agagcctgaa gctgctgagc 1980 ctccgagaca actacctate tttctttaac tggaccagte tgtccttcct gcccaacctg 2040 gaagteetag acctggcagg caaccageta aaggeeetga ccaatggcae eetgeetaat 2100 ggcaccctcc tccagaaact ggatgtcagc agcaacagta tcgtctctgt ggtcccagcc 2160 ttcttcgctc tggcggtcga gctgaaagag gtcaacctca gccacaacat tctcaagacg 2220 gtggatcgct cctggtttgg gcccattgtg atgaacctga cagttctaga cgtgagaagc 2280 aaccetetge actgtgcetg tggggcagee ttegtagaet taetgttgga ggtgcagaee 2340 aaggtgeetg geetggetaa tggtgtgaag tgtggeagee eeggeeaget geagggeegt 2400 agcatcttcg cacaggacct gcggctgtgc ctggatgagg tcctctcttg ggactgcttt 2460 2463 ggc

<210> 33

<211> 1032

<212> PRT

<213> Homo sapiens

<400> 33

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln 1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp 85 90 95

- Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110
- Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125
- Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser 130 140
- Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser 145 150 155 160
- Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
 165 170 175
- Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro 180 185 190
- Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205
- Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr 210 215 220
- Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu 225 230 235 240
- Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255
- Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe 260 265 270
- Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285
- Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe 290 295 300
- Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Glu Lys Val Trp Leu Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly 545 550 555

- Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr 565 570 575
- Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser 580 585 590
- Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605
- Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe 610 620
- Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635
- His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln 645 650 655
- Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser 660 665 670
- Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg 675 680 685
- Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg 690 695 700
- Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe 705 710 715 720
- Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 725 730 735
- Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu 740 745 750
- Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala 755 760 765
- Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu 770 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser 785 790 795 800

- Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 805 810 815
- Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val 820 825 830
- Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His 835 840 845
- Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp 850 855 860
- Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln 865 870 875
- Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu 885 890 895
- Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp 900 905 910
- Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr 915 920 925
- Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser 930 935 940
- Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu 945 950 955 960
- Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg 965 970 975
- Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val 980 985 990
- Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln 995 1000 1005
- Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg 1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu 1025 1030

<210> 34

<211> 820

<212> PRT

<213> Homo sapiens

<400> 34

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu 35 40

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn 50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp 65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp 85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met 100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu 115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser 130 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser 145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro 180 185 190 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr 210 215 220

Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe 260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe 290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu 305 310 315

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu 325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala 340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu 355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu 370 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met 385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly 405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu

420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu 450 455 460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser 465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser 485 490 495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val 500 505 510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
515 520 525

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu 530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly 545 550 555

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr 565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser 580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn 595 600 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe 610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu 625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln 645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg 695 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe 710 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala 730 . Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu 745 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala 760 755 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser 790 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp 810 805 Asp Cys Phe Ala 820 <210> 35 <211> 3352 <212> DNA <213> Homo sapiens <400> 35 aggetggtat aaaaatetta etteetetat tetetgagee getgetgeee etgtgggaag 60 ggacctcgag tgtgaagcat ccttccctgt agctgctgtc cagtctgccc gccagaccct 120 ctggagaagc ccctgccccc cagcatgggt ttctgccgca gcgccctgca cccgctgtct 180 ctcctggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc 240 ctaccetgtg agetecagee ccaeggeetg gtgaactgea actggetgtt cetgaagtet 300

gtgccccact	tctccatggc	agcaccccgt	ggcaatgtca	ccagcctttc	cttgtcctcc	360
aaccgcatcc	accacctcca	tgattctgac	tttgcccacc	tgcccagcct	gcggcatctc	420
aacctcaagt	ggaactgccc	gccggttggc	ctcagcccca	tgcacttccc	ctgccacatg	480
accatcgagc	ccagcacctt	cttggctgtg	cccaccctgg	aagagctaaa	cctgagctac	540
aacaacatca	tgactgtgcc	tgcgctgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcatgccct	gcgcttccta	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcactgga	ggtggccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tgttgtccta	caaccgcatc	840
gtcaaactgg	cgcctgagga	cctggccaat	ctgaccgccc	tgcgtgtgct	cgatgtgggc	900
ggaaattgcc	gccgctgcga	ccacgctccc	aacccctgca	tggagtgccc	tcgtcacttc	960
ccccagctac	atcccgatac	cttcagccac	ctgagccgtc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tggttccgtg	ggctgggaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcatcacta	aaaccaaggc	cttccagggc	1140
ctaacacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggt	gtcctttgcc	1200
cacctgtctc	tggccccttc	cttcgggagc	ctggtcgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	teegeteact	cgatgagacc	acgctccggc	cactggcccg	cctgcccatg	1320
ctccagactc	tgcgtctgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gccttccctg	gcctgcgcta	cgtggacctg	tcggacaacc	gcatcagcgg	agcttcggag	1440
ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgctccgg	ccccagtgga	cactcccagc	tctgaagact	tcaggcccaa	ctgcagcacc	1560
ctcaacttca	ccttggatct	gtcacggaac	aacctggtga	ccgtgcagcc	ggagatgttt	1620
gcccagctct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatctc	gcaggcagtc	1680
aatggctccc	agttcctgcc	gctgaccggt	ctgcaggtgc	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcacg	gagctaccgc	gactggaggc	cctggacctc	1800
agctacaaca	gccagccctt	tggcatgcag	ggcgtgggcc	acaacttcag	cttcgtggct	1860
cacctgcgca	ccctgcgcca	cctcagcctg	gcccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	gctgcgggcc	ctggacttca	gcggcaatgc	actgggccat	1980
atgtgggccg	agggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040

ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaaccctgcg	caacctcccc	2100
aagagcctac	aggtgctgcg	tctccgtgac	aattacctgg	ccttctttaa	gtggtggagc	2160
ctccacttcc	tgcccaaact	ggaagtcctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggcccccgg	cttcttttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaacg	ccctcaagac	agtggaccac	tcctggtttg	ggcccctggc	gagtgccctg	2400
caaatactag	atgtaagcgc	caaccctctg	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcaggc	tgccgtgccc	ggtctgccca	gccgggtgaa	gtgtggcagt	2520
ccgggccagc	tccagggcct	cagcatcttt	gcacaggacc	tgcgcctctg	cctggatgag	2580
gccctctcct	gggactgttt	cgccctctcg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctgggac	ctctggtact	gcttccacct	gtgcctggcc	2700
tggcttccct	ggcgggggcg	gcaaagtggg	cgagatgagg	atgccctgcc	ctacgatgcc	2760
ttcgtggtct	tcgacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	cgagcttcgg	2820
gggcagctgg	aggagtgccg	tgggcgctgg	gcactccgcc	tgtgcctgga	ggaacgcgac	2880
tggctgcctg	gcaaaaccct	ctttgagaac	ctgtgggcct	cggtctatgg	cagccgcaag	2940
acgctgtttg	tgctggccca	cacggaccgg	gtcagtggtc	tettgegege	cagcttcctg	3000
ctggcccagc	agcgcctgct	ggaggaccgc	aaggacgtcg	tggtgctggt	gatectgage	3060
cctgacggcc	geegeteeeg	ctacgtgcgg	ctgcgccagc	geetetgeeg	ccagagtgtc	3120
ctcctctggc	cccaccagcc	cagtggtcag	cgcagcttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cggaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatcct	gcacggtgcc	acctccacac	tcacctcacc	tctgcctgcc	3300
tggtctgacc	ctcccctgct	cgcctccctc	accccacacc	tgacacagag	ca	3352

<210> 36

<211> 2460

<212> DNA

<213> Homo sapiens

<400> 36

atgggtttct geegeagege cetgeaceeg etgtetetee tggtgeagge catcatgetg 60 geeatgacee tggeeetggg tacettgeet geetteetae eetgtgaget eeageeecae 120 ggeetggtga aetgeaactg getgtteetg aagtetgtge eecacttete eatggeagea 180 eecegtggea atgteaceag eettteettg teeteeaaee geateeacea eetecatgat 240

tctgactttg	cccacctgcc	cagcctgcgg	catctcaacc	tcaagtggaa	ctgcccgccg	300
gttggcctca	gccccatgca	cttcccctgc	cacatgacca	tcgagcccag	caccttcttg	360
gctgtgccca	ccctggaaga	gctaaacctg	agctacaaca	acatcatgac	tgtgcctgcg	420
ctgcccaaat	ccctcatatc	cctgtccctc	agccatacca	acatcctgat	gctagactct	480
gccagcctcg	ccggcctgca	tgccctgcgc	ttcctattca	tggacggcaa	ctgttattac	540
aagaacccct	gcaggcaggc	actggaggtg	gccccgggtg	ccctccttgg	cctgggcaac	600
ctcacccacc	tgtcactcaa	gtacaacaac	ctcactgtgg	tgccccgcaa	cctgccttcc	660
agcctggagt	atctgctgtt	gtcctacaac	cgcatcgtca	aactggcgcc	tgaggacctg	720
gccaatctga	ccgccctgcg	tgtgctcgat	gtgggcggaa	attgccgccg	ctgcgaccac	780
gctcccaacc	cctgcatgga	gtgccctcgt	cacttccccc	agctacatcc	cgataccttc	840
agccacctga	gccgtcttga	aggcctggtg	ttgaaggaca	gttctctctc	ctggctgaat	900
gccagttggt	tccgtgggct	gggaaacctc	cgagtgctgg	acctgagtga	gaacttcctc	960
tacaaatgca	tcactaaaac	caaggccttc	cagggcctaa	cacagctgcg	caagcttaac	1020
ctgtccttca	attaccaaaa	gagggtgtcc	tttgcccacc	tgtctctggc	cccttccttc	1080
gggagcctgg	tcgccctgaa	ggagctggac	atgcacggca	tettetteeg	ctcactcgat	1140
gagaccacgc	tccggccact	ggcccgcctg	cccatgctcc	agactctgcg	tctgcagatg	1200
aacttcatca	accaggccca	gctcggcatc	ttcagggcct	tecctggect	gegetaegtg	1260
gacctgtcgg	acaaccgcat	cagcggagct	teggagetga	cagccaccat	gggggaggca	1320
gatggagggg	agaaggtctg	gctgcagcct	ggggaccttg	ctccggcccc	agtggacact	1380
cccagctctg	aagacttcag	gcccaactgc	agcaccctca	acttcacctt	ggatctgtca	1440
cggaacaacc	tggtgaccgt	gcagccggag	atgtttgccc	agctctcgca	cctgcagtgc	1500
ctgcgcctga	gccacaactg	catctcgcag	gcagtcaatg	gctcccagtt	cctgccgctg	1560
accggtctgc	aggtgctaga	cctgtcccgc	aataagctgg	acctctacca	cgagcactca	1620
ttcacggagc	taccgcgact	ggaggccctg	gacctcagct	acaacagcca	gccctttggc	1680
atgcagggcg	tgggccacaa	cttcagcttc	gtggctcacc	tgcgcaccct	gcgccacctc	1740
agcctggccc	acaacaacat	ccacagccaa	gtgtcccagc	agctctgcag	tacgtcgctg	1800
cgggccctgg	acttcagcgg	caatgcactg	ggccatatgt	gggccgaggg	agacctctat	1860
ctgcacttct	tccaaggcct	gagcggtttg	atctggctgg	acttgtccca	gaaccgcctg	1920
cacaccctcc	tgccccaaac	cctgcgcaac	ctccccaaga	gcctacaggt	gctgcgtctc	1980
cgtgacaatt	acctggcctt	ctttaagtgg	tggagcctcc	acttcctgcc	caaactggaa	2040

gtcctc	gacc	tggcaggaaa	ccggctgaag	gccctgacca	atggcagcct	gcctgctggc	2100	
acccgg	ctcc	ggaggctgga	tgtcagctgc	aacagcatca	gettegtgge	ccccggcttc	2160	
ttttcca	aagg	ccaaggagct	gegagagete	aaccttagcg	ccaacgccct	caagacagtg	2220	
gaccact	tcct	ggtttgggc	: cctggcgagt	gccctgcaaa	tactagatgt	aagcgccaac	2280	
cctctg	cact	gcgcctgtgg	g ggcggccttt	ațggacttcc	tgctggaggt	gcaggctgcc	2340	
gtgcccg	ggtc	tgcccagccg	ggtgaagtgt	ggcagtccgg	gccagctcca	gggcctcagc	2400	
atcttt	gcac	aggacctgcg	cctctgcctg	gatgaggccc	tctcctggga	ctgtttcgcc	2460	
<210><211><211><212><213>	37 26 DNA Arti	ficial sec	quence					
<220> <223>	Synt	chetic oli	gonucleotide					
<400> accttg	37 cctg	ccttcctacc	: ctgtga				26	
<210><211><211><212><213>	38 21 DNA Arti	21						
<220> <223>	Synt	chetic olig	gonucleotide					
<400> gtccgtg	38 gtgg	gccagcacaa	ıa				21	
<210><211><211><212><213>	39 20 DNA Arti	ficial sec	quence					
<220> <223>	Synt	hetic olig	gonucleotide					
<400> tccatga	39 acgt	ttttgatgtt	:				20	
<210><211><211><212><213>	40 20 DNA Arti	ificial sec	quence					
<220> <223>	Synt	hetic olig	jonucleotide					

<400> tccata	40 acgt ttttgatgtt	20
<210>	41	
<211>	20	
<212>	DNA .	
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	41	
tccatc	acgt ttttgatgtt	20
<210>	42	
<211>	20	
<212>		
	Artificial sequence	
	•	
<220>		
<223>	Synthetic oligonucleotide	
<400>	42	
tccatt	acgt ttttgatgtt	20
<210>	43	
<211>	20	
<212>	DNA	
<213>	Artificial sequence	
.220		
<220>	Synthetic oligonucleotide	
12237	Synchetic dilgonacioniae	
<400>	43	
tccatg	gogt ttttgatgtt	20
<210>	44	
<211>	20	
<212>	DNA	
<213>	Artificial sequence	
222		
<220>	Combhatia alicanual astida	
<223>	Synthetic oligonucleotide	
<400>	44	
tccatg	ccgt ttttgatgtt	20
_		-
<210>	45	
<211>		
<212>		
	Artificial sequence	
<220>		

WO 2	WO 2004/026888	
<223>	Synthetic oligonucleotide	
<400>	45 tegt ttttgatgtt	20
cccarg	toge tottgatget	20
<210>	46	
<211>		
<212>		
	Artificial sequence	
<220> <223>	Synthetic oligonucleotide	
<400>		20
cccarg	atgt ttttgatgtt	20
<210>	47	
<211>		
<212> <213>		
(213)	Artificial sequence	
<220>	Combhatia alicenualastida	
<223>	Synthetic oligonucleotide	
<400>	47	
tccatg	aagt ttttgatgtt	20
.210.	40	
<210> <211>		
<212>		
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	48	
tccatg	aggt ttttgatgtt	20
<210>	49	
<212>		
<213>		
<220>		
<223>	Synthetic oligonucleotide	
<400>	49	
tccatg	acat ttttgatgtt	20
<210>	50	
<211> <212>		
	Artificial sequence	

<220> <223>	Synthetic oligonucleotide	
.400.	ro	
<400>	50 acct ttttgatgtt	20
cccacga	acci ciccgacyci	
<210>	51	
<211>		
<212>		
<213>	Artificial sequence	
<220>	Synthetic oligonucleotide	
<223>	Synchetic Origonacreotiae	
<400>	51	
	actt ttttgatgtt	20
<210>	52	
	20	
<212>		
<213>	Artificial sequence	
<220>		
	Synthetic oligonucleotide	
	2,	
<400>	52	
tccatg	acgc ttttgatgtt	20
-210-	E 2	
<210><211>		
<212>		
	Artificial sequence	
	•	
<220>		
<223>	Synthetic oligonucleotide	
	53	20
tccatg	acga ttttgatgtt	
<210>	54	
<211>	20	
<212>		
<213>	Artificial sequence	
<220>	Complete alicemual cotido	
<223>	Synthetic oligonucleotide	
<400>	54	
	gacgg ttttgatgtt	20
	- -	
<210>	55	
<211>		
<212>		
<213>	Artificial sequence	

<220> <223>	Synthetic oligonucleotide	
<400>	55	
		20
cecacge		
<210>	56	
<211>	20	
<212>		
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	56	
tccatga	ecgt atttgatgtt	20
<210>		
<211>	20	
<212>		
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	57	
tccatga	acgt gtttgatgtt	20
<210>	58	
<211>	24	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	58 .	
tcgtcgt	ttt gtcgttttgt cgtt	24
	\cdot	
<210>	59.	
<211>	24	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Synthetic oligonucleotide	
<400>	59	
tgctgct	ettt gtgcttttgt gctt	24
<210>	60	
<211>	20	
<212>	DNA	

```
<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide
<400> 60
tccatgacgt tcctgatgct
                                                                        20
<210> 61
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Synthetic oligonucleotide
<400> 61
tccatgagct tcctgatgct
                                                                        20
<210> 62
<211> 16
<212> PRT
<213> Artificial sequence
<220>
<223> Consensus oligopeptide
<220>
<221> MISC_FEATURE
<222> (4)..(5)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (7)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (14)..(15)
<223> Any amino acid
<400> 62
Gly Asn Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
                                     10
<210> 63
<211> 16
<212> PRT
<213> Homo sapiens
<400> 63
```

```
Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys
                5
                                     10
<210> 64
<211> 16
<212> PRT
<213> Mus musculus
<400> 64
Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys Met Ile Cys
                5
                                     10
<210> 65
<211> 31
<212> PRT
<213> Artificial sequence
<220>
<223> Consensus oligopeptide
<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid
<400> 65
Arg Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Asp Xaa Tyr Xaa Xaa Xaa
1 5
                                     10
```

- 112 -

```
25
<210> 66
<211> 31
<212> PRT
<213> Homo sapiens
<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid
<400> 66
Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa
            5
25
<210> 67
<211> 31
<212> PRT
<213> Mus musculus
<220>
<221> MISC_FEATURE
<222> (2)..(8)
<223> Any amino acid
```

```
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (14)..(22)
<223> Any amino acid
<220>
<221> MISC_FEATURE
<222> (25)..(30)
<223> Any amino acid
<400> 67
Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys Xaa Asp Xaa Tyr Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Gln Leu Xaa Xaa Xaa Xaa Xaa Tyr
<210> 68
<211> 31
<212> PRT
<213> Homo sapiens
<400> 68
Gln Val Leu Asp Leu Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His
Ser Phe Thr Glu Leu Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr
                                25
<210> 69
<211> 31
<212> PRT
<213> Mus musculus
<400> 69
Gln Val Leu Asp Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys
```

15 10

Ser Phe Ser Glu Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr 25 20

<210> 70

<211> 20

<212> DNA <213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 70

tccaggactt ctctcaggtt

20